CA2296897A1 - Piperidine derivates having anxiolytic effect - Google Patents
Piperidine derivates having anxiolytic effect Download PDFInfo
- Publication number
- CA2296897A1 CA2296897A1 CA002296897A CA2296897A CA2296897A1 CA 2296897 A1 CA2296897 A1 CA 2296897A1 CA 002296897 A CA002296897 A CA 002296897A CA 2296897 A CA2296897 A CA 2296897A CA 2296897 A1 CA2296897 A1 CA 2296897A1
- Authority
- CA
- Canada
- Prior art keywords
- piperidine
- spiro
- isobenzofuran
- butyl
- fluorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title claims description 28
- 230000000949 anxiolytic effect Effects 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 117
- 238000011282 treatment Methods 0.000 claims abstract description 24
- 208000016285 Movement disease Diseases 0.000 claims abstract description 7
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 7
- 208000028017 Psychotic disease Diseases 0.000 claims abstract description 7
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 6
- 206010010904 Convulsion Diseases 0.000 claims abstract description 6
- 206010039966 Senile dementia Diseases 0.000 claims abstract description 6
- 230000036461 convulsion Effects 0.000 claims abstract description 6
- 206010015037 epilepsy Diseases 0.000 claims abstract description 6
- 208000000044 Amnesia Diseases 0.000 claims abstract description 5
- 208000031091 Amnestic disease Diseases 0.000 claims abstract description 5
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 5
- 230000006986 amnesia Effects 0.000 claims abstract description 5
- 230000036506 anxiety Effects 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 53
- -1 piperidine compound Chemical class 0.000 claims description 32
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- 239000002253 acid Substances 0.000 claims description 24
- 229910052760 oxygen Inorganic materials 0.000 claims description 19
- BYOIMOJOKVUNTP-UHFFFAOYSA-N spiro[1h-2-benzofuran-3,4'-piperidine] Chemical compound C12=CC=CC=C2COC21CCNCC2 BYOIMOJOKVUNTP-UHFFFAOYSA-N 0.000 claims description 17
- 125000001424 substituent group Chemical group 0.000 claims description 16
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical group 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 claims description 5
- 125000004414 alkyl thio group Chemical group 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005977 Ethylene Substances 0.000 claims description 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 2
- 125000006850 spacer group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- QMTVKPIRPXBNQW-UHFFFAOYSA-N 1'-[3-(1-adamantyloxy)propyl]spiro[isochromene-3,4'-piperidine] Chemical compound O1C=C2C=CC=CC2=CC1(CC1)CCN1CCCOC1(C2)CC(C3)CC2CC3C1 QMTVKPIRPXBNQW-UHFFFAOYSA-N 0.000 claims 1
- 125000003884 phenylalkyl group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 150000003053 piperidines Chemical class 0.000 abstract description 9
- 238000010171 animal model Methods 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 136
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 116
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 97
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 84
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 84
- 125000003003 spiro group Chemical group 0.000 description 81
- 239000003921 oil Substances 0.000 description 71
- 235000019198 oils Nutrition 0.000 description 71
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 70
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 64
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 62
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 60
- 239000002904 solvent Substances 0.000 description 52
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 49
- 239000000243 solution Substances 0.000 description 48
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 44
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 43
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- 238000010992 reflux Methods 0.000 description 37
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 36
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 32
- 229960003390 magnesium sulfate Drugs 0.000 description 31
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 31
- 235000019341 magnesium sulphate Nutrition 0.000 description 31
- 239000012071 phase Substances 0.000 description 28
- 238000001035 drying Methods 0.000 description 27
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 27
- 230000000875 corresponding effect Effects 0.000 description 25
- 238000003756 stirring Methods 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 238000000605 extraction Methods 0.000 description 24
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 22
- 239000012280 lithium aluminium hydride Substances 0.000 description 22
- 239000003480 eluent Substances 0.000 description 21
- 239000011541 reaction mixture Substances 0.000 description 21
- 239000000741 silica gel Substances 0.000 description 21
- 229910002027 silica gel Inorganic materials 0.000 description 21
- 239000000725 suspension Substances 0.000 description 21
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 18
- 239000012074 organic phase Substances 0.000 description 17
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 16
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 238000001914 filtration Methods 0.000 description 15
- 235000011167 hydrochloric acid Nutrition 0.000 description 15
- 229960000443 hydrochloric acid Drugs 0.000 description 15
- 150000003891 oxalate salts Chemical class 0.000 description 15
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- 235000006408 oxalic acid Nutrition 0.000 description 14
- 238000006722 reduction reaction Methods 0.000 description 14
- 108010085082 sigma receptors Proteins 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 238000009739 binding Methods 0.000 description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 description 12
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 11
- 230000027455 binding Effects 0.000 description 11
- 239000003982 sigma receptor ligand Substances 0.000 description 11
- 229940086542 triethylamine Drugs 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 9
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 7
- 230000002152 alkylating effect Effects 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 125000005605 benzo group Chemical group 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- 150000007857 hydrazones Chemical class 0.000 description 6
- 238000005984 hydrogenation reaction Methods 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 230000036515 potency Effects 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- 238000010626 work up procedure Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 5
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 150000002576 ketones Chemical class 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- OPNUROKCUBTKLF-UHFFFAOYSA-N 1,2-bis(2-methylphenyl)guanidine Chemical compound CC1=CC=CC=C1N\C(N)=N\C1=CC=CC=C1C OPNUROKCUBTKLF-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N 1-butanol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 4
- GUDVQJXODNJRIJ-CALCHBBNSA-N 9-[3-[(3S,5R)-3,5-dimethyl-1-piperazinyl]propyl]carbazole Chemical compound C1[C@@H](C)N[C@@H](C)CN1CCCN1C2=CC=CC=C2C2=CC=CC=C21 GUDVQJXODNJRIJ-CALCHBBNSA-N 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 4
- 229920002873 Polyethylenimine Polymers 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000029936 alkylation Effects 0.000 description 4
- 238000005804 alkylation reaction Methods 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical compound C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 150000002688 maleic acid derivatives Chemical class 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 125000004043 oxo group Chemical group O=* 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 4
- 238000005932 reductive alkylation reaction Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229950004933 rimcazole Drugs 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 229910052727 yttrium Inorganic materials 0.000 description 4
- ZXUYYZPJUGQHLQ-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl]-1-butanol Chemical compound C=1C=C(F)C=CC=1C(O)CCCN(CC1)CCN1C1=NC=C(F)C=N1 ZXUYYZPJUGQHLQ-UHFFFAOYSA-N 0.000 description 3
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical group C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 3
- IGLKHWVIJCQODS-UHFFFAOYSA-N 4-(1h-indol-3-yl)butan-1-ol Chemical compound C1=CC=C2C(CCCCO)=CNC2=C1 IGLKHWVIJCQODS-UHFFFAOYSA-N 0.000 description 3
- 108060003345 Adrenergic Receptor Proteins 0.000 description 3
- 102000017910 Adrenergic receptor Human genes 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- 208000014094 Dystonic disease Diseases 0.000 description 3
- 239000001828 Gelatine Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 125000004450 alkenylene group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000006114 decarboxylation reaction Methods 0.000 description 3
- BEPAFCGSDWSTEL-UHFFFAOYSA-N dimethyl malonate Chemical compound COC(=O)CC(=O)OC BEPAFCGSDWSTEL-UHFFFAOYSA-N 0.000 description 3
- 208000010118 dystonia Diseases 0.000 description 3
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 235000001055 magnesium Nutrition 0.000 description 3
- 229940091250 magnesium supplement Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- QVKNICXDNWDLFN-UHFFFAOYSA-N spiro[1,3-benzodioxole-2,4'-piperidine] Chemical compound C1CNCCC21OC1=CC=CC=C1O2 QVKNICXDNWDLFN-UHFFFAOYSA-N 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 description 3
- 239000003039 volatile agent Substances 0.000 description 3
- 150000003751 zinc Chemical class 0.000 description 3
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- OUMVYPXVYMLOIC-UHFFFAOYSA-N 1-[2-chloro-5-(trifluoromethyl)phenyl]-5-hydroxypentan-1-one Chemical compound OCCCCC(=O)C1=CC(C(F)(F)F)=CC=C1Cl OUMVYPXVYMLOIC-UHFFFAOYSA-N 0.000 description 2
- ADHAJDDBRUOZHJ-UHFFFAOYSA-N 1-benzothiophen-3-one Chemical compound C1=CC=C2C(=O)CSC2=C1 ADHAJDDBRUOZHJ-UHFFFAOYSA-N 0.000 description 2
- KGNQDBQYEBMPFZ-UHFFFAOYSA-N 1-fluoro-4-iodobenzene Chemical compound FC1=CC=C(I)C=C1 KGNQDBQYEBMPFZ-UHFFFAOYSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical class C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- HYPPFDDKLRFGCC-UHFFFAOYSA-N 2-[5-chloro-1-(4-fluorophenyl)indol-3-yl]oxyethyl methanesulfonate Chemical compound C12=CC=C(Cl)C=C2C(OCCOS(=O)(=O)C)=CN1C1=CC=C(F)C=C1 HYPPFDDKLRFGCC-UHFFFAOYSA-N 0.000 description 2
- ILPBINAXDRFYPL-UHFFFAOYSA-N 2-octene Chemical compound CCCCCC=CC ILPBINAXDRFYPL-UHFFFAOYSA-N 0.000 description 2
- QKTMTSXUSCJFOV-UHFFFAOYSA-N 3-(3-chloropropyl)-5-fluoro-2,3-dihydro-1-benzofuran Chemical compound FC1=CC=C2OCC(CCCCl)C2=C1 QKTMTSXUSCJFOV-UHFFFAOYSA-N 0.000 description 2
- XNXGLTJWOZMRNZ-UHFFFAOYSA-N 3-(4-fluorophenyl)-8-azabicyclo[3.2.1]octane Chemical compound C1=CC(F)=CC=C1C1CC(N2)CCC2C1 XNXGLTJWOZMRNZ-UHFFFAOYSA-N 0.000 description 2
- QBFBBLJMOZRSBU-UHFFFAOYSA-N 3-(5-fluoro-2,3-dihydro-1-benzofuran-3-yl)propan-1-ol Chemical compound C1=C(F)C=C2C(CCCO)COC2=C1 QBFBBLJMOZRSBU-UHFFFAOYSA-N 0.000 description 2
- DYRMKCCGPIZVMM-UHFFFAOYSA-N 3-[4-(4-fluorophenyl)piperidin-1-yl]propan-1-ol Chemical compound C1CN(CCCO)CCC1C1=CC=C(F)C=C1 DYRMKCCGPIZVMM-UHFFFAOYSA-N 0.000 description 2
- LNGXBZDOEJQTMR-UHFFFAOYSA-N 4-(1,2-benzothiazol-3-yl)butan-1-ol Chemical compound C1=CC=C2C(CCCCO)=NSC2=C1 LNGXBZDOEJQTMR-UHFFFAOYSA-N 0.000 description 2
- KLJSBFIVRRCLJG-UHFFFAOYSA-N 4-(1,2-benzoxazol-3-yl)butyl methanesulfonate Chemical compound C1=CC=C2C(CCCCOS(=O)(=O)C)=NOC2=C1 KLJSBFIVRRCLJG-UHFFFAOYSA-N 0.000 description 2
- YRXISWUCZHJDKD-UHFFFAOYSA-N 4-(1-benzothiophen-3-yl)butan-1-ol Chemical compound C1=CC=C2C(CCCCO)=CSC2=C1 YRXISWUCZHJDKD-UHFFFAOYSA-N 0.000 description 2
- AFYALJSDFPSAAZ-UHFFFAOYSA-N 4-(4-fluorophenyl)piperidine Chemical compound C1=CC(F)=CC=C1C1CCNCC1 AFYALJSDFPSAAZ-UHFFFAOYSA-N 0.000 description 2
- NBWKZEUULFAUHU-UHFFFAOYSA-N 4-(5-fluoro-1-benzofuran-3-yl)butanoic acid Chemical compound C1=C(F)C=C2C(CCCC(=O)O)=COC2=C1 NBWKZEUULFAUHU-UHFFFAOYSA-N 0.000 description 2
- ADTZOEMCRIMQDB-UHFFFAOYSA-N 4-(5-fluoro-2,3-dihydro-1-benzofuran-3-yl)butanoyl chloride Chemical compound FC1=CC=C2OCC(CCCC(Cl)=O)C2=C1 ADTZOEMCRIMQDB-UHFFFAOYSA-N 0.000 description 2
- HXHGULXINZUGJX-UHFFFAOYSA-N 4-chlorobutanol Chemical compound OCCCCCl HXHGULXINZUGJX-UHFFFAOYSA-N 0.000 description 2
- VUEQAXHGKCKXFV-UHFFFAOYSA-N 4-phenylbutyl methanesulfonate Chemical compound CS(=O)(=O)OCCCCC1=CC=CC=C1 VUEQAXHGKCKXFV-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 208000016620 Tourette disease Diseases 0.000 description 2
- 229910052770 Uranium Inorganic materials 0.000 description 2
- 229940008309 acetone / ethanol Drugs 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 238000006254 arylation reaction Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- FQTIYMRSUOADDK-UHFFFAOYSA-N ethyl 3-bromopropanoate Chemical compound CCOC(=O)CCBr FQTIYMRSUOADDK-UHFFFAOYSA-N 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002473 indoazoles Chemical class 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229940087646 methanolamine Drugs 0.000 description 2
- RWIKCBHOVNDESJ-NSCUHMNNSA-N methyl (e)-4-bromobut-2-enoate Chemical compound COC(=O)\C=C\CBr RWIKCBHOVNDESJ-NSCUHMNNSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000003236 psychic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000006798 ring closing metathesis reaction Methods 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 230000006103 sulfonylation Effects 0.000 description 2
- 238000005694 sulfonylation reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- RUSDDKCNWDTJPN-UHFFFAOYSA-N (1-phenylindol-3-yl) acetate Chemical compound C12=CC=CC=C2C(OC(=O)C)=CN1C1=CC=CC=C1 RUSDDKCNWDTJPN-UHFFFAOYSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- AEVBPXDFDKBGLT-YOUFYPILSA-N (2s,3s,4r,5r)-n-[2-[4-(diethoxyphosphorylmethyl)anilino]-2-oxoethyl]-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolane-2-carboxamide Chemical compound C1=CC(CP(=O)(OCC)OCC)=CC=C1NC(=O)CNC(=O)[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 AEVBPXDFDKBGLT-YOUFYPILSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- CIWZXJOBXQEOJK-UHFFFAOYSA-N (5-fluoro-2,3-dihydro-1-benzofuran-3-yl)methanol Chemical compound C1=C(F)C=C2C(CO)COC2=C1 CIWZXJOBXQEOJK-UHFFFAOYSA-N 0.000 description 1
- KBZKCCABOUKYMQ-UHFFFAOYSA-N (5-fluoro-2,3-dihydro-1-benzofuran-3-yl)methyl methanesulfonate Chemical compound C1=C(F)C=C2C(COS(=O)(=O)C)COC2=C1 KBZKCCABOUKYMQ-UHFFFAOYSA-N 0.000 description 1
- JHFKGEIDLLULOC-UHFFFAOYSA-N 1'-(3-phenoxypropyl)spiro[isochromene-3,4'-piperidine] Chemical compound C1CC2(C=C3C=CC=CC3=CO2)CCN1CCCOC1=CC=CC=C1 JHFKGEIDLLULOC-UHFFFAOYSA-N 0.000 description 1
- SEJJECIQLYCFOZ-UHFFFAOYSA-N 1'-[4-(1-benzothiophen-3-yl)butyl]spiro[1,4-dihydroisochromene-3,4'-piperidine] Chemical compound C1C2=CC=CC=C2COC1(CC1)CCN1CCCCC1=CSC2=CC=CC=C12 SEJJECIQLYCFOZ-UHFFFAOYSA-N 0.000 description 1
- VUFUIDNKBYKSMC-UHFFFAOYSA-N 1'-[4-[1-(4-fluorophenyl)indol-3-yl]butyl]spiro[2,3-dihydrochromene-4,4'-piperidine] Chemical compound C1=CC(F)=CC=C1N1C2=CC=CC=C2C(CCCCN2CCC3(C4=CC=CC=C4OCC3)CC2)=C1 VUFUIDNKBYKSMC-UHFFFAOYSA-N 0.000 description 1
- DHOFYDZDRBSHJB-UHFFFAOYSA-N 1'-benzylspiro[1,4-dihydroisochromene-3,4'-piperidine] Chemical compound C1CC2(OCC3=CC=CC=C3C2)CCN1CC1=CC=CC=C1 DHOFYDZDRBSHJB-UHFFFAOYSA-N 0.000 description 1
- CRKWADRIYCMTBU-UHFFFAOYSA-N 1'-benzylspiro[3,4-dihydrochromene-2,4'-piperidine] Chemical compound C1CC2(OC3=CC=CC=C3CC2)CCN1CC1=CC=CC=C1 CRKWADRIYCMTBU-UHFFFAOYSA-N 0.000 description 1
- YNMVLXLZUYHTJZ-UHFFFAOYSA-N 1'-benzylspiro[chromene-2,4'-piperidine] Chemical compound C1CC2(C=CC3=CC=CC=C3O2)CCN1CC1=CC=CC=C1 YNMVLXLZUYHTJZ-UHFFFAOYSA-N 0.000 description 1
- XQDPZHGZBNOCCC-UHFFFAOYSA-N 1'-benzylspiro[chromene-4,4'-piperidine] Chemical compound C1CC2(C3=CC=CC=C3OC=C2)CCN1CC1=CC=CC=C1 XQDPZHGZBNOCCC-UHFFFAOYSA-N 0.000 description 1
- JJLDPXGTSZUDFN-UHFFFAOYSA-N 1'-butylspiro[indene-1,4'-piperidine] Chemical compound C1CN(CCCC)CCC21C1=CC=CC=C1C=C2 JJLDPXGTSZUDFN-UHFFFAOYSA-N 0.000 description 1
- JUXAVSAMVBLDKO-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-3-[3-(1h-indol-3-yl)-1-oxo-1-spiro[1,2-dihydroindene-3,4'-piperidine]-1'-ylpropan-2-yl]urea Chemical group C1N(CC2)CCC2C1NC(=O)NC(C(=O)N1CCC2(C3=CC=CC=C3CC2)CC1)CC1=CNC2=CC=CC=C12 JUXAVSAMVBLDKO-UHFFFAOYSA-N 0.000 description 1
- KZOMPPGAMFPYDX-UHFFFAOYSA-N 1-(1-benzothiophen-3-yl)ethanol Chemical compound C1=CC=C2C(C(O)C)=CSC2=C1 KZOMPPGAMFPYDX-UHFFFAOYSA-N 0.000 description 1
- GKHWNTOEJMAEHE-UHFFFAOYSA-N 1-(1-benzothiophen-3-ylmethoxy)ethanol Chemical class C1=CC=C2C(COC(O)C)=CSC2=C1 GKHWNTOEJMAEHE-UHFFFAOYSA-N 0.000 description 1
- VUUPVGPBBHUYFY-UHFFFAOYSA-N 1-(4-chlorobutyl)-3-cyclohexylimidazolidin-2-one Chemical compound O=C1N(CCCCCl)CCN1C1CCCCC1 VUUPVGPBBHUYFY-UHFFFAOYSA-N 0.000 description 1
- NGVLXUDHOKGWPG-UHFFFAOYSA-N 1-(4-fluorophenyl)-3-[4-[4-(4-fluorophenyl)piperidin-1-yl]butyl]indole Chemical compound C1=CC(F)=CC=C1C1CCN(CCCCC=2C3=CC=CC=C3N(C=3C=CC(F)=CC=3)C=2)CC1 NGVLXUDHOKGWPG-UHFFFAOYSA-N 0.000 description 1
- FPSNEPLNXKCSKH-UHFFFAOYSA-N 1-(4-fluorophenyl)-3-[4-[4-(4-methylphenyl)piperidin-1-yl]butyl]indole Chemical compound C1=CC(C)=CC=C1C1CCN(CCCCC=2C3=CC=CC=C3N(C=3C=CC(F)=CC=3)C=2)CC1 FPSNEPLNXKCSKH-UHFFFAOYSA-N 0.000 description 1
- XYJLLLIRAHLYEO-UHFFFAOYSA-N 1-(4-fluorophenyl)-3-[4-[4-(4-propan-2-ylphenyl)piperidin-1-yl]butyl]indole Chemical compound C1=CC(C(C)C)=CC=C1C1CCN(CCCCC=2C3=CC=CC=C3N(C=3C=CC(F)=CC=3)C=2)CC1 XYJLLLIRAHLYEO-UHFFFAOYSA-N 0.000 description 1
- GLGMGEWPXJFMBW-UHFFFAOYSA-N 1-(4-fluorophenyl)-3-[4-[4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]butyl]indole Chemical compound C1=CC(F)=CC=C1N1C2=CC=CC=C2C(CCCCN2CCC(CC2)C=2C=C(C=CC=2)C(F)(F)F)=C1 GLGMGEWPXJFMBW-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- QLJSLFWQRIMBDY-UHFFFAOYSA-N 1-[3-(5-fluoro-2,3-dihydro-1-benzofuran-3-yl)propyl]-4-(4-fluorophenyl)piperidine Chemical compound C1=CC(F)=CC=C1C1CCN(CCCC2C3=CC(F)=CC=C3OC2)CC1 QLJSLFWQRIMBDY-UHFFFAOYSA-N 0.000 description 1
- MJRROXATWDPUNQ-UHFFFAOYSA-N 1-[4-(1,2-benzoxazol-3-yl)butyl]spiro[isochromene-3,4'-piperidine] Chemical compound N=1OC2=CC=CC=C2C=1CCCCC(O1)=C2C=CC=CC2=CC21CCNCC2 MJRROXATWDPUNQ-UHFFFAOYSA-N 0.000 description 1
- FRJNKYGTHPUSJR-UHFFFAOYSA-N 1-benzothiophene 1,1-dioxide Chemical class C1=CC=C2S(=O)(=O)C=CC2=C1 FRJNKYGTHPUSJR-UHFFFAOYSA-N 0.000 description 1
- AITNMTXHTIIIBB-UHFFFAOYSA-N 1-bromo-4-fluorobenzene Chemical compound FC1=CC=C(Br)C=C1 AITNMTXHTIIIBB-UHFFFAOYSA-N 0.000 description 1
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- TYHUGKGZNOULKD-UHFFFAOYSA-N 1-fluoro-2-iodobenzene Chemical compound FC1=CC=CC=C1I TYHUGKGZNOULKD-UHFFFAOYSA-N 0.000 description 1
- CTTGZEDHPSNKQT-UHFFFAOYSA-N 2,2,2-trichloroethyl 5-(4-fluorophenyl)-8-azabicyclo[3.2.1]oct-3-ene-8-carboxylate Chemical compound C1=CC(F)=CC=C1C1(N2C(=O)OCC(Cl)(Cl)Cl)C=CCC2CC1 CTTGZEDHPSNKQT-UHFFFAOYSA-N 0.000 description 1
- YJUFGFXVASPYFQ-UHFFFAOYSA-N 2,3-dihydro-1-benzothiophene Chemical class C1=CC=C2SCCC2=C1 YJUFGFXVASPYFQ-UHFFFAOYSA-N 0.000 description 1
- BVSIAYQIMUUCRW-UHFFFAOYSA-N 2-(1,2-benzoxazol-3-yl)acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=NOC2=C1 BVSIAYQIMUUCRW-UHFFFAOYSA-N 0.000 description 1
- ULLKKVHOLFDNFB-UHFFFAOYSA-N 2-[3-(4-hydroxybutyl)indol-1-yl]-n,n-dimethylacetamide Chemical compound C1=CC=C2N(CC(=O)N(C)C)C=C(CCCCO)C2=C1 ULLKKVHOLFDNFB-UHFFFAOYSA-N 0.000 description 1
- WWSJZGAPAVMETJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethoxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCC WWSJZGAPAVMETJ-UHFFFAOYSA-N 0.000 description 1
- KWWHFBHPKIUFMP-UHFFFAOYSA-N 2-[5-chloro-1-(4-fluorophenyl)indol-3-yl]oxyacetic acid Chemical compound C12=CC=C(Cl)C=C2C(OCC(=O)O)=CN1C1=CC=C(F)C=C1 KWWHFBHPKIUFMP-UHFFFAOYSA-N 0.000 description 1
- HGIIXSOMYKBJKN-UHFFFAOYSA-N 2-[5-chloro-1-(4-fluorophenyl)indol-3-yl]oxyethanol Chemical compound C12=CC=C(Cl)C=C2C(OCCO)=CN1C1=CC=C(F)C=C1 HGIIXSOMYKBJKN-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- GEHMLBFNZKJDQM-UHFFFAOYSA-N 2-chloro-4-(trifluoromethyl)benzonitrile Chemical compound FC(F)(F)C1=CC=C(C#N)C(Cl)=C1 GEHMLBFNZKJDQM-UHFFFAOYSA-N 0.000 description 1
- XBPPLECAZBTMMK-UHFFFAOYSA-N 2-chloro-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CCl XBPPLECAZBTMMK-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- UVECZJOMLAWTEK-UHFFFAOYSA-N 3-(1,2-benzoxazol-3-yl)propanenitrile Chemical compound C1=CC=C2C(CCC#N)=NOC2=C1 UVECZJOMLAWTEK-UHFFFAOYSA-N 0.000 description 1
- WCXNAOFYNLMQAZ-UHFFFAOYSA-N 3-(1,2-benzoxazol-3-yl)propanoic acid Chemical compound C1=CC=C2C(CCC(=O)O)=NOC2=C1 WCXNAOFYNLMQAZ-UHFFFAOYSA-N 0.000 description 1
- LLCUDRDRIOYTEI-UHFFFAOYSA-N 3-(1-benzothiophen-3-yloxy)propan-1-ol Chemical compound C1=CC=C2C(OCCCO)=CSC2=C1 LLCUDRDRIOYTEI-UHFFFAOYSA-N 0.000 description 1
- PHVCYNPWGWZJCD-UHFFFAOYSA-N 3-(1-benzothiophen-3-ylsulfanyl)propan-1-ol Chemical compound C1=CC=C2C(SCCCO)=CSC2=C1 PHVCYNPWGWZJCD-UHFFFAOYSA-N 0.000 description 1
- HEVCXANBEHDQBH-UHFFFAOYSA-N 3-(1-benzothiophen-3-ylsulfanyl)propanoic acid Chemical compound C1=CC=C2C(SCCC(=O)O)=CSC2=C1 HEVCXANBEHDQBH-UHFFFAOYSA-N 0.000 description 1
- IGHNXBCBDIKWOF-UHFFFAOYSA-N 3-(1-phenylindol-3-yl)oxypropan-1-ol Chemical compound C12=CC=CC=C2C(OCCCO)=CN1C1=CC=CC=C1 IGHNXBCBDIKWOF-UHFFFAOYSA-N 0.000 description 1
- ADZPWSMSFZVHNT-UHFFFAOYSA-N 3-(1h-indol-3-yloxy)propan-1-ol Chemical class C1=CC=C2C(OCCCO)=CNC2=C1 ADZPWSMSFZVHNT-UHFFFAOYSA-N 0.000 description 1
- VUVTVEOGOFEBKR-UHFFFAOYSA-N 3-(2-chloroethyl)-1-benzothiophene Chemical compound C1=CC=C2C(CCCl)=CSC2=C1 VUVTVEOGOFEBKR-UHFFFAOYSA-N 0.000 description 1
- LKSXLNMBLGXHQS-UHFFFAOYSA-N 3-(4-fluorophenyl)-8-azabicyclo[3.2.1]oct-3-ene Chemical compound C1=CC(F)=CC=C1C(C1)=CC2NC1CC2 LKSXLNMBLGXHQS-UHFFFAOYSA-N 0.000 description 1
- HERUOVVKVXUUKK-UHFFFAOYSA-N 3-(5-fluoro-1-benzofuran-3-yl)propan-1-ol Chemical compound C1=C(F)C=C2C(CCCO)=COC2=C1 HERUOVVKVXUUKK-UHFFFAOYSA-N 0.000 description 1
- PBSIHSPJXGVELM-UHFFFAOYSA-N 3-(5-fluoro-1-benzofuran-3-yl)propanoic acid Chemical compound C1=C(F)C=C2C(CCC(=O)O)=COC2=C1 PBSIHSPJXGVELM-UHFFFAOYSA-N 0.000 description 1
- LQIHNVZYUXEWAQ-UHFFFAOYSA-N 3-(5-fluoro-2,3-dihydro-1-benzofuran-3-yl)propanoic acid Chemical compound C1=C(F)C=C2C(CCC(=O)O)COC2=C1 LQIHNVZYUXEWAQ-UHFFFAOYSA-N 0.000 description 1
- FJDUBXIMFKKOPV-UHFFFAOYSA-N 3-(5-fluoro-2,3-dihydro-1-benzofuran-3-yl)propyl methanesulfonate Chemical compound C1=C(F)C=C2C(CCCOS(=O)(=O)C)COC2=C1 FJDUBXIMFKKOPV-UHFFFAOYSA-N 0.000 description 1
- MTEMZLYNDSLNST-UHFFFAOYSA-N 3-[3-[4-(4-fluorophenyl)piperidin-1-yl]propoxy]-1,2-benzothiazole Chemical compound C1=CC(F)=CC=C1C1CCN(CCCOC=2C3=CC=CC=C3SN=2)CC1 MTEMZLYNDSLNST-UHFFFAOYSA-N 0.000 description 1
- OKQALJBWMOZBSK-UHFFFAOYSA-N 3-[4-[3-(4-fluorophenyl)-8-azabicyclo[3.2.1]octan-8-yl]butyl]-1,2-benzoxazole Chemical compound C1=CC(F)=CC=C1C1CC(N2CCCCC=3C4=CC=CC=C4ON=3)CCC2C1 OKQALJBWMOZBSK-UHFFFAOYSA-N 0.000 description 1
- OVTHWSXLADCZIL-UHFFFAOYSA-N 3-[4-[4-(2,6-dichlorophenyl)piperidin-1-yl]butyl]-1,2-benzoxazole Chemical compound ClC1=CC=CC(Cl)=C1C1CCN(CCCCC=2C3=CC=CC=C3ON=2)CC1 OVTHWSXLADCZIL-UHFFFAOYSA-N 0.000 description 1
- GNKWZQFMKSMGEV-UHFFFAOYSA-N 3-[4-[4-(2-methoxyphenyl)piperidin-1-yl]butyl]-2,3-dihydro-1h-indole Chemical compound COC1=CC=CC=C1C1CCN(CCCCC2C3=CC=CC=C3NC2)CC1 GNKWZQFMKSMGEV-UHFFFAOYSA-N 0.000 description 1
- QLVPKVJVNZJRMP-UHFFFAOYSA-N 3-[4-[4-(4-fluorophenyl)piperidin-1-yl]butyl]-1,2-benzoxazole Chemical compound C1=CC(F)=CC=C1C1CCN(CCCCC=2C3=CC=CC=C3ON=2)CC1 QLVPKVJVNZJRMP-UHFFFAOYSA-N 0.000 description 1
- LOYDXBAFBVMXSN-UHFFFAOYSA-N 3-[4-[4-(4-fluorophenyl)piperidin-1-yl]butyl]indol-2-one Chemical compound C1=CC(F)=CC=C1C1CCN(CCCCC=2C(N=C3C=CC=CC3=2)=O)CC1 LOYDXBAFBVMXSN-UHFFFAOYSA-N 0.000 description 1
- IWKGLMYMNLYLTK-UHFFFAOYSA-N 3-[6-[4-(4-fluorophenyl)piperidin-1-yl]hexyl]-1h-indole Chemical compound C1=CC(F)=CC=C1C1CCN(CCCCCCC=2C3=CC=CC=C3NC=2)CC1 IWKGLMYMNLYLTK-UHFFFAOYSA-N 0.000 description 1
- BCPVKLRBQLRWDQ-UHFFFAOYSA-N 3-chloro-1,2-benzothiazole Chemical compound C1=CC=C2C(Cl)=NSC2=C1 BCPVKLRBQLRWDQ-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- AVCMPZUZKVCNNW-UHFFFAOYSA-N 4-(1,2-benzothiazol-3-yl)butanoic acid Chemical compound C1=CC=C2C(CCCC(=O)O)=NSC2=C1 AVCMPZUZKVCNNW-UHFFFAOYSA-N 0.000 description 1
- ZSMBCOAESGSKIP-UHFFFAOYSA-N 4-(1,2-benzoxazol-3-yl)butan-1-ol Chemical compound C1=CC=C2C(CCCCO)=NOC2=C1 ZSMBCOAESGSKIP-UHFFFAOYSA-N 0.000 description 1
- OOEBMSIXFBAKMV-UHFFFAOYSA-N 4-(2,3-dihydro-1h-inden-1-yl)but-3-en-1-ol Chemical compound C1=CC=C2C(C=CCCO)CCC2=C1 OOEBMSIXFBAKMV-UHFFFAOYSA-N 0.000 description 1
- ZZTYFFFQSMINNC-UHFFFAOYSA-N 4-(3h-inden-1-yl)butan-1-ol Chemical compound C1=CC=C2C(CCCCO)=CCC2=C1 ZZTYFFFQSMINNC-UHFFFAOYSA-N 0.000 description 1
- TXEIVBLZGAMLOL-UHFFFAOYSA-N 4-(5-fluoro-2,3-dihydro-1-benzofuran-3-yl)butanoic acid Chemical compound C1=C(F)C=C2C(CCCC(=O)O)COC2=C1 TXEIVBLZGAMLOL-UHFFFAOYSA-N 0.000 description 1
- KZLXEOUFQIJXMZ-UHFFFAOYSA-N 4-[5-(trifluoromethyl)-2h-indazol-3-yl]butan-1-ol Chemical compound C1=C(C(F)(F)F)C=C2C(CCCCO)=NNC2=C1 KZLXEOUFQIJXMZ-UHFFFAOYSA-N 0.000 description 1
- HXAOUYGZEOZTJO-UHFFFAOYSA-N 4-chloro-1-(4-fluorophenyl)butan-1-one Chemical compound FC1=CC=C(C(=O)CCCCl)C=C1 HXAOUYGZEOZTJO-UHFFFAOYSA-N 0.000 description 1
- LDZLXQFDGRCELX-UHFFFAOYSA-N 4-phenylbutan-1-ol Chemical compound OCCCCC1=CC=CC=C1 LDZLXQFDGRCELX-UHFFFAOYSA-N 0.000 description 1
- UTBULQCHEUWJNV-UHFFFAOYSA-N 4-phenylpiperidine Chemical class C1CNCCC1C1=CC=CC=C1 UTBULQCHEUWJNV-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- CKLMHKQLDWEKRE-UHFFFAOYSA-N 5,6-dichloro-3-[4-[4-(4-fluorophenyl)piperidin-1-yl]butyl]-1h-indole Chemical compound C1=CC(F)=CC=C1C1CCN(CCCCC=2C3=CC(Cl)=C(Cl)C=C3NC=2)CC1 CKLMHKQLDWEKRE-UHFFFAOYSA-N 0.000 description 1
- JNVYAGHJOBXUHS-UHFFFAOYSA-N 5-chloro-1-(4-fluorophenyl)-3-[3-[4-(4-methylphenyl)piperidin-1-yl]propoxy]indole Chemical compound C1=CC(C)=CC=C1C1CCN(CCCOC=2C3=CC(Cl)=CC=C3N(C=3C=CC(F)=CC=3)C=2)CC1 JNVYAGHJOBXUHS-UHFFFAOYSA-N 0.000 description 1
- CNGNGGBYKPBLCU-UHFFFAOYSA-N 5-fluoro-1-benzofuran-3-carboxylic acid Chemical compound C1=C(F)C=C2C(C(=O)O)=COC2=C1 CNGNGGBYKPBLCU-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FIPWRIJSWJWJAI-UHFFFAOYSA-N Butyl carbitol 6-propylpiperonyl ether Chemical compound C1=C(CCC)C(COCCOCCOCCCC)=CC2=C1OCO2 FIPWRIJSWJWJAI-UHFFFAOYSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 206010021113 Hypothermia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- JBOPQACSHPPKEP-UHFFFAOYSA-N Indoxyl acetate Chemical class C1=CC=C2C(OC(=O)C)=CNC2=C1 JBOPQACSHPPKEP-UHFFFAOYSA-N 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 241000212342 Sium Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 241001533587 Spironucleus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000006887 Ullmann reaction Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DDSZWBCJXDRQDU-UHFFFAOYSA-N [N].C1CCNCC1 Chemical group [N].C1CCNCC1 DDSZWBCJXDRQDU-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 229910000091 aluminium hydride Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003496 anti-amnesic effect Effects 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000004350 aryl cycloalkyl group Chemical group 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 125000004532 benzofuran-3-yl group Chemical group O1C=C(C2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 150000004802 benzothiophens Chemical class 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- UORVGPXVDQYIDP-BJUDXGSMSA-N borane Chemical class [10BH3] UORVGPXVDQYIDP-BJUDXGSMSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- CSLSXAGTXJLWCI-UHFFFAOYSA-N butanoic acid;1h-indole Chemical compound CCCC(O)=O.C1=CC=C2NC=CC2=C1 CSLSXAGTXJLWCI-UHFFFAOYSA-N 0.000 description 1
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- INGKGLJMYBPGKZ-UHFFFAOYSA-N dimethyl 2-[(5-fluoro-2,3-dihydro-1-benzofuran-3-yl)methyl]propanedioate Chemical compound C1=C(F)C=C2C(CC(C(=O)OC)C(=O)OC)COC2=C1 INGKGLJMYBPGKZ-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- OISPPYAHNHQFSI-UHFFFAOYSA-N ethyl 3-[4-(4-fluorophenyl)piperidin-1-yl]propanoate Chemical compound C1CN(CCC(=O)OCC)CCC1C1=CC=C(F)C=C1 OISPPYAHNHQFSI-UHFFFAOYSA-N 0.000 description 1
- LUBGFMZTGFXIIN-UHFFFAOYSA-N ethyl 4-oxopiperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(=O)CC1 LUBGFMZTGFXIIN-UHFFFAOYSA-N 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000000295 fuel oil Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000000999 hypotriglyceridemic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 150000002468 indanes Chemical class 0.000 description 1
- 150000002469 indenes Chemical class 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical class C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- 150000005624 indolones Chemical class 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003384 isochromanyl group Chemical class C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- DRNPDJFBLZLRAL-QPJJXVBHSA-N methyl (e)-4-(1-hydroxy-2,3-dihydroinden-1-yl)but-2-enoate Chemical compound C1=CC=C2C(C/C=C/C(=O)OC)(O)CCC2=C1 DRNPDJFBLZLRAL-QPJJXVBHSA-N 0.000 description 1
- FSJAXBXCHWMNAB-UHFFFAOYSA-N methyl 1-benzothiophene-3-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=CSC2=C1 FSJAXBXCHWMNAB-UHFFFAOYSA-N 0.000 description 1
- VKNXYAQLRDOEFK-UHFFFAOYSA-N methyl 2-(1,2-benzoxazol-3-yl)acetate Chemical compound C1=CC=C2C(CC(=O)OC)=NOC2=C1 VKNXYAQLRDOEFK-UHFFFAOYSA-N 0.000 description 1
- ODKSYEYDLVKYNI-UHFFFAOYSA-N methyl 2-(1-benzothiophen-3-yl)acetate Chemical compound C1=CC=C2C(CC(=O)OC)=CSC2=C1 ODKSYEYDLVKYNI-UHFFFAOYSA-N 0.000 description 1
- MSMYCGYVKSREQJ-UHFFFAOYSA-N methyl 3-(1,2-benzoxazol-3-yl)propanoate Chemical compound C1=CC=C2C(CCC(=O)OC)=NOC2=C1 MSMYCGYVKSREQJ-UHFFFAOYSA-N 0.000 description 1
- YEMBDVNAZOGVLD-UHFFFAOYSA-N methyl 4-(1,2-benzoxazol-3-yl)butanoate Chemical compound C1=CC=C2C(CCCC(=O)OC)=NOC2=C1 YEMBDVNAZOGVLD-UHFFFAOYSA-N 0.000 description 1
- ZEJUFCOACOWDPP-UHFFFAOYSA-N methyl 4-(1h-indol-3-yl)butanoate Chemical compound C1=CC=C2C(CCCC(=O)OC)=CNC2=C1 ZEJUFCOACOWDPP-UHFFFAOYSA-N 0.000 description 1
- NNVYRRAPFAOSTL-UHFFFAOYSA-N methyl 5-chloro-3-(2-ethoxy-2-oxoethoxy)-1-(4-fluorophenyl)indole-2-carboxylate Chemical compound C12=CC=C(Cl)C=C2C(OCC(=O)OCC)=C(C(=O)OC)N1C1=CC=C(F)C=C1 NNVYRRAPFAOSTL-UHFFFAOYSA-N 0.000 description 1
- LRKHQYYRUOJNRW-UHFFFAOYSA-N methyl 5-fluoro-1-benzofuran-3-carboxylate Chemical compound C1=C(F)C=C2C(C(=O)OC)=COC2=C1 LRKHQYYRUOJNRW-UHFFFAOYSA-N 0.000 description 1
- ZOXRNCDTPJXOAI-UHFFFAOYSA-N methyl 5-fluoro-2,3-dihydro-1-benzofuran-3-carboxylate Chemical compound C1=C(F)C=C2C(C(=O)OC)COC2=C1 ZOXRNCDTPJXOAI-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- YRCHYHRCBXNYNU-UHFFFAOYSA-N n-[[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-(4-fluorophenyl)acetamide Chemical compound N1=CC(CNCCOC)=CC=C1C1=CC2=NC=CC(OC=3C(=CC(NC(=S)NC(=O)CC=4C=CC(F)=CC=4)=CC=3)F)=C2S1 YRCHYHRCBXNYNU-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- ZBYFQSPEUIVDTF-UHFFFAOYSA-N spiro[1,2-dihydroindene-3,4'-piperidine] Chemical compound C12=CC=CC=C2CCC21CCNCC2 ZBYFQSPEUIVDTF-UHFFFAOYSA-N 0.000 description 1
- PLWMBYBVKVUTBR-UHFFFAOYSA-N spiro[2,3-dihydro-1h-naphthalene-4,4'-piperidine] Chemical class C1CCC2=CC=CC=C2C21CCNCC2 PLWMBYBVKVUTBR-UHFFFAOYSA-N 0.000 description 1
- BYGRWGNUWGBFRX-UHFFFAOYSA-N spiro[2,4-dihydrochromene-3,4'-piperidine] Chemical compound C1CNCCC21CC1=CC=CC=C1OC2 BYGRWGNUWGBFRX-UHFFFAOYSA-N 0.000 description 1
- QDBDZPRAHGLILC-UHFFFAOYSA-N spiro[benzo[7]annulene-5,4'-piperidine] Chemical class C1CNCCC21C1=CC=CC=C1C=CC=C2 QDBDZPRAHGLILC-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 150000003577 thiophenes Chemical class 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 125000000165 tricyclic carbocycle group Chemical group 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000011679 wistar WU rat Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Piperidine compounds having formula (I):
(see formula I) wherein R1 is a group -D-B-A-R.
These compounds have shown effect in animal models indicative of anxiolytic properties. Accordingly they are useful as medicines for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases, senile dementia of the Alzheimer type or Parkinson's disease.
(see formula I) wherein R1 is a group -D-B-A-R.
These compounds have shown effect in animal models indicative of anxiolytic properties. Accordingly they are useful as medicines for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases, senile dementia of the Alzheimer type or Parkinson's disease.
Description
PIPERIDINE DERIVATES HAVING ANXIOhYTIC EFFECT
This application is a division of application serial N°
This application is a division of application serial N°
2,111,204 filed on June 12, 1992.
BACKGROUND OF THE INVENTION
Field of the Invention The invention disclosed in patent application N° 2,111,204 relates to a class of piperidine compounds having anxiolytic effect and potentially binding to the sigma receptors and therefore being useful in the treatment of psychic and neurologic disorders.
The present invention as claimed hereinafter relates to others piperidine compounds from the same class of compounds.
Description of the Related Art Various related compounds are known from the prior art.
So, US patents Nos. 3,686,186 and 3,745,165 disclose spiro[phthalan-1,4'-piperidinej and spiro[isochroman-3,4'-piperidinej compounds optionally having a benzyl substituent at the piperidine N-atom. The phthalan compounds are said to be 2o useful as antidepressants as indicated by their ability to reverse reserpine hypother-mia, whereas the isochromane compounds are stated tb be useful as hypotri-glyceridemics.
German Offenlegungsschrift No. 2,458,176 and the corresponding US patent No.
la 3,985,889 generically describe infer a6a 1,3-dihydrospiro[isobenzofuran-1,4'-piperidinej or 1,3-dihydrospiro[isobenzofu ran-1,3'-pyrrolidinej compounds sub-stituted at the ring N-atom with lower alkyl, cycloalkyl or phenyl(C2-4)alkyl and optionally having an oxo group attached to the furan ring. The compounds are alleged to be useful as tranquilizers as demonstrated by their ability to display effects on behaviour and reflex depression and on muscle relaxation, and they are claimed also to be useful in the treatment of pain as demonstrated in the 2-phenyl-1,4-quinone induced writhing assay in mice. However, only pharmacological data 1o for one such compound without an oxo substituent in the furan ring, i.e.
the com-pound 1,3-dihydro-1'-methyl-spiro[isobenzofuran-1,4'-piperidinej, are presented, and only four such compounds having a substituent different from methyl on the piperidine N-atom are specifically disclosed, i.e. 1 '-cyclopropylmethyl-, 1 '-[3-(4-fluoro-benzoyl)propylj-, 1 '-[4,4-bis(4-fluorophenyl)buty Ij- and 1 '-acetyl-1,3-dihydro-spiro[iso-benzofuran-1,4'-piperidinej . No indication of effect on sigma-receptors is given.
Japanese patent publication JP Kokai 55 143,980 generically describes inter alia a very broad class of spiro[chromane-piperidine] compounds which are optionally substituted at the piperidine N-atom with an alkyl, cycloalkyl, allyl, aryl, aralkyl, or arylcycloalkyl group and optionally substituted in the chromane ring with an oxo group. However, with respect to such spirochromane compounds having no oxo s substituent in the chromane ring only compounds having a methyl, phenyl or benzyl group at the piperidine N-atom are specifically disclosed. These compounds are claimed to possess antiallergic activity and no suggestion of activity in the central nervous system is given.
~o European patent publication No EP 0 414 289 A1 generically describes a class of 1,2,3,4-tetrahydro-spiro[naphthalene-1,4'-piperidine] and 1,4-dihydro-spiro[naph-thalene-1,4'-piperidine] derivatives substituted at the piperidine N-atom with a "hydrocarbon" and aleged to have selective sigma receptor antagonistic activity.
The term "hydrocarbon" as defined in said patent covers all possible straight ~s chained, cyclic, heterocyclic etc. groups; however, only compounds having benzyl, phenethyl, cycloalkylmethyl, furyl- or thienyl~nethyl or lower alkyl or alkenyl as the "hyd-rocarbon" substituent at the piperidine nitrogen atom being specifically disclosed. The compounds are stated to displace tritiated di-tolyl guanidine (DTG) from sigma sites with potencies better than 200 nM. As a particularly preferred zo compound is mentioned 1 '-benzyl-1,2,3,4-tetrahydro-spiro[naphthalene-1,4'-piperidi-ne]. European patent publication No EP 0 445 974 A2 generically describes the corresponding spiro[indane-1,4'-piperidinej and spiro[benzocycloheptene-5,4'-piperidine] derivatives. Again the compounds are only stated to displace tritiated di-tolyl guanidine (DTG) from sigma sites with potencies better than 200 nM
2s EP Application No. EP-A2-0 431 943 relates to a further extremely broad class of spiropiperidine compounds substituted at the piperidine N-atom. Said compounds are alleged to be useful as antiarrhythmics and for impaired cardiac pump function.
so Said application exemplifies several compounds, the majority of which contain an oxo and/or a sulfonylamino substituent in the spiro cyclic ring system. Of the remainder compounds, the main part has another polar substituent, such as vitro, amino, . a fused imidazo group etc. attached to the spiro nucleus and/or they have some polar substituents, such as sulfonylamino, vitro, amino, etc. in the substituent on the piperidine N-atom. Furthermore some of the compounds have heteroaryl alkyl substituents on the piperidine N-atom, whereas only a very few of those compounds exemplified do not have such substituents, i.e. a couple of 6-methoxy-s spiro[2H-1-benzopyran-2,4'-piperidinesj having a phenylsubstituent on the piperi-dine N-atom and a few spiro[3H-1-benzopyran-3,4'-piperidine]'s having a benzyl, phenethyl, hexyl or heptyl substituent on the piperidine N-atom. No suggestion or indication of effect of the compounds on the sigma receptors is given.
io US patent No. 4,420,485 discloses 1'-[3-(6-fluoro-1,2-benzoisoxazol-3-yl)propyl]-spiro(benzofuran-2(H),4'-piperidinesJ optionally having one or two substituents in the benzofuran ring. The compounds are claimed to be useful as antihypertensives.
No mention or suggestion of effects in the treatment of psychic or neurological disorders is given.
~s German Offenlegungsschrift No 28 27 874 corresponding to U.S. Patent No.
BACKGROUND OF THE INVENTION
Field of the Invention The invention disclosed in patent application N° 2,111,204 relates to a class of piperidine compounds having anxiolytic effect and potentially binding to the sigma receptors and therefore being useful in the treatment of psychic and neurologic disorders.
The present invention as claimed hereinafter relates to others piperidine compounds from the same class of compounds.
Description of the Related Art Various related compounds are known from the prior art.
So, US patents Nos. 3,686,186 and 3,745,165 disclose spiro[phthalan-1,4'-piperidinej and spiro[isochroman-3,4'-piperidinej compounds optionally having a benzyl substituent at the piperidine N-atom. The phthalan compounds are said to be 2o useful as antidepressants as indicated by their ability to reverse reserpine hypother-mia, whereas the isochromane compounds are stated tb be useful as hypotri-glyceridemics.
German Offenlegungsschrift No. 2,458,176 and the corresponding US patent No.
la 3,985,889 generically describe infer a6a 1,3-dihydrospiro[isobenzofuran-1,4'-piperidinej or 1,3-dihydrospiro[isobenzofu ran-1,3'-pyrrolidinej compounds sub-stituted at the ring N-atom with lower alkyl, cycloalkyl or phenyl(C2-4)alkyl and optionally having an oxo group attached to the furan ring. The compounds are alleged to be useful as tranquilizers as demonstrated by their ability to display effects on behaviour and reflex depression and on muscle relaxation, and they are claimed also to be useful in the treatment of pain as demonstrated in the 2-phenyl-1,4-quinone induced writhing assay in mice. However, only pharmacological data 1o for one such compound without an oxo substituent in the furan ring, i.e.
the com-pound 1,3-dihydro-1'-methyl-spiro[isobenzofuran-1,4'-piperidinej, are presented, and only four such compounds having a substituent different from methyl on the piperidine N-atom are specifically disclosed, i.e. 1 '-cyclopropylmethyl-, 1 '-[3-(4-fluoro-benzoyl)propylj-, 1 '-[4,4-bis(4-fluorophenyl)buty Ij- and 1 '-acetyl-1,3-dihydro-spiro[iso-benzofuran-1,4'-piperidinej . No indication of effect on sigma-receptors is given.
Japanese patent publication JP Kokai 55 143,980 generically describes inter alia a very broad class of spiro[chromane-piperidine] compounds which are optionally substituted at the piperidine N-atom with an alkyl, cycloalkyl, allyl, aryl, aralkyl, or arylcycloalkyl group and optionally substituted in the chromane ring with an oxo group. However, with respect to such spirochromane compounds having no oxo s substituent in the chromane ring only compounds having a methyl, phenyl or benzyl group at the piperidine N-atom are specifically disclosed. These compounds are claimed to possess antiallergic activity and no suggestion of activity in the central nervous system is given.
~o European patent publication No EP 0 414 289 A1 generically describes a class of 1,2,3,4-tetrahydro-spiro[naphthalene-1,4'-piperidine] and 1,4-dihydro-spiro[naph-thalene-1,4'-piperidine] derivatives substituted at the piperidine N-atom with a "hydrocarbon" and aleged to have selective sigma receptor antagonistic activity.
The term "hydrocarbon" as defined in said patent covers all possible straight ~s chained, cyclic, heterocyclic etc. groups; however, only compounds having benzyl, phenethyl, cycloalkylmethyl, furyl- or thienyl~nethyl or lower alkyl or alkenyl as the "hyd-rocarbon" substituent at the piperidine nitrogen atom being specifically disclosed. The compounds are stated to displace tritiated di-tolyl guanidine (DTG) from sigma sites with potencies better than 200 nM. As a particularly preferred zo compound is mentioned 1 '-benzyl-1,2,3,4-tetrahydro-spiro[naphthalene-1,4'-piperidi-ne]. European patent publication No EP 0 445 974 A2 generically describes the corresponding spiro[indane-1,4'-piperidinej and spiro[benzocycloheptene-5,4'-piperidine] derivatives. Again the compounds are only stated to displace tritiated di-tolyl guanidine (DTG) from sigma sites with potencies better than 200 nM
2s EP Application No. EP-A2-0 431 943 relates to a further extremely broad class of spiropiperidine compounds substituted at the piperidine N-atom. Said compounds are alleged to be useful as antiarrhythmics and for impaired cardiac pump function.
so Said application exemplifies several compounds, the majority of which contain an oxo and/or a sulfonylamino substituent in the spiro cyclic ring system. Of the remainder compounds, the main part has another polar substituent, such as vitro, amino, . a fused imidazo group etc. attached to the spiro nucleus and/or they have some polar substituents, such as sulfonylamino, vitro, amino, etc. in the substituent on the piperidine N-atom. Furthermore some of the compounds have heteroaryl alkyl substituents on the piperidine N-atom, whereas only a very few of those compounds exemplified do not have such substituents, i.e. a couple of 6-methoxy-s spiro[2H-1-benzopyran-2,4'-piperidinesj having a phenylsubstituent on the piperi-dine N-atom and a few spiro[3H-1-benzopyran-3,4'-piperidine]'s having a benzyl, phenethyl, hexyl or heptyl substituent on the piperidine N-atom. No suggestion or indication of effect of the compounds on the sigma receptors is given.
io US patent No. 4,420,485 discloses 1'-[3-(6-fluoro-1,2-benzoisoxazol-3-yl)propyl]-spiro(benzofuran-2(H),4'-piperidinesJ optionally having one or two substituents in the benzofuran ring. The compounds are claimed to be useful as antihypertensives.
No mention or suggestion of effects in the treatment of psychic or neurological disorders is given.
~s German Offenlegungsschrift No 28 27 874 corresponding to U.S. Patent No.
4,251,538 generically discloses a class of 3-[4-(4-phenyl-piperidin-i-yl)-butyl]- or 3-[4-(4-phenyl-tetrahydropyridyl-1-yl)-butyl]indole derivatives optionally substituted in the indole, piperidinyl or tetrahydropyridyl and/or phenyl groups. The compounds 2o are said to show dopamine agonist effects and serotonin reuptake inhibiting effects in the central nervous system, and accordingly to be useful in the ,treatment of Parkinson's disease and depression. However, no documentation for such effects is given in the specification, no pharmacological data at all being given, and certainly no indication or suggestion of effect on the sigma receptor is given.
Furthermore, the majority of the compounds listed in the specification, of which obviously only a few have actually been prepared, are tetrahydropyridyl compounds and/or they have an oxo substituent in the butyl chain. Only a few piperidyl com-pounds without an oxo substituent in the butyl chain are mentioned, i.e. 3-[4-(4-so phenyl-1-piperidyl)-butylj-indole and the 1-methyl-, 1-phenyl- and 2-methyl-derivatives thereof as well as derivatives thereof substituted with halogen, methyl or trifluoromethyl in the 4-phenyl substituent on the piperidyi group thereof.
With respect to physical data only melting point for one such compounds is given.
International Patent Application No WO 91 /09594 published on July 11, 1991 relates i.a. to sigma receptor ligands being 4-phenyl-piperidine compounds and having an optionally substituted "heteroaryl"-alkyl, -alkenyl, -alkynyl, -alkoxy or -alkoxy-alkyl substituent on the piperidine N-atom. The term "heteroaryl"-alkyl is s defined by mention of a very broad class of such substituents. However only four N-substituted, 4-phenyl-piperidine compounds are specifically disclosed which are all 1-(phenyl-lower alkyl)-4-phenyl-piperidines and only four compounds having a "heteroaryl"-alkyl substituent are specifically mentioned, which are all piperazine (and not piperidine) compounds.The compounds are stated to be antipsychotics.
From studies of the biology and function of sigma receptors, evidence has been presented that sigma receptor ligands may be useful in the treatment of psychosis and movement disorders, such as dystonia and tardive dyskinesia, and motor disturbances associated with Huntington's chorea or Tourette's syndrome and in 1s Parkinson's disease (Walker, J. M. et al, Pharmacological Reviews, 1990, 42, 355).
The known sigma receptor ligand rimcazole clinically shows effects in the treatment of psychosis (Snyder, S.H., Largent, B.L. J. Neuropsychiatry 1989, 1, 7) and a group of sigma receptor ligands have been descibed to show antihallucinogenic activity in animal models (International Patent Publication No WO 9103243).
Furthermore, sigma receptor ligands have been reported to be involved in modula-tion of NMDA receptor mediated events in the brain and to act as anti-ischemic agents in in vivo tests (Rao, T. S. et al, Molecular Pharmacology, 1990, 37, 978). In addition to ischemia they may also be useful in the treatment of other such NMDA
2s receptor mediated events, e.g. epilepsy and convulsion.
Also, some sigma receptor ligands have been found to show anti-amnesic effects in an animal model (Early et al., Brain Research 1991, 546, 281-286).
Sigma ligands have been shown to influence central acetylcholine levels in animal ao models (Matsuno et al, Brain Research 1992, 575, 315-319; Junien et al, Eur. J.
Pharm. 1991, 200, 343-345) and may, therefore, have potential in the treatment of senile dementia of the Alzheimer type.
Finally, some guanidine derivatives having sigma receptor activity have been disclosed to be useful as anxiolytics (International Patent Publication N° WO 9014067).
Accordingly, agents potently acting on the sigma receptors in the central nervous system are believed to be of potential use in the therapy of such conditions.
DETAILED DESCRIPTION OF THE INVENTION
As described and claimed in parent application N°
2,111,204, it has now been found that a certain class of piperidine compounds bind at sigma receptors with potencies which generally are 2-3 orders of magnitude higher than the potency limit indicated in European patent publication EP 0 414 289 A1. Furthermore the compounds of said class have been found to show anxiolytic effects in animal models.
Said class of compounds consists of compounds having the general Formula I
\N-R' R6 Z3 ~ I
Rs R4 wherein R1 is a) a group -D-B-A-R
wherein B is an up to 19 membered spacer group selected from alkylene, alkenylene and alkynylene which may be branched or straight chain and optionally substituted with hydroxy, which again may b~ esterified with an aliphatic carboxylic acid having from two to twentyfour carbon atoms, inclusive, 5a W
A is a bond or a divalent group selected from O, S, SO, S02, and _N~N- ' W being O or S and the dotted line designating an optional bond ;
R is alkyl, alkenyl, cycloalkyl, cycloalkenyl, phenyl, cycloalkylalkyl, cycloalkenyl-alkvl. ohenvlalkyl, diphenylalkyl, any alkylgroup optionally being substituted with one or two hydroxy groups, which again may be optionally esterified with an aliphatic carboxylic acid having from two to twentyfour carbon atoms inclusive, and any phenyl group being optionally substituted with one or more substituents in the phenyl ring; and .
s D is CReR9 where Re and R9 are independently selected from the substituents defined below for R4 - R~, or a cycloalkylene group; or b) a group having the general Formula II
Ra Rb ~. .G?2-~.U./
to II
Rc Rd wherein X is CHRIO, O, S, SO, S02 or NRIO, Rio being hydrogen, lower alkyl or alkenyl, cycloalkyl or cycloalkylalkyl, cycloalkenyl or cycloalkenylalkyl, acyl, aminoalkyl, mono- or dialkylaminoalkyl, sulfonyl or arylalkyl or phenyl optionally ~s substituted with one or more substituents independently selected from the following: halogen, lower alkyl, lower alkoxy, hydroxy, trifluoromethyl, and cyano, or Rio is a hetero aromatic group, preferably 2-thienyl, 3-thienyl, 2-furanyl, 3-furanyl, 2-thiazolyl, 2-oxazolyl, 2-imidazolyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl;
20 one or two of the dotted lines may be a bond;
when the dotted line emanating from Y indicates a bond, Y is N or CH; or when said dotted line indicates no bond, Y is CH2, NH, C=O or C=S;
Ra - Rd are independently selected from hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy, lower alkylthio, lower alkylsulphonyl, lower alkyl- or dialkyl-2s amino, cyano, trifluoromethyl, or trifluoromethylthio;
U is CH2, O or S; or when, one of the dotted lines emanating from U indicates a bond, U is CH;
the bond between U and Q~ or Q2, respectively, may also be a triple bond and in such case U is °C";
so Q~ is selected from a bond, alkylene or alkenylene and Q2 is alkylene having at least two C-atoms, alkenylene or a group Q2'D wherein G1~' is as defined for C~
and D is as defined above, Q~ and Q2 having together from 2 to 20 carbon atoms and being optionally substituted with one or more hydroxy groups, any such hydroxy group being optionally esterified with an aliphatic carboxylic acid having from two to twentyfour carbon atoms inclusive; and R2 and R3 are independently hydrogen, lower alkyl or they may be linked together thereby forming an ethylene or propylene bridge;
R4 to R~ are independently selected from hydrogen, halogen, lower alkyl , lower alkoxy, hydroxy, lower alkylthio, lower alkyl- or dialkylamino, cyano, trifluoromethyl, or trifluoromethylthio; and i) Z~ and Z2 are linked together in which case: Z~ is CH2, O or S;
Z2 and Z3 are independently (CH2)~, n being 0 or 1, O or S, with the proviso that Z~ may not be S or O when Z2 is S or O, and that Z2 and Z3 may not both be (CH2)~ wherein n is 0:
or Z~ and Z2 may together represent a group -CH=CH-;
or when Z3 is (CH2)r, wherein n is 0, Z~ and Z2 may together represent a 3-membered divalent group, optionally containing one unsaturated bond, and optionally containing one O- or S-heteroatom; or ii) when R~ is a group as defined in b) Z~ ,and Z2 may also be unlinked, in which case: Z~ is a group as defined for R4 - R~, ZZ is hydrogen and Z3 is (CH2)~
wherein n is 0;
with the proviso that when Z1 - Z3 are as defined in i) wherein Z3 is (CH2)~
where n is 0, and Z~ and Z2 together represent a 2- or 3-mernbered divalent hydrocarbon group, optionally containing one unsaturated bond, and R1 is a group defined in a) 3o then D-B-A-R may not be phenyl-C,~_3-alkyl, lower alkyl or lower alkenyl;
and acid addition salts or prodrugs thereof.
.. CA 02296897 2000-O1-13 7a The present invention as claimed hereinafter is restricted to the compounds of general formula (I) as defined hereinabove, wherein Z1 and Z~ are linked together ana wherein Rl is a group -D-B-A-R. The present invention provides the use of such piperidine compounds or acid addition salts or prodrugs thereof for the manufacture of a pharmaceutical preparation for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amne-sia, cerebrovascular diseases, senile dementia of the Alzheimer type or Parkinson's disease.
s Some of the compounds of the general Formula I may exist as optical isomers thereof; and such optical isomers are also embraced by the invention.
The term alkyl is intended to mean a C~-C2o straight chain or branched alkyl group and similarly alkenyl means a C2-CZO straight chain or branched alkenyl. group ~o having one or more unsaturated bonds in the chain. The term cycloalkyl designates a carbocyclic ring having 3-8 carbon atoms inclusive or a bicyclic or tricyclic carbocycle, such as adamantyl.
The terms lower alkyl, lower alkoxy, lower alkylthio, etc. designate such branched or ~s unbranched groups having from one to six carbon atoms inclusive. Exemplary of such groups are methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl, 2-methyl-1-propyl, methoxy, ethoxy,l-propoxy, 2-propoxy, methylthio, ethylthio, 1-propylthio, 2-propylthio, methylsulphonyl, ethylsulphonyl, or the like.
2o Halogen means fluoro, chloro, bromo or iodo.
The term "sulfonyl" is used in the meaning alkyl or aryl substituted sulfonyl, and similarly "acyl" is used in the meaning alkyl- or arylcarbonyl 25 The term "one or two of the dotted lines may be a bond" is intended to mean that each of the dotted lines may or may not represent a bond, i.e. that the ring and the side chain respectively may or may not have a double bond in the positions of the dotted lines in Formula II, provided that only two at a time indicate a bond and that adjacent dotted lines do not both indicate a bond.
The. optional substituents in the phenyl groups in the definition of R may indepen-dently be selected from halogen, lower alkyl, lower alkoxy, hydroxy, lower alkylthio, lower alkylsulphonyl, lower alkyl- or dialkylamino, cyano, trifluoromethyl, or trifluoro-methylthio. Each phenyl group may carry one or more substituents.
The acid addition salts of the invention are pharmaceutically acceptable salts of the compounds of Formula I formed with non-toxic acids. Exemplary of such organic s salts are those with malefic, fumaric, benzoic, ascorbic, embonic, succinic, oxalic, bis-methylenesalicylic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-amino-benzoic, glutamic, benzene sulfonic and theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromo-~o theophylline. Exemplary of such inorganic salts are those with hydrochloric, hydro-bromic, sulfuric, sulfamic, phosphoric and nitric acids.
The movement disorders and motor disturbances which may be treated by the preparation according to the invention are e.g. dystonia and tardive dyskinesia and motor disturbances associated with Huntington's chorea or Tourette's syndrome.
Dystonia may be acute or tardive and may be caused by neuroleptics or have another reason.
Cerebrovascular diseases are such disorders caused by cerebral infarction, 2o cerebral hemorrhage, cerebral arteriosclerosis, subarachnoid hemorrhage, cerebral thrombosis, cerebral embolism, or the like, e.g. ischemia, hypoxia, anoxia.
The compounds of the invention have been found to displace tritiated di-tolyl guanidine (DTG) from sigma sites in vitro with potencies better than about 40 nM, 25 and the great majority better than 1 nM, i.e. they are binding at the sigma receptors much more potently than sigma receptor ligands such as e.g. BMY 14802 and rimcazole. Furthermore, most of the present compounds have proven to be very selective iigands on the sigma receptors. For example as compared to the aj adrenoceptors and dopamine DZ receptors, the main part of the present compounds so have been found to show ratios of binding affinities (ICSO alpha/sigma and dopami-ne/sigma, respectively) of 30-10000. Furthermore, the compounds have proven to show very potent anxiolytic effects in an animal behaviour test in extremely low doses i.e. with ECSO values in the ng - p.g/kg range.
When Z~ and Z2 are linked together, preferably at least one of Z~, Z2 and Z3 designates O or S, and more preferably Z3 is (CH2)~ wherein n is 0, and Z2 is "O" or "S" and Z is CH2 or Z~ and ZZ together represent CH2-0-CI-~. Other preferred groups are those wherein Z1 is CH2, Z2 is O and Z3 is CHz; or Z3 is O and Z~-Z2~is s CH=CH; or Z~ is O, Z3 is O and Z2 is (CH2)~ where n =0, Particularly proffered compounds are:
1'-(3-Adamantyloxy-1-propyi)spiro[3H 2-benzopyran-3,4'-piperidine];
l0 1'-[4-(1-Benzyl-3-indolyl)-1-butyl]-spiro[isobenzofuran-1 (3H),4'-piperidine];
1'-(3-(3-Phenylimidazolidin-2-on-1-yl)-1-propyl)spiro[isobenzofuran-1 (3H),4'-piperidinej;
1'-[4-[1-(4-Fluorophenyl)-3-indolyl)-1-butyl]-spiro[isobenzofuran-1 (3H),4'-piperidine];
1,4-Dihydro-1'-[4-[1-(4-Fluorophenyl)-3-indolyl]-1-butyl]spiro[3H-2-benzopyran-3,4'-piperidine);
1'-(4-(1-p-Toluenesulfonyl-3-indolyl)-1-butyl)spiro[isobenzofuran-1 (3H),4'-piperidine];
1'-[4-[5-Fluoro-1-(4-fluorophenyl)-3-indolylj-1-butyl]spirojisobenzofuran-1 (3H),4'-piperidine];
6-Fluoro-1'-[4-[1-(4-fluoropheriyl)-3-indolyl]-1-butyl]spiro[isobenzofuran-1 (3H),4'-2o piperidine];
1'-[4-[1-(4-Methylphenyl)-3-indolyl]-1-butyljspiro(1 H-2-benzopyran-4(3H),4'-piperidine];
1-(4-Fluorophenyl)-3-[4-(4-(4-fluorophenyl)-1-piperidyl)-1-butyl]indole;
1'-[4-(1-(2-Thiazolyl)-3-indolyl)-1-butyl]spiro[isobenzofuran-1 (3H),4'-piperidine];
2s 1'-[3-(5-Fluorobenzofuran-3-yl)-1-propyl]spiro[isobenzofuran-1 (3H),4'-piperidine];
1'-[4-(5-Fluorobenzofuran-3-yl)-1-butyl]-spiro[isobenzofuran-1 (3H),4'-piperidine];
1'-[4-[1-(4-Fluorophenyl)-5-trifluoromethylindazol-3-ylj-1-butyl]spiro[isobenzofuran-1 (3H),4'-piperidinej;
4-Fluorophenyl-3-[4-(4-(4-fluorophenyl)-1-piperidinyl)-1-butyl]-5-trifluoromethyl-ao indazol;
1'-(4-(1,2-Benzisoxazol-3-yl)-1-butyl)spiro[isobenzofuran-1 (3f-~,4'-piperidine]; and 1'-[3-(Benzo[bjthiophen-3-ylthio)-1-propyljspiro[isobenzofuran-1 (3H),4'-piperidine].
Some of the compounds used in accordance with the invention are novel, and accor-dingly in another aspect the present invention relates to novel piperidine derivatives having the general Formula I as defined above with the proviso that if R1 is a group of the Formula II as defined above under b), Z1, Z2, and Z3 are .as defined above under ii), X is NH, Y is CH and the dotted line emanating from Y
indicates a bond, then -Q1-U-C~- may not be alkyl having less than 5 carbon atoms; , if R~ is a group of the Formula 11 as defined above wherein Z3 is O, Z~ is CH2, Z2 is (CH2)", n being 0, X is O, Y is N, the dotted line emanating from Y indicates a 1o bond, and -Q1-U-C~- indicates -(CHZ)3, then R~ may not be fluoro;
if Z3 is O, Z2 and Z1 are both CH2 and D-B-A-R is optionally substituted phenethyl, then R6 may not be methoxy; and if Z~ is O, and Z2 and Z3 are both CH2, then D-B-A-R may not be phenethyl, or optionally hydroxy substituted hexyl or heptyl.
The present invention also provides a pharmaceutical composition comprising at least one novel piperidine compound according to the invention.as defined above or a pharmaceutically acceptable acid addition salt thereof or prodrug therefore in combination with one or more pharmaceutically acceptable carriers or diluents.
The pharmaceutical compositions of this invention or those which are manufactured in accordance with this invention may be administered by any suitable route, for example orally in the form of tablets, capsules, powders, syrups, etc., or parenteral-ly in the form of solutions for injection. For preparing such compositions methods well known in the art may be used, and any pharmaceutically acceptable carriers, diluents, exipients, or other additive usually used in in the art may be used.
Conveniently, the compounds of the invention are administered in unit dosage form containing said compound in an amount of about 0.01 to 50 mg.
The total daily dose usually ranges of about 0.05 - 100 mg, and most preferably about 0.1 to 20 mg of the active compound of the invention.
The compounds of Formula 1 may be prepared by:
a) reducing the amide carbonyl of a compound of Formula III
R Z~ ZZ
N
Rs ~ ~ Za R»
Rs R4 III
wherein R2 - R~ and Z~ - Z3 are as previously defined and R> > is such a group that CH2-R» is a group comprised by the definition of R~;
b) alkylating a compound of Formula IV
~o R Z' Z2 Rs / \ Z3 NH
R3 , Rs R4 wherein R2 - R~ and Z1 - Z3 are as previously defined, with an alkylating reagent of the formula R~-V wherein R~ is as previously defined and V is a suitable leaving group such as halogen, mesylate or tosylate;
c) reductive alkylation of amines of Formula IV with aldehydes of the formula R> >-CHO or carboxylic acids of the formula R»-COOH or ketones of the formula R~2-CO-R~3 wherein R2-R~, R», and Z~-Z3 are as previously defined and R~2 and R~3 zo are such groups that R~z-CH-R~3 is a group comprised by the definition of R~;
d) reducing the C=Y~ double bond in a compound of Formula V
R Z' Z2 Ra Rs ~ ~ Z3 N ~2\ U'O' ~ Rb _ R3 Y' Rs Re X Rc V
Rd s wherein Ra-Rd, X, U, Q~, C~, R2-R7, and Z1-Z3 are as previously defined and Y~
is CH or N;
e) oxidizing a compound of Formula VI to an oxo compound of Formula VII:
R Z' Z2 Ra Rs ~ ~ Z3 'N ~1 U ~~' ~ Rb R3 ~ \
X Rc RS R4 Rd VI
R Z1 ZZ Ra v Rs ~ ~ Zs N ~2\ U ~4' ~ Rb R3 \
R5 R4 O X Rc Rd VII
wherein Ra-Rd, X, U, Q~, Q2, R2-R~, and Z~-Z3 are as previously defined;
io f) alkylating a compound of Formula VIII for obtaining a compound of general Formula I wherein X = NR~o; Rio' being lower alkyl, alkenyl, cycloalkyl, cycloafkyl-alkyl, cycloalkenyl or cycloaikenylalkyl, R Z' Z2 Ra Rs ~ ~ Z3 N ~Z~U~ ~~ , ~ Rb Rs 't~ \
Rs R4 H R° V II I __ Rd 1s wherein Ra-Rd, Y, U, Q~, Q2, R2-R~, and Z1-Z3 are as previously defined, with an alkylating reagent of the formula Rio=V~, wherein R~o'is as previously defined and V~ is a suitable leaving group, e.g. halogen, mesylate, or tosylate; or acylating a compound of the Formula VIII with an acylating reagent having the formula R~o'=CO-2o Hal, wherein Hal is halogen and Rio" is a group which together with CH2 form the group Rio', and subsequently reducing the acylated compound of Formula Vlll;
g) arylating a compound of Formula VIII for obtaining a compound of general Formula 1 wherein X = NRIO'", R1o"' being optionally substituted phenyl or heteroaryl, with an arylating agent of the formula Ar-V1 wherein Ar is optionally substituted phenyl or heteroaryl and V1 is as previously defined;
s h) for obtaining a compound of general Formula I wherein X = N-CO-R1o' or N-CO-Ar, wherein R1o' and Ar are as previously defined, acylating a compound of Formula VIII with an acylating agent of the formula R1o'-CO-Hal or Ar-CO-Hal. wherein Hal is as previously defined;
i) for obtaining a compound of general Formula I wherein X = N-S02-R1o' or N-Ar, wherein R1o' and Ar are as previously defined, sulfonylating a compound of Formula VIII with a sulfonylating agent of the formula R1o'-S02-Hal or Ar-S02-Hal, wherein Hal is as previously defined;
j) reductive alkylation of compounds of Formula VIII with carbonyl compounds of formula R14-CO-R15 wherein R14 and R~5 are such groups that R~4--CH-R~5 is a group R1o as previously defined;
2o k) making a ring closure reaction of the hydrazone IX to the indazole derivative X
RZ R~°-NH
Ra R Z~ ZZ
~N-~~. ~Q' / R
Rs / \ Z3 U ~ b~.
R3 Hal Rc Rs R4 Rd IX
R 2~ Z2 Ra Rs / ~ Za N ~z~ U'~, ~ Rb I
Rs N' \
Rs R4 Rio d Rc X
R
wherein Ra-Rd, U, Q1, Q2, RZ-R~. Rlo, and Z1-Z3 are as previously defined and Hal 2s is halogen;
1) reducing the quarternized pyridine derivative of Formula XI
R Z' R2 Rs ~ ~ ~ ~N R' RS R4 'Rs s in which R~-R~. Z~ and V~ are as previously defined;
whereupon the compound of Formula I is isolated as the free base or a pharmaceuti-cally acceptable acid addition salt thereof.
~o The reduction according to method a) may preferably be carried out in an inert organic solvent such as diethyl ether or tetrahydrofuran in the presence of lithium aluminium hydride at reflux temperature.
The amides of Formula III are conveniently prepared by treating piperidine deriva-ls tives of Formula IV with suitable carboxylic. acid chlorides of formula R»-COCI in the presence of base (potassium carbonate or triethylamine). When R»-CH2 designates a group of formula -D-B-A-R the corresponding carboxylic acid chlorides of formula R> >-COCI are either commercially available or prepared according to standard procedures.
When R~ 1-CH2 designates a group of Formula II the corresponding carboxylic acid chlorides of Formula XII, Ra CI ~ C12;' ~~C~', / Rb ,. U , Yw X ~ Fic Rd X~~
wherein Ra-Rd, X, Y, U, and Q~ are as previously defined and Q2' is such a group that Q2-CH2 is a group Q2 as previously defined, are prepared from the correspond-ing carboxylic acids by known methods.
The piperidine derivatives of Formula IV where Z~ and Z2 are linked together, are prepared as follows:
Spiro[isobenzofuran-1 (3H),4'-piperidine] according to the method described.
by s Marxer et al, J. Org. Chem. 1975, 40, 1427.
2,3-Dihydro-spiro[1 H-indene-1,4'-piperidine] and 3,4-dihydro-spiro[naphtalene-1 (2H) ,4'-piperidine] according to the method described in French Patent. No.
1,335,831.
l0 1'-Methyl-spiro[benzo[c]thiophene-1 (3H),4'-piperidine) according to the method described by Parham et al, J. Org. Chem. 1976, 41, 2628. The corresponding demethylated derivative was obtained by treatment with ethyl chloroformate followed by alkaline hydrolysis of the intermediary ethyl carbamate.
15 1'-Phenylmethyl-spiro[1 H-2-benzopyran-4(3H),4'-piperidine] according to the method described by Yamamoto et al, J. Med. Chem., 1981, 24, 194. The corres-ponding debenzylated derivative is obtained by hydrogenation in the presence of a palladium catalyst.
20 3,4-Dihydro-1'-phenylmethyl-spiro[2H-1-benzopyran-2,4'-piperidine]
according to the method described by Yamamoto et al, Chem. Pharm. Bull. 1981, 29, 3494. The cor-responding debenzylated derivative is obtained by treatment with ethyl chloro-formate followed by alkaline hydrolysis of the intermediary ethyl carbamate.
z5 1'-Phenylmethyl-spiro[2H-1-benzopyran-2,4'-piperidine] is obtained according to the method described by Yamamoto et al, Chem. Pharm. Bull. 1981, 29, 3494. The cor-responding debenzylated derivative is obtained by hydrogenation in the presence of a palladium catalyst.
so 1'-Phenyimethyl-spiro[3H-2-benzopyran-3,4'-piperidineJ-1 (4H)-one according to the method described by Yamamoto et a!, J. Med. Chem. 1981, 24, 194. Reduction with lithium aluminium hydride followed by treatment with phosphoric acid according to the procedure described by Marxer et al, J. Org. Chem. 1975, 40, 1427 yields 1,4-dihydro-1'-phenylmethyl-spiro[3H-2-benzopyran-3,4'-piperidine] which is debenzyl-ated by hydrogenation in the presence of a palladium catalyst.
1'-Benzylspiro[4H-1-benzopyran-4,4'-piperidine] is obtained by a method analogous-s ly to the method described in EP 0 414 289 A1 for the synthesis of 1'-benzyl-1,4-dihydrospiro[naphtalene-1,4'-piperidine]. Hydrogenation in the presence of a palladium catalyst gave 2,3-dihydrospiro[4N-1-benzopyran-4,4'-piperidine].
Spiro[1,3-benzodioxole-2,4'-piperidine] is obtained by refluxing 1-ethoxycarbonyl-4-io piperidinone and catechol in toluene solution in the presence of p-toluenesulfonic acid with continous removal of water followed by removal of the benzyl group by hydrogenation in the presence of a palladium catalyst.
The substituents R2-R~ are introduced by applying suitably substituted starting com-~s pounds to methods analogously to the above mentioned.
The piperidine derivatives of Formula IV where Z~ and Z2 are not linked are prepared by known methods, see e.g. US Pat. No. 2,891,066; McElvain et al J.
Amer. Chem. Soc.1950, 72, 3134; Bally et al Chem.Ber.1887, 20, 2590.
Alkylation of a compound of Formula IV according to method b) is conveniently performed in an inert organic solvent such as a suitably boiling alcohol or ketone, preferably in the presence of a base (potassium carbonate or methyl amine) at reflux temperature.
The alkylating reagents of formula R~-V where R~ designates -D-B-A-R wherein A
is O, S, or a bond and D, B, and R are as previously defined, are prepared by standard literature methods. The corresponding sulfoxides and sulfones are obtained by oxidation of the sulfides according to methods well known in the art.
W
Such alkylating agents in which A represents a group ~N~N~ wherein W is O
or S are prepared by the method disclosed in DE-OS No 2035370.
The preparations of alkylating reagents of formula R~-V where Rt designates a s group having the general Formula II are illustrated by examples in the following reaction schemes. In the formulas of the reaction schemes Ra-Rd, V and Ar are as previously defined, and E designates a t-piperidyl group of general Formula IV.
Indenes of Formula II are conveniently prepared according to Scheme 1, in~
which Ra - F~ and V are as previously defined.
to Ra Rb O
Br / Method 1i Rc / O
Rd Ra Ra R OH O Rb OH
b \ OCH3 Method 2~. I \ OH
% /
Rc Rc Rd Rd Ra Rb ~ OH
Method 3- ~ I , Method 4_ Rc Rd Ra .
Rb ~ V
Rc ~' Rd Scheme 1 Method 1 is a conventional Reformatsky condensation performed with activated zinc. Method 2 consists of a lithium aluminium hydride reduction performed in an inert organic solvent such as diethyl ether or tetrahydrofuran at reflux temperature.
The elimination in Method 3 is preferably performed in a suitable alcohol, e.g.
methanol, in the presence of a strong mineral acid, e.g. concentrated hydrochloric acid. Preferably, Method 4 is treatment with methanesulfonyl chloride in the presence of methyl amine in dichloromethane, thus giving the corresponding ~o methanesulfonate, but may alternatively be conversion of the hydroxy group to a halogen by means of a suitable reagent, e.g. thionyl choride.
Indanes of Formula II are prepared according to Scheme 2, in which Ra - Rd and V
are as previously defined.
Ra Rb \ O
/ + B~ ~ Method 1 a Rc O
Rd Ra Ra Rb ( \ I / OCH3 Rb \ / / OCH3 / p Rc ~ -,~ Rc ~ ... .
Rd Rd Method 2 Ra Ra Rb \ \ OH Rb \ / OH
/ ~ _ _ Rc Rc Rd Rd Ra Method 4 R° \ OH
+ ~ /
Rc Ra R
Rb V Method 5 \ \~/ ~/ Ra Rc / Rb \ OH
Rd ~ /
R°
Rd Method 4 Ra ~
Rb \' V
/
Rc Rd Scheme 2 Method 1 a is analogous to Method 1 with the modification that elimination of water is performed directly on the crude product by means of concentrated hydrochloric acid. The mixture of isomers obtained is reduced according to Method 2. One of the isomers obtained is isolated while the remaining mixture is hydrogenated in a conventional Parr apparatus (Method 5) in the presence of a suitable noble metal catalyst, e.g. palladium or platinum.
s Indoles of Formula II are most conveniently prepared either from indole alkanoic acid, exemplified by indole butanoic acid as described in Eur. Pat. Appl. No.
376607, or according to Scheme 3, in which Ra - Rd, Ar and V are as previously defined.
Ra Ra O
Rb O Rb O~~
/
Method S ~ " OEt R~ ~ N COOCH3 R~ ~ ~N COOCH3 Rd Ar Rd Ar Ra O
b R ~ O~OEt Method 6 --... Rc N
Rd Ar Ra . Ra b b R I ~ I OOH R ~ ~ I O~ V
Rc / N J Method 4 Rc / N J
Rd Ar Rd Ar 1 o Scheme 3 The starting indoxyl ester is prepared by the method described in US Pat. No.
4,710,500 and references therein. The alkylation in Method 5 is performed in an inert, suitably boiling, organic solvent, e.g. an alcohol or a ketone, preferably in the presence of a base (potassium carbonate or methyl amine). The decarboxylation in Method 6 is preferably performed thermally, after hydrolysis of the diester to the diacid, in a suitable inert solvent, e.g. quinoline, dirnethyl formamide, or N-methyl-2-pyrrolidinone (NMP) in the presence of copper.
Indol-3-yloxypropyl derivatives can also be obtained by heating a mixture of 3-acetoxyindoles and 1,3-propylene glycol in the presence of sulfuric acid, thereby obtaining 3-(indol-3-yloxy)-1-propanol derivatives which are converted to th.e s corresponding methanesulfonates or halides by Method 4.
Benzofuranes and 2,3-dihydrobenzofuranes of Formula II are prepared according to Schemes 4 and 5, in which Ra - Rd and E are as previously defined.
Ra Ra Rb ~ COOH Rb \ COOCH3 Method;
R~ ~ of ~ ~ o R
Rd Rd Ra Rb COOCH3 Method ' I \ ~ Method Rc / O J
Rd Ra Ra OH Rb ~ COOCH3 i Mew R~ O R~ / O~ COOCH3 Rd Rd Ra b Method 11 R ( \ ' COOH
-~ i R~ ~ of Rd Scheme 4 Method 7 is a conventional conversion to the methyl ester by treating the carboxylic acid with thionyl chloride followed by addition of methanol to the intermediate carboxylic acid chloride. The 2,3-dihydrobenzofuranes are obtained by reduction ~s with magnesium (Method 8) at this stage, while the benzofuranes are obtained by skipping this step. Method 9 consists of conversion of the alcohol group to the corresponding chloride by means of thionyl chloride followed by treatment with dimethyl malonate in a suitable solvent, e.g. NMP, in the presence of base, preferably potassium tert-butoxide. Method 11 is similar to Method 6 except the s decarboxylation is performed without addition of copper.
Ra Ra O
Rb \ COOH Rb \ E
: Method 12 ~ / :
Rc O ~ Rc 0 Rd Rd Method 2 Ra Ra Rb ~ \ ~ OH Rb ~ , CI
/ ~ Method 13 Rc ~ \O ~ Rc O
Rd Rd , Method 4 ~ Method 14 Ra Ra Rb Rb \ ~ ~ ~ V \ , v ~CN
Rc ~ ~0 Rc ~ _O
Rd Rd Method 15 Ra Ra b b _ R ~ E R ~ COOH
ll Mec c / O c /
R Rd R Rd Scheme 5 Method 12 consists of a conventional conversion of the carboxylic acid to the amide via the carboxylic acid chloride. Prolongation of the side chain is accomplished by conversion of the hydroxy group to the chloride by treatment with preferably thionyl y CA 02296897 2000-O1-13 chloride in dichloromethane in the presence of a few drops of dimethyl formamide (Method 13) followed by treatment with a cyanide salt, e.g. potassium cyanide, in a suitable aprotic dipolar solvent, preferably dimethyl sulfoxide, at 100 - 200 °C
(Method 14). Hydrolysis of the cyano group is accomplished with mineral acid.
at s elevated temperature (Method 15).
Benzo[b)thiophenes and 2,3-dihydrobenzo[b]thiophenes of Formula Il are prepared by methods analogous to the methods described in Schemes 4 and 5. Benzo[b]thio-phen-3-ylmethyloxyethyl derivatives are prepared from methyl benzo[b]thiophene-lo carboxylate by reduction to the methanol derivative with lithium aluminium hydride followed by alkylation with ethyl bromoacetate and subsequent reduction to benzo[b]thiophen-3-ylmethyloxyethanol derivatives which are converted to the target compounds via Method 4. Benzofuran-3-ylmethyloxyethy! derivatives are prepared analogously.
~s Benzo[b]thiophene-S,S-dioxide derivatives are obtained .by oxidation of the corres-ponding benzo[b]thiophene derivatives according to standard literature methods.
2,3-Dihydroindoles of Formula II are prepared by methods analogous to method d).
Indolones of Formula II are prepared by methods analogous to method e).
2o Indazoles of Formula II are prepared by methods analogous to method j).
Reductive alkylation of amines of Formula IV according to method c) is performed by standard literature procedures. The aldehydes , carboxylic acids, and ketones of formulas R»-CHO, R»-COOH, and R~2-CO-R~3, respectively, are either commer-2s cially available or are prepared according according to standard procedures or according to methods analogous to the methods described in Schemes i-5.
Reduction of the C=Y~ double bond according to method d) is conveniently per-formed by catalytic hydrogenation in an alcohol with a platinum catalyst or by so hydrogenation with diborane or a diborane precursor such as trimethyl amine or dimethyl sulfide complex in tetrahydrofuran or dioxane from 0 °C to reflux tempera-ture, followed by acid catalyzed hydrolysis of the intermediate borane derivative.
Alternatively, the double bond can be reduced by sodium borohydride in methanol in the presence of trifluoroacetic acid (see e.g. Berger et al J. Med. Chem.
1977, 20, 600).
Furthermore, the majority of the compounds listed in the specification, of which obviously only a few have actually been prepared, are tetrahydropyridyl compounds and/or they have an oxo substituent in the butyl chain. Only a few piperidyl com-pounds without an oxo substituent in the butyl chain are mentioned, i.e. 3-[4-(4-so phenyl-1-piperidyl)-butylj-indole and the 1-methyl-, 1-phenyl- and 2-methyl-derivatives thereof as well as derivatives thereof substituted with halogen, methyl or trifluoromethyl in the 4-phenyl substituent on the piperidyi group thereof.
With respect to physical data only melting point for one such compounds is given.
International Patent Application No WO 91 /09594 published on July 11, 1991 relates i.a. to sigma receptor ligands being 4-phenyl-piperidine compounds and having an optionally substituted "heteroaryl"-alkyl, -alkenyl, -alkynyl, -alkoxy or -alkoxy-alkyl substituent on the piperidine N-atom. The term "heteroaryl"-alkyl is s defined by mention of a very broad class of such substituents. However only four N-substituted, 4-phenyl-piperidine compounds are specifically disclosed which are all 1-(phenyl-lower alkyl)-4-phenyl-piperidines and only four compounds having a "heteroaryl"-alkyl substituent are specifically mentioned, which are all piperazine (and not piperidine) compounds.The compounds are stated to be antipsychotics.
From studies of the biology and function of sigma receptors, evidence has been presented that sigma receptor ligands may be useful in the treatment of psychosis and movement disorders, such as dystonia and tardive dyskinesia, and motor disturbances associated with Huntington's chorea or Tourette's syndrome and in 1s Parkinson's disease (Walker, J. M. et al, Pharmacological Reviews, 1990, 42, 355).
The known sigma receptor ligand rimcazole clinically shows effects in the treatment of psychosis (Snyder, S.H., Largent, B.L. J. Neuropsychiatry 1989, 1, 7) and a group of sigma receptor ligands have been descibed to show antihallucinogenic activity in animal models (International Patent Publication No WO 9103243).
Furthermore, sigma receptor ligands have been reported to be involved in modula-tion of NMDA receptor mediated events in the brain and to act as anti-ischemic agents in in vivo tests (Rao, T. S. et al, Molecular Pharmacology, 1990, 37, 978). In addition to ischemia they may also be useful in the treatment of other such NMDA
2s receptor mediated events, e.g. epilepsy and convulsion.
Also, some sigma receptor ligands have been found to show anti-amnesic effects in an animal model (Early et al., Brain Research 1991, 546, 281-286).
Sigma ligands have been shown to influence central acetylcholine levels in animal ao models (Matsuno et al, Brain Research 1992, 575, 315-319; Junien et al, Eur. J.
Pharm. 1991, 200, 343-345) and may, therefore, have potential in the treatment of senile dementia of the Alzheimer type.
Finally, some guanidine derivatives having sigma receptor activity have been disclosed to be useful as anxiolytics (International Patent Publication N° WO 9014067).
Accordingly, agents potently acting on the sigma receptors in the central nervous system are believed to be of potential use in the therapy of such conditions.
DETAILED DESCRIPTION OF THE INVENTION
As described and claimed in parent application N°
2,111,204, it has now been found that a certain class of piperidine compounds bind at sigma receptors with potencies which generally are 2-3 orders of magnitude higher than the potency limit indicated in European patent publication EP 0 414 289 A1. Furthermore the compounds of said class have been found to show anxiolytic effects in animal models.
Said class of compounds consists of compounds having the general Formula I
\N-R' R6 Z3 ~ I
Rs R4 wherein R1 is a) a group -D-B-A-R
wherein B is an up to 19 membered spacer group selected from alkylene, alkenylene and alkynylene which may be branched or straight chain and optionally substituted with hydroxy, which again may b~ esterified with an aliphatic carboxylic acid having from two to twentyfour carbon atoms, inclusive, 5a W
A is a bond or a divalent group selected from O, S, SO, S02, and _N~N- ' W being O or S and the dotted line designating an optional bond ;
R is alkyl, alkenyl, cycloalkyl, cycloalkenyl, phenyl, cycloalkylalkyl, cycloalkenyl-alkvl. ohenvlalkyl, diphenylalkyl, any alkylgroup optionally being substituted with one or two hydroxy groups, which again may be optionally esterified with an aliphatic carboxylic acid having from two to twentyfour carbon atoms inclusive, and any phenyl group being optionally substituted with one or more substituents in the phenyl ring; and .
s D is CReR9 where Re and R9 are independently selected from the substituents defined below for R4 - R~, or a cycloalkylene group; or b) a group having the general Formula II
Ra Rb ~. .G?2-~.U./
to II
Rc Rd wherein X is CHRIO, O, S, SO, S02 or NRIO, Rio being hydrogen, lower alkyl or alkenyl, cycloalkyl or cycloalkylalkyl, cycloalkenyl or cycloalkenylalkyl, acyl, aminoalkyl, mono- or dialkylaminoalkyl, sulfonyl or arylalkyl or phenyl optionally ~s substituted with one or more substituents independently selected from the following: halogen, lower alkyl, lower alkoxy, hydroxy, trifluoromethyl, and cyano, or Rio is a hetero aromatic group, preferably 2-thienyl, 3-thienyl, 2-furanyl, 3-furanyl, 2-thiazolyl, 2-oxazolyl, 2-imidazolyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl;
20 one or two of the dotted lines may be a bond;
when the dotted line emanating from Y indicates a bond, Y is N or CH; or when said dotted line indicates no bond, Y is CH2, NH, C=O or C=S;
Ra - Rd are independently selected from hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy, lower alkylthio, lower alkylsulphonyl, lower alkyl- or dialkyl-2s amino, cyano, trifluoromethyl, or trifluoromethylthio;
U is CH2, O or S; or when, one of the dotted lines emanating from U indicates a bond, U is CH;
the bond between U and Q~ or Q2, respectively, may also be a triple bond and in such case U is °C";
so Q~ is selected from a bond, alkylene or alkenylene and Q2 is alkylene having at least two C-atoms, alkenylene or a group Q2'D wherein G1~' is as defined for C~
and D is as defined above, Q~ and Q2 having together from 2 to 20 carbon atoms and being optionally substituted with one or more hydroxy groups, any such hydroxy group being optionally esterified with an aliphatic carboxylic acid having from two to twentyfour carbon atoms inclusive; and R2 and R3 are independently hydrogen, lower alkyl or they may be linked together thereby forming an ethylene or propylene bridge;
R4 to R~ are independently selected from hydrogen, halogen, lower alkyl , lower alkoxy, hydroxy, lower alkylthio, lower alkyl- or dialkylamino, cyano, trifluoromethyl, or trifluoromethylthio; and i) Z~ and Z2 are linked together in which case: Z~ is CH2, O or S;
Z2 and Z3 are independently (CH2)~, n being 0 or 1, O or S, with the proviso that Z~ may not be S or O when Z2 is S or O, and that Z2 and Z3 may not both be (CH2)~ wherein n is 0:
or Z~ and Z2 may together represent a group -CH=CH-;
or when Z3 is (CH2)r, wherein n is 0, Z~ and Z2 may together represent a 3-membered divalent group, optionally containing one unsaturated bond, and optionally containing one O- or S-heteroatom; or ii) when R~ is a group as defined in b) Z~ ,and Z2 may also be unlinked, in which case: Z~ is a group as defined for R4 - R~, ZZ is hydrogen and Z3 is (CH2)~
wherein n is 0;
with the proviso that when Z1 - Z3 are as defined in i) wherein Z3 is (CH2)~
where n is 0, and Z~ and Z2 together represent a 2- or 3-mernbered divalent hydrocarbon group, optionally containing one unsaturated bond, and R1 is a group defined in a) 3o then D-B-A-R may not be phenyl-C,~_3-alkyl, lower alkyl or lower alkenyl;
and acid addition salts or prodrugs thereof.
.. CA 02296897 2000-O1-13 7a The present invention as claimed hereinafter is restricted to the compounds of general formula (I) as defined hereinabove, wherein Z1 and Z~ are linked together ana wherein Rl is a group -D-B-A-R. The present invention provides the use of such piperidine compounds or acid addition salts or prodrugs thereof for the manufacture of a pharmaceutical preparation for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amne-sia, cerebrovascular diseases, senile dementia of the Alzheimer type or Parkinson's disease.
s Some of the compounds of the general Formula I may exist as optical isomers thereof; and such optical isomers are also embraced by the invention.
The term alkyl is intended to mean a C~-C2o straight chain or branched alkyl group and similarly alkenyl means a C2-CZO straight chain or branched alkenyl. group ~o having one or more unsaturated bonds in the chain. The term cycloalkyl designates a carbocyclic ring having 3-8 carbon atoms inclusive or a bicyclic or tricyclic carbocycle, such as adamantyl.
The terms lower alkyl, lower alkoxy, lower alkylthio, etc. designate such branched or ~s unbranched groups having from one to six carbon atoms inclusive. Exemplary of such groups are methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl, 2-methyl-1-propyl, methoxy, ethoxy,l-propoxy, 2-propoxy, methylthio, ethylthio, 1-propylthio, 2-propylthio, methylsulphonyl, ethylsulphonyl, or the like.
2o Halogen means fluoro, chloro, bromo or iodo.
The term "sulfonyl" is used in the meaning alkyl or aryl substituted sulfonyl, and similarly "acyl" is used in the meaning alkyl- or arylcarbonyl 25 The term "one or two of the dotted lines may be a bond" is intended to mean that each of the dotted lines may or may not represent a bond, i.e. that the ring and the side chain respectively may or may not have a double bond in the positions of the dotted lines in Formula II, provided that only two at a time indicate a bond and that adjacent dotted lines do not both indicate a bond.
The. optional substituents in the phenyl groups in the definition of R may indepen-dently be selected from halogen, lower alkyl, lower alkoxy, hydroxy, lower alkylthio, lower alkylsulphonyl, lower alkyl- or dialkylamino, cyano, trifluoromethyl, or trifluoro-methylthio. Each phenyl group may carry one or more substituents.
The acid addition salts of the invention are pharmaceutically acceptable salts of the compounds of Formula I formed with non-toxic acids. Exemplary of such organic s salts are those with malefic, fumaric, benzoic, ascorbic, embonic, succinic, oxalic, bis-methylenesalicylic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-amino-benzoic, glutamic, benzene sulfonic and theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromo-~o theophylline. Exemplary of such inorganic salts are those with hydrochloric, hydro-bromic, sulfuric, sulfamic, phosphoric and nitric acids.
The movement disorders and motor disturbances which may be treated by the preparation according to the invention are e.g. dystonia and tardive dyskinesia and motor disturbances associated with Huntington's chorea or Tourette's syndrome.
Dystonia may be acute or tardive and may be caused by neuroleptics or have another reason.
Cerebrovascular diseases are such disorders caused by cerebral infarction, 2o cerebral hemorrhage, cerebral arteriosclerosis, subarachnoid hemorrhage, cerebral thrombosis, cerebral embolism, or the like, e.g. ischemia, hypoxia, anoxia.
The compounds of the invention have been found to displace tritiated di-tolyl guanidine (DTG) from sigma sites in vitro with potencies better than about 40 nM, 25 and the great majority better than 1 nM, i.e. they are binding at the sigma receptors much more potently than sigma receptor ligands such as e.g. BMY 14802 and rimcazole. Furthermore, most of the present compounds have proven to be very selective iigands on the sigma receptors. For example as compared to the aj adrenoceptors and dopamine DZ receptors, the main part of the present compounds so have been found to show ratios of binding affinities (ICSO alpha/sigma and dopami-ne/sigma, respectively) of 30-10000. Furthermore, the compounds have proven to show very potent anxiolytic effects in an animal behaviour test in extremely low doses i.e. with ECSO values in the ng - p.g/kg range.
When Z~ and Z2 are linked together, preferably at least one of Z~, Z2 and Z3 designates O or S, and more preferably Z3 is (CH2)~ wherein n is 0, and Z2 is "O" or "S" and Z is CH2 or Z~ and ZZ together represent CH2-0-CI-~. Other preferred groups are those wherein Z1 is CH2, Z2 is O and Z3 is CHz; or Z3 is O and Z~-Z2~is s CH=CH; or Z~ is O, Z3 is O and Z2 is (CH2)~ where n =0, Particularly proffered compounds are:
1'-(3-Adamantyloxy-1-propyi)spiro[3H 2-benzopyran-3,4'-piperidine];
l0 1'-[4-(1-Benzyl-3-indolyl)-1-butyl]-spiro[isobenzofuran-1 (3H),4'-piperidine];
1'-(3-(3-Phenylimidazolidin-2-on-1-yl)-1-propyl)spiro[isobenzofuran-1 (3H),4'-piperidinej;
1'-[4-[1-(4-Fluorophenyl)-3-indolyl)-1-butyl]-spiro[isobenzofuran-1 (3H),4'-piperidine];
1,4-Dihydro-1'-[4-[1-(4-Fluorophenyl)-3-indolyl]-1-butyl]spiro[3H-2-benzopyran-3,4'-piperidine);
1'-(4-(1-p-Toluenesulfonyl-3-indolyl)-1-butyl)spiro[isobenzofuran-1 (3H),4'-piperidine];
1'-[4-[5-Fluoro-1-(4-fluorophenyl)-3-indolylj-1-butyl]spirojisobenzofuran-1 (3H),4'-piperidine];
6-Fluoro-1'-[4-[1-(4-fluoropheriyl)-3-indolyl]-1-butyl]spiro[isobenzofuran-1 (3H),4'-2o piperidine];
1'-[4-[1-(4-Methylphenyl)-3-indolyl]-1-butyljspiro(1 H-2-benzopyran-4(3H),4'-piperidine];
1-(4-Fluorophenyl)-3-[4-(4-(4-fluorophenyl)-1-piperidyl)-1-butyl]indole;
1'-[4-(1-(2-Thiazolyl)-3-indolyl)-1-butyl]spiro[isobenzofuran-1 (3H),4'-piperidine];
2s 1'-[3-(5-Fluorobenzofuran-3-yl)-1-propyl]spiro[isobenzofuran-1 (3H),4'-piperidine];
1'-[4-(5-Fluorobenzofuran-3-yl)-1-butyl]-spiro[isobenzofuran-1 (3H),4'-piperidine];
1'-[4-[1-(4-Fluorophenyl)-5-trifluoromethylindazol-3-ylj-1-butyl]spiro[isobenzofuran-1 (3H),4'-piperidinej;
4-Fluorophenyl-3-[4-(4-(4-fluorophenyl)-1-piperidinyl)-1-butyl]-5-trifluoromethyl-ao indazol;
1'-(4-(1,2-Benzisoxazol-3-yl)-1-butyl)spiro[isobenzofuran-1 (3f-~,4'-piperidine]; and 1'-[3-(Benzo[bjthiophen-3-ylthio)-1-propyljspiro[isobenzofuran-1 (3H),4'-piperidine].
Some of the compounds used in accordance with the invention are novel, and accor-dingly in another aspect the present invention relates to novel piperidine derivatives having the general Formula I as defined above with the proviso that if R1 is a group of the Formula II as defined above under b), Z1, Z2, and Z3 are .as defined above under ii), X is NH, Y is CH and the dotted line emanating from Y
indicates a bond, then -Q1-U-C~- may not be alkyl having less than 5 carbon atoms; , if R~ is a group of the Formula 11 as defined above wherein Z3 is O, Z~ is CH2, Z2 is (CH2)", n being 0, X is O, Y is N, the dotted line emanating from Y indicates a 1o bond, and -Q1-U-C~- indicates -(CHZ)3, then R~ may not be fluoro;
if Z3 is O, Z2 and Z1 are both CH2 and D-B-A-R is optionally substituted phenethyl, then R6 may not be methoxy; and if Z~ is O, and Z2 and Z3 are both CH2, then D-B-A-R may not be phenethyl, or optionally hydroxy substituted hexyl or heptyl.
The present invention also provides a pharmaceutical composition comprising at least one novel piperidine compound according to the invention.as defined above or a pharmaceutically acceptable acid addition salt thereof or prodrug therefore in combination with one or more pharmaceutically acceptable carriers or diluents.
The pharmaceutical compositions of this invention or those which are manufactured in accordance with this invention may be administered by any suitable route, for example orally in the form of tablets, capsules, powders, syrups, etc., or parenteral-ly in the form of solutions for injection. For preparing such compositions methods well known in the art may be used, and any pharmaceutically acceptable carriers, diluents, exipients, or other additive usually used in in the art may be used.
Conveniently, the compounds of the invention are administered in unit dosage form containing said compound in an amount of about 0.01 to 50 mg.
The total daily dose usually ranges of about 0.05 - 100 mg, and most preferably about 0.1 to 20 mg of the active compound of the invention.
The compounds of Formula 1 may be prepared by:
a) reducing the amide carbonyl of a compound of Formula III
R Z~ ZZ
N
Rs ~ ~ Za R»
Rs R4 III
wherein R2 - R~ and Z~ - Z3 are as previously defined and R> > is such a group that CH2-R» is a group comprised by the definition of R~;
b) alkylating a compound of Formula IV
~o R Z' Z2 Rs / \ Z3 NH
R3 , Rs R4 wherein R2 - R~ and Z1 - Z3 are as previously defined, with an alkylating reagent of the formula R~-V wherein R~ is as previously defined and V is a suitable leaving group such as halogen, mesylate or tosylate;
c) reductive alkylation of amines of Formula IV with aldehydes of the formula R> >-CHO or carboxylic acids of the formula R»-COOH or ketones of the formula R~2-CO-R~3 wherein R2-R~, R», and Z~-Z3 are as previously defined and R~2 and R~3 zo are such groups that R~z-CH-R~3 is a group comprised by the definition of R~;
d) reducing the C=Y~ double bond in a compound of Formula V
R Z' Z2 Ra Rs ~ ~ Z3 N ~2\ U'O' ~ Rb _ R3 Y' Rs Re X Rc V
Rd s wherein Ra-Rd, X, U, Q~, C~, R2-R7, and Z1-Z3 are as previously defined and Y~
is CH or N;
e) oxidizing a compound of Formula VI to an oxo compound of Formula VII:
R Z' Z2 Ra Rs ~ ~ Z3 'N ~1 U ~~' ~ Rb R3 ~ \
X Rc RS R4 Rd VI
R Z1 ZZ Ra v Rs ~ ~ Zs N ~2\ U ~4' ~ Rb R3 \
R5 R4 O X Rc Rd VII
wherein Ra-Rd, X, U, Q~, Q2, R2-R~, and Z~-Z3 are as previously defined;
io f) alkylating a compound of Formula VIII for obtaining a compound of general Formula I wherein X = NR~o; Rio' being lower alkyl, alkenyl, cycloalkyl, cycloafkyl-alkyl, cycloalkenyl or cycloaikenylalkyl, R Z' Z2 Ra Rs ~ ~ Z3 N ~Z~U~ ~~ , ~ Rb Rs 't~ \
Rs R4 H R° V II I __ Rd 1s wherein Ra-Rd, Y, U, Q~, Q2, R2-R~, and Z1-Z3 are as previously defined, with an alkylating reagent of the formula Rio=V~, wherein R~o'is as previously defined and V~ is a suitable leaving group, e.g. halogen, mesylate, or tosylate; or acylating a compound of the Formula VIII with an acylating reagent having the formula R~o'=CO-2o Hal, wherein Hal is halogen and Rio" is a group which together with CH2 form the group Rio', and subsequently reducing the acylated compound of Formula Vlll;
g) arylating a compound of Formula VIII for obtaining a compound of general Formula 1 wherein X = NRIO'", R1o"' being optionally substituted phenyl or heteroaryl, with an arylating agent of the formula Ar-V1 wherein Ar is optionally substituted phenyl or heteroaryl and V1 is as previously defined;
s h) for obtaining a compound of general Formula I wherein X = N-CO-R1o' or N-CO-Ar, wherein R1o' and Ar are as previously defined, acylating a compound of Formula VIII with an acylating agent of the formula R1o'-CO-Hal or Ar-CO-Hal. wherein Hal is as previously defined;
i) for obtaining a compound of general Formula I wherein X = N-S02-R1o' or N-Ar, wherein R1o' and Ar are as previously defined, sulfonylating a compound of Formula VIII with a sulfonylating agent of the formula R1o'-S02-Hal or Ar-S02-Hal, wherein Hal is as previously defined;
j) reductive alkylation of compounds of Formula VIII with carbonyl compounds of formula R14-CO-R15 wherein R14 and R~5 are such groups that R~4--CH-R~5 is a group R1o as previously defined;
2o k) making a ring closure reaction of the hydrazone IX to the indazole derivative X
RZ R~°-NH
Ra R Z~ ZZ
~N-~~. ~Q' / R
Rs / \ Z3 U ~ b~.
R3 Hal Rc Rs R4 Rd IX
R 2~ Z2 Ra Rs / ~ Za N ~z~ U'~, ~ Rb I
Rs N' \
Rs R4 Rio d Rc X
R
wherein Ra-Rd, U, Q1, Q2, RZ-R~. Rlo, and Z1-Z3 are as previously defined and Hal 2s is halogen;
1) reducing the quarternized pyridine derivative of Formula XI
R Z' R2 Rs ~ ~ ~ ~N R' RS R4 'Rs s in which R~-R~. Z~ and V~ are as previously defined;
whereupon the compound of Formula I is isolated as the free base or a pharmaceuti-cally acceptable acid addition salt thereof.
~o The reduction according to method a) may preferably be carried out in an inert organic solvent such as diethyl ether or tetrahydrofuran in the presence of lithium aluminium hydride at reflux temperature.
The amides of Formula III are conveniently prepared by treating piperidine deriva-ls tives of Formula IV with suitable carboxylic. acid chlorides of formula R»-COCI in the presence of base (potassium carbonate or triethylamine). When R»-CH2 designates a group of formula -D-B-A-R the corresponding carboxylic acid chlorides of formula R> >-COCI are either commercially available or prepared according to standard procedures.
When R~ 1-CH2 designates a group of Formula II the corresponding carboxylic acid chlorides of Formula XII, Ra CI ~ C12;' ~~C~', / Rb ,. U , Yw X ~ Fic Rd X~~
wherein Ra-Rd, X, Y, U, and Q~ are as previously defined and Q2' is such a group that Q2-CH2 is a group Q2 as previously defined, are prepared from the correspond-ing carboxylic acids by known methods.
The piperidine derivatives of Formula IV where Z~ and Z2 are linked together, are prepared as follows:
Spiro[isobenzofuran-1 (3H),4'-piperidine] according to the method described.
by s Marxer et al, J. Org. Chem. 1975, 40, 1427.
2,3-Dihydro-spiro[1 H-indene-1,4'-piperidine] and 3,4-dihydro-spiro[naphtalene-1 (2H) ,4'-piperidine] according to the method described in French Patent. No.
1,335,831.
l0 1'-Methyl-spiro[benzo[c]thiophene-1 (3H),4'-piperidine) according to the method described by Parham et al, J. Org. Chem. 1976, 41, 2628. The corresponding demethylated derivative was obtained by treatment with ethyl chloroformate followed by alkaline hydrolysis of the intermediary ethyl carbamate.
15 1'-Phenylmethyl-spiro[1 H-2-benzopyran-4(3H),4'-piperidine] according to the method described by Yamamoto et al, J. Med. Chem., 1981, 24, 194. The corres-ponding debenzylated derivative is obtained by hydrogenation in the presence of a palladium catalyst.
20 3,4-Dihydro-1'-phenylmethyl-spiro[2H-1-benzopyran-2,4'-piperidine]
according to the method described by Yamamoto et al, Chem. Pharm. Bull. 1981, 29, 3494. The cor-responding debenzylated derivative is obtained by treatment with ethyl chloro-formate followed by alkaline hydrolysis of the intermediary ethyl carbamate.
z5 1'-Phenylmethyl-spiro[2H-1-benzopyran-2,4'-piperidine] is obtained according to the method described by Yamamoto et al, Chem. Pharm. Bull. 1981, 29, 3494. The cor-responding debenzylated derivative is obtained by hydrogenation in the presence of a palladium catalyst.
so 1'-Phenyimethyl-spiro[3H-2-benzopyran-3,4'-piperidineJ-1 (4H)-one according to the method described by Yamamoto et a!, J. Med. Chem. 1981, 24, 194. Reduction with lithium aluminium hydride followed by treatment with phosphoric acid according to the procedure described by Marxer et al, J. Org. Chem. 1975, 40, 1427 yields 1,4-dihydro-1'-phenylmethyl-spiro[3H-2-benzopyran-3,4'-piperidine] which is debenzyl-ated by hydrogenation in the presence of a palladium catalyst.
1'-Benzylspiro[4H-1-benzopyran-4,4'-piperidine] is obtained by a method analogous-s ly to the method described in EP 0 414 289 A1 for the synthesis of 1'-benzyl-1,4-dihydrospiro[naphtalene-1,4'-piperidine]. Hydrogenation in the presence of a palladium catalyst gave 2,3-dihydrospiro[4N-1-benzopyran-4,4'-piperidine].
Spiro[1,3-benzodioxole-2,4'-piperidine] is obtained by refluxing 1-ethoxycarbonyl-4-io piperidinone and catechol in toluene solution in the presence of p-toluenesulfonic acid with continous removal of water followed by removal of the benzyl group by hydrogenation in the presence of a palladium catalyst.
The substituents R2-R~ are introduced by applying suitably substituted starting com-~s pounds to methods analogously to the above mentioned.
The piperidine derivatives of Formula IV where Z~ and Z2 are not linked are prepared by known methods, see e.g. US Pat. No. 2,891,066; McElvain et al J.
Amer. Chem. Soc.1950, 72, 3134; Bally et al Chem.Ber.1887, 20, 2590.
Alkylation of a compound of Formula IV according to method b) is conveniently performed in an inert organic solvent such as a suitably boiling alcohol or ketone, preferably in the presence of a base (potassium carbonate or methyl amine) at reflux temperature.
The alkylating reagents of formula R~-V where R~ designates -D-B-A-R wherein A
is O, S, or a bond and D, B, and R are as previously defined, are prepared by standard literature methods. The corresponding sulfoxides and sulfones are obtained by oxidation of the sulfides according to methods well known in the art.
W
Such alkylating agents in which A represents a group ~N~N~ wherein W is O
or S are prepared by the method disclosed in DE-OS No 2035370.
The preparations of alkylating reagents of formula R~-V where Rt designates a s group having the general Formula II are illustrated by examples in the following reaction schemes. In the formulas of the reaction schemes Ra-Rd, V and Ar are as previously defined, and E designates a t-piperidyl group of general Formula IV.
Indenes of Formula II are conveniently prepared according to Scheme 1, in~
which Ra - F~ and V are as previously defined.
to Ra Rb O
Br / Method 1i Rc / O
Rd Ra Ra R OH O Rb OH
b \ OCH3 Method 2~. I \ OH
% /
Rc Rc Rd Rd Ra Rb ~ OH
Method 3- ~ I , Method 4_ Rc Rd Ra .
Rb ~ V
Rc ~' Rd Scheme 1 Method 1 is a conventional Reformatsky condensation performed with activated zinc. Method 2 consists of a lithium aluminium hydride reduction performed in an inert organic solvent such as diethyl ether or tetrahydrofuran at reflux temperature.
The elimination in Method 3 is preferably performed in a suitable alcohol, e.g.
methanol, in the presence of a strong mineral acid, e.g. concentrated hydrochloric acid. Preferably, Method 4 is treatment with methanesulfonyl chloride in the presence of methyl amine in dichloromethane, thus giving the corresponding ~o methanesulfonate, but may alternatively be conversion of the hydroxy group to a halogen by means of a suitable reagent, e.g. thionyl choride.
Indanes of Formula II are prepared according to Scheme 2, in which Ra - Rd and V
are as previously defined.
Ra Rb \ O
/ + B~ ~ Method 1 a Rc O
Rd Ra Ra Rb ( \ I / OCH3 Rb \ / / OCH3 / p Rc ~ -,~ Rc ~ ... .
Rd Rd Method 2 Ra Ra Rb \ \ OH Rb \ / OH
/ ~ _ _ Rc Rc Rd Rd Ra Method 4 R° \ OH
+ ~ /
Rc Ra R
Rb V Method 5 \ \~/ ~/ Ra Rc / Rb \ OH
Rd ~ /
R°
Rd Method 4 Ra ~
Rb \' V
/
Rc Rd Scheme 2 Method 1 a is analogous to Method 1 with the modification that elimination of water is performed directly on the crude product by means of concentrated hydrochloric acid. The mixture of isomers obtained is reduced according to Method 2. One of the isomers obtained is isolated while the remaining mixture is hydrogenated in a conventional Parr apparatus (Method 5) in the presence of a suitable noble metal catalyst, e.g. palladium or platinum.
s Indoles of Formula II are most conveniently prepared either from indole alkanoic acid, exemplified by indole butanoic acid as described in Eur. Pat. Appl. No.
376607, or according to Scheme 3, in which Ra - Rd, Ar and V are as previously defined.
Ra Ra O
Rb O Rb O~~
/
Method S ~ " OEt R~ ~ N COOCH3 R~ ~ ~N COOCH3 Rd Ar Rd Ar Ra O
b R ~ O~OEt Method 6 --... Rc N
Rd Ar Ra . Ra b b R I ~ I OOH R ~ ~ I O~ V
Rc / N J Method 4 Rc / N J
Rd Ar Rd Ar 1 o Scheme 3 The starting indoxyl ester is prepared by the method described in US Pat. No.
4,710,500 and references therein. The alkylation in Method 5 is performed in an inert, suitably boiling, organic solvent, e.g. an alcohol or a ketone, preferably in the presence of a base (potassium carbonate or methyl amine). The decarboxylation in Method 6 is preferably performed thermally, after hydrolysis of the diester to the diacid, in a suitable inert solvent, e.g. quinoline, dirnethyl formamide, or N-methyl-2-pyrrolidinone (NMP) in the presence of copper.
Indol-3-yloxypropyl derivatives can also be obtained by heating a mixture of 3-acetoxyindoles and 1,3-propylene glycol in the presence of sulfuric acid, thereby obtaining 3-(indol-3-yloxy)-1-propanol derivatives which are converted to th.e s corresponding methanesulfonates or halides by Method 4.
Benzofuranes and 2,3-dihydrobenzofuranes of Formula II are prepared according to Schemes 4 and 5, in which Ra - Rd and E are as previously defined.
Ra Ra Rb ~ COOH Rb \ COOCH3 Method;
R~ ~ of ~ ~ o R
Rd Rd Ra Rb COOCH3 Method ' I \ ~ Method Rc / O J
Rd Ra Ra OH Rb ~ COOCH3 i Mew R~ O R~ / O~ COOCH3 Rd Rd Ra b Method 11 R ( \ ' COOH
-~ i R~ ~ of Rd Scheme 4 Method 7 is a conventional conversion to the methyl ester by treating the carboxylic acid with thionyl chloride followed by addition of methanol to the intermediate carboxylic acid chloride. The 2,3-dihydrobenzofuranes are obtained by reduction ~s with magnesium (Method 8) at this stage, while the benzofuranes are obtained by skipping this step. Method 9 consists of conversion of the alcohol group to the corresponding chloride by means of thionyl chloride followed by treatment with dimethyl malonate in a suitable solvent, e.g. NMP, in the presence of base, preferably potassium tert-butoxide. Method 11 is similar to Method 6 except the s decarboxylation is performed without addition of copper.
Ra Ra O
Rb \ COOH Rb \ E
: Method 12 ~ / :
Rc O ~ Rc 0 Rd Rd Method 2 Ra Ra Rb ~ \ ~ OH Rb ~ , CI
/ ~ Method 13 Rc ~ \O ~ Rc O
Rd Rd , Method 4 ~ Method 14 Ra Ra Rb Rb \ ~ ~ ~ V \ , v ~CN
Rc ~ ~0 Rc ~ _O
Rd Rd Method 15 Ra Ra b b _ R ~ E R ~ COOH
ll Mec c / O c /
R Rd R Rd Scheme 5 Method 12 consists of a conventional conversion of the carboxylic acid to the amide via the carboxylic acid chloride. Prolongation of the side chain is accomplished by conversion of the hydroxy group to the chloride by treatment with preferably thionyl y CA 02296897 2000-O1-13 chloride in dichloromethane in the presence of a few drops of dimethyl formamide (Method 13) followed by treatment with a cyanide salt, e.g. potassium cyanide, in a suitable aprotic dipolar solvent, preferably dimethyl sulfoxide, at 100 - 200 °C
(Method 14). Hydrolysis of the cyano group is accomplished with mineral acid.
at s elevated temperature (Method 15).
Benzo[b)thiophenes and 2,3-dihydrobenzo[b]thiophenes of Formula Il are prepared by methods analogous to the methods described in Schemes 4 and 5. Benzo[b]thio-phen-3-ylmethyloxyethyl derivatives are prepared from methyl benzo[b]thiophene-lo carboxylate by reduction to the methanol derivative with lithium aluminium hydride followed by alkylation with ethyl bromoacetate and subsequent reduction to benzo[b]thiophen-3-ylmethyloxyethanol derivatives which are converted to the target compounds via Method 4. Benzofuran-3-ylmethyloxyethy! derivatives are prepared analogously.
~s Benzo[b]thiophene-S,S-dioxide derivatives are obtained .by oxidation of the corres-ponding benzo[b]thiophene derivatives according to standard literature methods.
2,3-Dihydroindoles of Formula II are prepared by methods analogous to method d).
Indolones of Formula II are prepared by methods analogous to method e).
2o Indazoles of Formula II are prepared by methods analogous to method j).
Reductive alkylation of amines of Formula IV according to method c) is performed by standard literature procedures. The aldehydes , carboxylic acids, and ketones of formulas R»-CHO, R»-COOH, and R~2-CO-R~3, respectively, are either commer-2s cially available or are prepared according according to standard procedures or according to methods analogous to the methods described in Schemes i-5.
Reduction of the C=Y~ double bond according to method d) is conveniently per-formed by catalytic hydrogenation in an alcohol with a platinum catalyst or by so hydrogenation with diborane or a diborane precursor such as trimethyl amine or dimethyl sulfide complex in tetrahydrofuran or dioxane from 0 °C to reflux tempera-ture, followed by acid catalyzed hydrolysis of the intermediate borane derivative.
Alternatively, the double bond can be reduced by sodium borohydride in methanol in the presence of trifluoroacetic acid (see e.g. Berger et al J. Med. Chem.
1977, 20, 600).
5 Oxidation of a compound of Formula VI according to method d) is performed according to Szabo-Pustay et al., Synthesis , 1979, 276.
Alkylation, acylation or sulfonylation of compounds of Formula VIII according to methods f), h) and i), respectively, are performed in an inert solvent such as a ~o suitably boiling alcohol or ketone, preferably in the presence of a base (potassium carbonate or triethyl amine). The alkylating reagents Rio'-V~, the acylating reagents Rio"-CO-V~, Rio'-CO-V~, and Ar-CO-V~, and the sulfonylation reagents Rio'-S02-V~, and Ar-S02-V~ respectively, are commercially available or are prepared by standard procedures.
Arylation of a compound of Formula VIII according to method g) is most convenient-ly performed by applying the well known Ullmann reaction. The arylating reagents Ar-V~ are commercially available.
2o Reductive alkylation of compounds of Formula VIII according to method j) are performed by standard literature methods.
The ring closure of compounds of Formula IX according to method k) is most conveniently performed by heating a compound of Formula IX in a suitable inert 2s organic solvent such as dimethyl formamide in the presence of a base, preferably potassium tert-butoxide.
Hydrazones of Formula IX are prepared according to Scheme 6, in which Ra-F~, Rio and Hal are as previously defined.
Ra Ra O
b b R ~ ~ CN Method 16 R ~ ~ OH
Rc / Hal ~ Rc / Hal Rd Rd Meihod 18 Method 17 Ra Rz a ,NHR~o Rb O Z2 Z' R~ b R N
\ (CH2~a-N R \
v v 'OH
Za ~ ~ Rs ( /
Rc / Hal Rs Rc Hal Rd R< Rs Rd Method 17 Ra ~NHR~o Rz Rb N Zz Zi R7 Rs (CHz>4 N
Rc Hal Rs Rd Re Rs Scheme 6 Method 16 is an addition of the Grignard reagent of 4-chloro-1-butanol to o-halo-benzonitriles under standard conditions for Grignard reactions. Conversion to the s hydrazone (Method 17) is accomplished by reflux in ethanol in the presence of a hydrazine. Alternatively, the hydroxy derivative resulting from Method l6.may be converted to the amine via the corresponding mesylate analogous to Method 4 and a) before conversion of the keto group.
1o The reduction according to method I) is most conveniently performed by catalytic hydrogenation in an alcohol with a platinum catalyst. Compounds of Formulas V, VI, and VIII are prepared by methods a), b), j), k), or I). Compounds of Formula XI are prepared by treating a compound of formula R1-Vt with a 4-aryl-pyridine in a suitably boiling alcohol.
In the following the invention is further illustrated by examples which, however, may not be construed as limiting:
s 1'-Butylspiro[isobenzofuran-1(3H),4'-piperidineJ, oxalate, 1a.
A mixture of spiro(isobenzofuran-1 (3H),4'-piperidine] (2 g), n-butyl bromide (4 g), potassium carbonate (5 g), and potassium iodide (0.2 g) in 100 ml of 4-methyl-~o pentanone was refluxed for 16 h. After cooling the reaction mixture was washed with 100 ml of water and concentrated in vacuo. The title compound crystallized as the oxalate salt from acetone by addition of oxalic acid. Recrystallized from an ethanol/ether mixture. Yield: 1.2 g, mp: 171-73 °C. -~s In a similar manner was also prepared:
1'-Pentylspiro[isobenzofuran-1 (3H),4'-piperidine], oxalate, 1 b, mp: 170-72 °C.
Zo 1'-(4-Phenyl-1-butyl)spiro[isobenzofuran-1 (3H),4'-piperidine], fumarate, 2a To an ice cooled solution of 4-phenyl-1-butanol (20 g) and triethyl amine (15 g) in 200 ml of dichloromethane, a solution of methanesulfonyl chloride (12 ml) in 50 ml of dichloromethane was added dropwise. After stirring for 1 h at 10 °C
the reaction 2s mixture was washed with water. Extraction of the water phase with dichloro-methane, drying of the combined organic phases over MgSO 4 followed by removal of the volatile components in vacuo, gave 29 g of a slightly yellow oil, 4-phenyl-1-butyl methanesulfonate, which was sufficiently pure for use in the next step.
A mixture of spiro(isobenzofuran-1 (3H),4'-piperidine] (2 g), 4-phenyl-1-butyl so methanesulfonate (6 g) and potassium carbonate (14 g) in 75 ml of 4-methyl-pentanone was refluxed for 20 h. After cooling the reaction mixture was filtered and concentrated in vacuo. The remaining viscous oil was applied to a silica gel column (eluent: ether/methanol/triethyl amine = 93:5:2) giving a colorless oil which crystal-lized as the fumarate salt, 2a, from acetone by addition of fumaric acid.
Yield: 0.7 g, mp: 197-99 °C.
In a similar manner were also prepared:
s 1'-(4-Cyclohexyl-1-butyl)spiro[isobenzofuran-1(3l-r7,4'-piperidinej, oxalate, 2b, mp:
139-42 °C.
2,3-Dihydro-1'-(4-phenyl-1-butyl)spiro[1H-indene-1,4'-piperidineJ, fumarate, 2c, mp:
207-11 °C.
1'-(4-Phenyl-1-butyl)spiro[benzo[cJthiophene-1 (31,4'-piperidineJ, maleate, 2d, mp:
~ 0 176-77 °C.
3,4-Dihydro-1'-(4-phenyl-1-butyl)spiro[naphtalene-1 (2H),4'-piperidineJ, fumarate, 2e, mp: 191-93 °C.
1'-(4-Phenyl-1-butyl)spiro[1 H-2-benzopyran-4(3H),4'-piperidinej, maleate, 2f, mp:
169-70 °C.
~s 1,4-Dihydro-1'-(4-phenyl-1-butyl)spiro[3H-2-benzopyran-3,4'-piperidineJ, maleate, 2g, rtip: 152-53 °C.
3,4-Dihydro-1'-(4-phenyl-1-butyl)spiro[2H-1-benzopyran-2,4'-piperidineJ, oxalate, 2h, mp: 155-57 °C.
1'-(4-Phenyl-1-butyl)spiro[2H 1-benzopyran-2,4'-piperidineJ, fumarate, 2i, mp:
20 85 °C.
1'-(3-Cyclohexyloxy-1-propyl)spiro[isobenzofuran-1(3H),4'-piperidinej, fumarate, 2j, mp: 154-55 °C.
1'-(3-Phenoxy-1-propyl)spiro[isobenzofuran-1 (3H),4'-piperidine], 2k, mp: 143-44 °C.
1'-(3-Phenoxy-1-propyl)spiro[3H-2-benzopyran-3,4'-piperidine], maleate, 21, mp:
2s 171-73 °C.
1'-(3-Adamantyloxy-1-propyl)spiro[3H-2-benzopyran-3,4'-piperidineJ, maleate,-2m, mp: 221-24 °C.
1'-(3-Methylthio-1-propyl)spiro[isobenzofuran-1 (3H),4'-piperidineJ, oxalate, 2n, mp:
126-27 °.
ao 1'-(3-Cyclohexylthio-1-propyl)spiro[isobenzofuran-1 (3H),4'-piperidine], oxalate, 20, mp: 170-74 °C.
1'-(3-Phenylthio-1-propyl)spiro[isobenzofuran-1 (3H),4'-piperidine), oxalate,2p, 152-55 °C.
.. CA 02296897 2000-O1-13 1'-(3-Methylsulfonyl-1-propyl)spiro[isobenzofuran-1 (3H),4'-piperidineJ, 2q, mp: 163-64 °C.
. 1'-(3-Cyclohexylsulfonyl-1-propyl)spiro[isobenzofuran-1 (3l-f),4'-piperidineJ, 2r, mp:
118-20 °C.
s 1'-(3-Phenylsulfonyl-1-propyl)spiro[isobenzofuran-1 (3f~,4'-piperidine]., 2s, mp: 197-202 °C.
8'-(4-Phenyl-1-butyl)spiro[isobenzofuran-1 (3H),3'-8-azabicyclo[3,2,1 ]octane], maleate, 2t, mp: 180-81 °C.
1'-[4-(3-Indolyl)-1-butyl]-spiro[isobenzofuran-1(3H),4'-piperidine], 2u, mp:
150=55 °C.
l0 1'-[4-(3-Indolyl)-1-butyl)-spiro[1 H-2-benzopyran-4(3H),4'-piperidine], oxalate, 2v, . mp: 222-25 °C.
1'-[5-(3-Indolyl)-1-pentyl]-spiro[1 H-2-benzopyran-4(3H),4'-piperidine], oxalate, 2x, mp: 145-46 °C. , 1'-[6-(3-Indolyl)-1-hexyl]-spiro[1 H 2-benzopyran-4(3H),4'-piperidineJ, oxalate, 2y, is mp: 117-18 °C.
.1'-[4-(5,6-Dichloro-3-indolyl)-1-butyl]-spiro[isobenzofuran; 1(3H),4'-piperidine], 2z, mp: 122-23 °C.
1'-(4-(5-Fluoro-3-indolyl)-1-butyl]-spiro[isobenzofuran-1 (3H),4'-piperidine], 2aa, mp:
185-87 °C.
20 1'-(4-(1-Methyl-3-indolyl)-1-butyl]-spiro(isobenzofuran-1 (3H),4'-piperidine], 2bb, mp:
101-2 °C.
3-(4-(4-Phenyl-1-piperidyl)-1-butyl]indole, 2cc, mp: 131-32 °C.
3-(4-(4-(3,4-Dichlorophenyl)-1-piperidyl)-1-butyl]indole, 2dd, mp: 118-19 °C.
5,6-Dichloro-3-[4-(4-(4-fluorophenyl)-1-piperidyl)-1-butyl]-indole, Zee, mp:
120-21 °C.
2s 3-[6-(4-(4-Fluorophenyl)-1-piperidinyl)-1-hexyl]indole, 2ff, mp: 90-91 ~°C.
3-(4-(4-(2-Methoxyphenyl)-1-piperidinyl)-1-butyl]indol, oxalate, 2gg, mp: 183-88 °C.
1'-[4-(1-Benzyl-3-indolyl)-1-butyl]-spiro[isobenzofuran-1 (3H),4'-piperidine], 2hh, mp:
166-68 °C.
3-[4-(4-(4-Fluorophenyl)-1-piperidyl)-1-butyl]indol-2-one, 2ii, mp: 108-10 °C.
30 6-Fluoro-1'-(4-(3-indolyl)-1-butyl)spiro[isobenzofuran-1 (3H),4'-piperidineJ, 2jj, mp:
189-91 °C.
~XAMPLE~
1'-(4-(3-Cyclohexylimidazolidin-2-on-1-yl)-1-butyl)spiro(isobenzofuran-1 (3f-~,4'-piperidineJ, hydrochloride, 3a.
A mixture of 1-cyclohexyl-3-(4-chloro-1-butyl)-2-imidazolidinon (2.0 g, prepared according to the method described in Ger. Offen. 2035370), spiro[isobenzofuran-1 (3!-x,4'-piperidine] (1.5 g), potassium carbonate (4.4 g), and potassium iodide (0.1 g) in 60 ml of methyl isobutyl ketone was refluxed for 17 h. After cooling to room 1o temperature the mixture was filtered and the solvent removed in vacuo. The remaining oil was purified by column chromatography (silica gel, eluent: ethyl acetate/heptane/triethyl amine = 9:1:1 ). The title compound crystallized as the hydrochloride from an acetone/ether mixture by addition of en etheral solution of HCI. Yield: 1.9 g, mp: 203-7 °C.
In a similar manner were also prepared:
1'-(2-(3-Phenylimidazolidin-2-on-1-yl)-1-ethyl)spiro[isobenzofuran-1 (31~,4'-piperidine], hydrochloride, 3b, mp: 151-54 °C.
1'-(3-(3-Phenylimidazolidin-2-on-1-yl)-1-propyl)spiro[isobenzofuran-1 (3i-~,4'-piperidineJ, hydrochloride, 3c, mp: 232-50 °C.
1'-(2-(3-Cyclohexylimidazolidin-2-on-1-yl)-1-ethyl)spiro[isobenzofuran-1 (3I-~,4'-piperidine], hydrochloride, 3d, mp: 160-61 °C'.
1'-Propyl-spiro[isobenzofuran-1 (31,4'-piperidine], maleate, 4a.
To a mixture of spiro[isobenzofuran-1 (3t-f),4'-piperidine] (3 g), potassium carbonate ( 5 g), and i 00 ml of water in 100 ml of toluene, propionyl chloride (3 g) was added so dropwise. After stirring for 3 h at room temperature the toluene phase was sepa-rated, washed with water and concentrated in vacuo.
The remaining oil was dissolved in 100 ml of tetrahydrofuran and lithium aluminium hydride (1 g) was added. After 3 h of reflux the reaction mixture was cooled and, successively, water (2 ml), 9 N NaOH (1 ml), and water (5 ml) was added. The mixture was filtered and concentrated in vacuo and the titel compound crystallized as the maleate salt, 4a, from ethyl acetat by addition of malefic acid.
Recrystallized from an acetone/ether mixture. Yield: 0.7 g, mp: 107-9 °C.
In a similar manner were also prepared:
1'-(5-Methyl-1-hexyl)-spiro[isobenzofuran-1 (31-x,4'-piperidineJ, oxalate, 4b, mp: 162-64 °C.
1'-(2-Phenyl-1-ethyl)-spiro[isobenzofuran-1(3t~,4'-piperidine], maleate, 4c, mp: 161-~0 63 °C.
1'-(3-Phenyl-1-propyl)-spiro[isobenzofuran-1 (31,4'-piperidineJ, maleate, 4d, mp:
142-44 °C.
1'-(5-Phenyl-1-pentyl)-spiro[isobenzofuran-1 (3f-i),4'-piperfdineJ, oxalate, 4e, mp: 115-17 °C.
~s 1'-(6-Phenyl-1-hexyl)-spiro[isobenzofuran-1(31,4'-piperidineJ, oxalate, 4f, mp: 156-57 °C.
1'-Octadecanyl-spiro[isobenzofuran-1 (3I~-~,4'-piperidineJ, oxalate, 4g, mp:
°C.
2o EXAMPLE 5 1'-[4-[1-(4-Fluorophenyl)-3-indolylJ-1-butylJ-spiro[isobenzofuran-1 (3f~,4'-piperidineJ, 5a.
2s A mixture of 2u (3 g), 1-fluoro-4-iodobenzene (5 g), copper powder (0.5 g), and potassium carbonate (2 g) in 50 ml of NMP was kept at 160-170 °C for 5 h. After filtration, water was added followed by extraction with ether. Removal of solvent in vacuo gave a red oil which was applied to a silica gel column (eluent: ethyl acetate). The title compound, 5a, crystallized as the oxalate salt from acetone by $o addition of oxalic acid. Yield: 1.3 g, mp: 169-70 °C.
In a similar manner were also prepared:
1,4-Dihydro-1'-[4-[1-(4-Fluorophenyl)-3-indolylJ-1-butyl]spiro[3H 2-benzopyran-3,4'-piperidineJ, maleate, 5b, mp: 142-43 °C.
1'-[4-[1-(3-Thienyl)-3-indolyl)-1-butyl]spiro[isobenzofuran-1 (31,4'-piperidinej, 5c, mp: 182-83 °C.
1'-[4-[1-(2-Thienyl)-3-indolyl]-1-butylJspiro[isobenzofuran-1 (3f~,4'-piperidineJ, 5d, mp: 198-202 °C.
s 1'-[4-[1-(3-Furanyl)-3-indolylj-1-butyl]spiro[isobenzofuran-1(31-x,4'-piperidine], 5e, mp: 141-42 °C.
1-(4-Fluorophenyl)-3-[4-(4-phenyl-1-piperidyl)-1-butyljindole, oxalate, 5f, mp: 171-73 °C.
1'-[4-[1-(4-Pyridyl)-3-i ndolylJ-1-butylJspiro[isobenzofuran-1 (3f~,4'-piperidineJ, ~o oxalate, 5g, mp: 127-29 °C.
1'-(4-(1-Methanesulfonyl-3-indolyl)-1-butyl)spiro[isobenzofuran-1 (3l-~,4'-piperidine], ~s oxalate, 6a.
A solution of NaOH (20 g) in water (20 ml) was cooled to 10 °C and a solution of 4-(3-indolyl)-1-butanol (4 g) in methylene chloride (60 ml) was added together with tetrabutylammonium hydrogensulfate (0.8 g). Methanesulfonyl chloride (2.5 ml) in 2o methylene chloride (25 ml) was added dropwise at 15 °C followed by stirring for 20 min. at room temperature. The phases were separated and the organic phase washed with water. Drying over magnesium sulfate and removal of solvent in vacuo gave an oil which was purified by column chromatography (silica gel, eluent:
ether/methylene chloride/heptane = 1:1:1 ) giving 1.8 g of a heavy oil, 4-(1-2s methanesulfonyl-3-indolyl)-1-butyl methanesulfonate which was converted to the title compound by the method described in EXAMPLE 2. The oxalate salt crystal-lized from acetone by addition of oxalic acid. Yield: 1.0 g, mp: 83-85 °C.
In a similar manner were also prepared:
ao 1'-(4-(1-p-Toluenesulfonyl-3-indolyl)-1-butyl)spiro[isobenzofuran-1(31-x,4'-piperidineJ, oxalate, 6b, mp: 201-4 °C.
Alkylation, acylation or sulfonylation of compounds of Formula VIII according to methods f), h) and i), respectively, are performed in an inert solvent such as a ~o suitably boiling alcohol or ketone, preferably in the presence of a base (potassium carbonate or triethyl amine). The alkylating reagents Rio'-V~, the acylating reagents Rio"-CO-V~, Rio'-CO-V~, and Ar-CO-V~, and the sulfonylation reagents Rio'-S02-V~, and Ar-S02-V~ respectively, are commercially available or are prepared by standard procedures.
Arylation of a compound of Formula VIII according to method g) is most convenient-ly performed by applying the well known Ullmann reaction. The arylating reagents Ar-V~ are commercially available.
2o Reductive alkylation of compounds of Formula VIII according to method j) are performed by standard literature methods.
The ring closure of compounds of Formula IX according to method k) is most conveniently performed by heating a compound of Formula IX in a suitable inert 2s organic solvent such as dimethyl formamide in the presence of a base, preferably potassium tert-butoxide.
Hydrazones of Formula IX are prepared according to Scheme 6, in which Ra-F~, Rio and Hal are as previously defined.
Ra Ra O
b b R ~ ~ CN Method 16 R ~ ~ OH
Rc / Hal ~ Rc / Hal Rd Rd Meihod 18 Method 17 Ra Rz a ,NHR~o Rb O Z2 Z' R~ b R N
\ (CH2~a-N R \
v v 'OH
Za ~ ~ Rs ( /
Rc / Hal Rs Rc Hal Rd R< Rs Rd Method 17 Ra ~NHR~o Rz Rb N Zz Zi R7 Rs (CHz>4 N
Rc Hal Rs Rd Re Rs Scheme 6 Method 16 is an addition of the Grignard reagent of 4-chloro-1-butanol to o-halo-benzonitriles under standard conditions for Grignard reactions. Conversion to the s hydrazone (Method 17) is accomplished by reflux in ethanol in the presence of a hydrazine. Alternatively, the hydroxy derivative resulting from Method l6.may be converted to the amine via the corresponding mesylate analogous to Method 4 and a) before conversion of the keto group.
1o The reduction according to method I) is most conveniently performed by catalytic hydrogenation in an alcohol with a platinum catalyst. Compounds of Formulas V, VI, and VIII are prepared by methods a), b), j), k), or I). Compounds of Formula XI are prepared by treating a compound of formula R1-Vt with a 4-aryl-pyridine in a suitably boiling alcohol.
In the following the invention is further illustrated by examples which, however, may not be construed as limiting:
s 1'-Butylspiro[isobenzofuran-1(3H),4'-piperidineJ, oxalate, 1a.
A mixture of spiro(isobenzofuran-1 (3H),4'-piperidine] (2 g), n-butyl bromide (4 g), potassium carbonate (5 g), and potassium iodide (0.2 g) in 100 ml of 4-methyl-~o pentanone was refluxed for 16 h. After cooling the reaction mixture was washed with 100 ml of water and concentrated in vacuo. The title compound crystallized as the oxalate salt from acetone by addition of oxalic acid. Recrystallized from an ethanol/ether mixture. Yield: 1.2 g, mp: 171-73 °C. -~s In a similar manner was also prepared:
1'-Pentylspiro[isobenzofuran-1 (3H),4'-piperidine], oxalate, 1 b, mp: 170-72 °C.
Zo 1'-(4-Phenyl-1-butyl)spiro[isobenzofuran-1 (3H),4'-piperidine], fumarate, 2a To an ice cooled solution of 4-phenyl-1-butanol (20 g) and triethyl amine (15 g) in 200 ml of dichloromethane, a solution of methanesulfonyl chloride (12 ml) in 50 ml of dichloromethane was added dropwise. After stirring for 1 h at 10 °C
the reaction 2s mixture was washed with water. Extraction of the water phase with dichloro-methane, drying of the combined organic phases over MgSO 4 followed by removal of the volatile components in vacuo, gave 29 g of a slightly yellow oil, 4-phenyl-1-butyl methanesulfonate, which was sufficiently pure for use in the next step.
A mixture of spiro(isobenzofuran-1 (3H),4'-piperidine] (2 g), 4-phenyl-1-butyl so methanesulfonate (6 g) and potassium carbonate (14 g) in 75 ml of 4-methyl-pentanone was refluxed for 20 h. After cooling the reaction mixture was filtered and concentrated in vacuo. The remaining viscous oil was applied to a silica gel column (eluent: ether/methanol/triethyl amine = 93:5:2) giving a colorless oil which crystal-lized as the fumarate salt, 2a, from acetone by addition of fumaric acid.
Yield: 0.7 g, mp: 197-99 °C.
In a similar manner were also prepared:
s 1'-(4-Cyclohexyl-1-butyl)spiro[isobenzofuran-1(3l-r7,4'-piperidinej, oxalate, 2b, mp:
139-42 °C.
2,3-Dihydro-1'-(4-phenyl-1-butyl)spiro[1H-indene-1,4'-piperidineJ, fumarate, 2c, mp:
207-11 °C.
1'-(4-Phenyl-1-butyl)spiro[benzo[cJthiophene-1 (31,4'-piperidineJ, maleate, 2d, mp:
~ 0 176-77 °C.
3,4-Dihydro-1'-(4-phenyl-1-butyl)spiro[naphtalene-1 (2H),4'-piperidineJ, fumarate, 2e, mp: 191-93 °C.
1'-(4-Phenyl-1-butyl)spiro[1 H-2-benzopyran-4(3H),4'-piperidinej, maleate, 2f, mp:
169-70 °C.
~s 1,4-Dihydro-1'-(4-phenyl-1-butyl)spiro[3H-2-benzopyran-3,4'-piperidineJ, maleate, 2g, rtip: 152-53 °C.
3,4-Dihydro-1'-(4-phenyl-1-butyl)spiro[2H-1-benzopyran-2,4'-piperidineJ, oxalate, 2h, mp: 155-57 °C.
1'-(4-Phenyl-1-butyl)spiro[2H 1-benzopyran-2,4'-piperidineJ, fumarate, 2i, mp:
20 85 °C.
1'-(3-Cyclohexyloxy-1-propyl)spiro[isobenzofuran-1(3H),4'-piperidinej, fumarate, 2j, mp: 154-55 °C.
1'-(3-Phenoxy-1-propyl)spiro[isobenzofuran-1 (3H),4'-piperidine], 2k, mp: 143-44 °C.
1'-(3-Phenoxy-1-propyl)spiro[3H-2-benzopyran-3,4'-piperidine], maleate, 21, mp:
2s 171-73 °C.
1'-(3-Adamantyloxy-1-propyl)spiro[3H-2-benzopyran-3,4'-piperidineJ, maleate,-2m, mp: 221-24 °C.
1'-(3-Methylthio-1-propyl)spiro[isobenzofuran-1 (3H),4'-piperidineJ, oxalate, 2n, mp:
126-27 °.
ao 1'-(3-Cyclohexylthio-1-propyl)spiro[isobenzofuran-1 (3H),4'-piperidine], oxalate, 20, mp: 170-74 °C.
1'-(3-Phenylthio-1-propyl)spiro[isobenzofuran-1 (3H),4'-piperidine), oxalate,2p, 152-55 °C.
.. CA 02296897 2000-O1-13 1'-(3-Methylsulfonyl-1-propyl)spiro[isobenzofuran-1 (3H),4'-piperidineJ, 2q, mp: 163-64 °C.
. 1'-(3-Cyclohexylsulfonyl-1-propyl)spiro[isobenzofuran-1 (3l-f),4'-piperidineJ, 2r, mp:
118-20 °C.
s 1'-(3-Phenylsulfonyl-1-propyl)spiro[isobenzofuran-1 (3f~,4'-piperidine]., 2s, mp: 197-202 °C.
8'-(4-Phenyl-1-butyl)spiro[isobenzofuran-1 (3H),3'-8-azabicyclo[3,2,1 ]octane], maleate, 2t, mp: 180-81 °C.
1'-[4-(3-Indolyl)-1-butyl]-spiro[isobenzofuran-1(3H),4'-piperidine], 2u, mp:
150=55 °C.
l0 1'-[4-(3-Indolyl)-1-butyl)-spiro[1 H-2-benzopyran-4(3H),4'-piperidine], oxalate, 2v, . mp: 222-25 °C.
1'-[5-(3-Indolyl)-1-pentyl]-spiro[1 H-2-benzopyran-4(3H),4'-piperidine], oxalate, 2x, mp: 145-46 °C. , 1'-[6-(3-Indolyl)-1-hexyl]-spiro[1 H 2-benzopyran-4(3H),4'-piperidineJ, oxalate, 2y, is mp: 117-18 °C.
.1'-[4-(5,6-Dichloro-3-indolyl)-1-butyl]-spiro[isobenzofuran; 1(3H),4'-piperidine], 2z, mp: 122-23 °C.
1'-(4-(5-Fluoro-3-indolyl)-1-butyl]-spiro[isobenzofuran-1 (3H),4'-piperidine], 2aa, mp:
185-87 °C.
20 1'-(4-(1-Methyl-3-indolyl)-1-butyl]-spiro(isobenzofuran-1 (3H),4'-piperidine], 2bb, mp:
101-2 °C.
3-(4-(4-Phenyl-1-piperidyl)-1-butyl]indole, 2cc, mp: 131-32 °C.
3-(4-(4-(3,4-Dichlorophenyl)-1-piperidyl)-1-butyl]indole, 2dd, mp: 118-19 °C.
5,6-Dichloro-3-[4-(4-(4-fluorophenyl)-1-piperidyl)-1-butyl]-indole, Zee, mp:
120-21 °C.
2s 3-[6-(4-(4-Fluorophenyl)-1-piperidinyl)-1-hexyl]indole, 2ff, mp: 90-91 ~°C.
3-(4-(4-(2-Methoxyphenyl)-1-piperidinyl)-1-butyl]indol, oxalate, 2gg, mp: 183-88 °C.
1'-[4-(1-Benzyl-3-indolyl)-1-butyl]-spiro[isobenzofuran-1 (3H),4'-piperidine], 2hh, mp:
166-68 °C.
3-[4-(4-(4-Fluorophenyl)-1-piperidyl)-1-butyl]indol-2-one, 2ii, mp: 108-10 °C.
30 6-Fluoro-1'-(4-(3-indolyl)-1-butyl)spiro[isobenzofuran-1 (3H),4'-piperidineJ, 2jj, mp:
189-91 °C.
~XAMPLE~
1'-(4-(3-Cyclohexylimidazolidin-2-on-1-yl)-1-butyl)spiro(isobenzofuran-1 (3f-~,4'-piperidineJ, hydrochloride, 3a.
A mixture of 1-cyclohexyl-3-(4-chloro-1-butyl)-2-imidazolidinon (2.0 g, prepared according to the method described in Ger. Offen. 2035370), spiro[isobenzofuran-1 (3!-x,4'-piperidine] (1.5 g), potassium carbonate (4.4 g), and potassium iodide (0.1 g) in 60 ml of methyl isobutyl ketone was refluxed for 17 h. After cooling to room 1o temperature the mixture was filtered and the solvent removed in vacuo. The remaining oil was purified by column chromatography (silica gel, eluent: ethyl acetate/heptane/triethyl amine = 9:1:1 ). The title compound crystallized as the hydrochloride from an acetone/ether mixture by addition of en etheral solution of HCI. Yield: 1.9 g, mp: 203-7 °C.
In a similar manner were also prepared:
1'-(2-(3-Phenylimidazolidin-2-on-1-yl)-1-ethyl)spiro[isobenzofuran-1 (31~,4'-piperidine], hydrochloride, 3b, mp: 151-54 °C.
1'-(3-(3-Phenylimidazolidin-2-on-1-yl)-1-propyl)spiro[isobenzofuran-1 (3i-~,4'-piperidineJ, hydrochloride, 3c, mp: 232-50 °C.
1'-(2-(3-Cyclohexylimidazolidin-2-on-1-yl)-1-ethyl)spiro[isobenzofuran-1 (3I-~,4'-piperidine], hydrochloride, 3d, mp: 160-61 °C'.
1'-Propyl-spiro[isobenzofuran-1 (31,4'-piperidine], maleate, 4a.
To a mixture of spiro[isobenzofuran-1 (3t-f),4'-piperidine] (3 g), potassium carbonate ( 5 g), and i 00 ml of water in 100 ml of toluene, propionyl chloride (3 g) was added so dropwise. After stirring for 3 h at room temperature the toluene phase was sepa-rated, washed with water and concentrated in vacuo.
The remaining oil was dissolved in 100 ml of tetrahydrofuran and lithium aluminium hydride (1 g) was added. After 3 h of reflux the reaction mixture was cooled and, successively, water (2 ml), 9 N NaOH (1 ml), and water (5 ml) was added. The mixture was filtered and concentrated in vacuo and the titel compound crystallized as the maleate salt, 4a, from ethyl acetat by addition of malefic acid.
Recrystallized from an acetone/ether mixture. Yield: 0.7 g, mp: 107-9 °C.
In a similar manner were also prepared:
1'-(5-Methyl-1-hexyl)-spiro[isobenzofuran-1 (31-x,4'-piperidineJ, oxalate, 4b, mp: 162-64 °C.
1'-(2-Phenyl-1-ethyl)-spiro[isobenzofuran-1(3t~,4'-piperidine], maleate, 4c, mp: 161-~0 63 °C.
1'-(3-Phenyl-1-propyl)-spiro[isobenzofuran-1 (31,4'-piperidineJ, maleate, 4d, mp:
142-44 °C.
1'-(5-Phenyl-1-pentyl)-spiro[isobenzofuran-1 (3f-i),4'-piperfdineJ, oxalate, 4e, mp: 115-17 °C.
~s 1'-(6-Phenyl-1-hexyl)-spiro[isobenzofuran-1(31,4'-piperidineJ, oxalate, 4f, mp: 156-57 °C.
1'-Octadecanyl-spiro[isobenzofuran-1 (3I~-~,4'-piperidineJ, oxalate, 4g, mp:
°C.
2o EXAMPLE 5 1'-[4-[1-(4-Fluorophenyl)-3-indolylJ-1-butylJ-spiro[isobenzofuran-1 (3f~,4'-piperidineJ, 5a.
2s A mixture of 2u (3 g), 1-fluoro-4-iodobenzene (5 g), copper powder (0.5 g), and potassium carbonate (2 g) in 50 ml of NMP was kept at 160-170 °C for 5 h. After filtration, water was added followed by extraction with ether. Removal of solvent in vacuo gave a red oil which was applied to a silica gel column (eluent: ethyl acetate). The title compound, 5a, crystallized as the oxalate salt from acetone by $o addition of oxalic acid. Yield: 1.3 g, mp: 169-70 °C.
In a similar manner were also prepared:
1,4-Dihydro-1'-[4-[1-(4-Fluorophenyl)-3-indolylJ-1-butyl]spiro[3H 2-benzopyran-3,4'-piperidineJ, maleate, 5b, mp: 142-43 °C.
1'-[4-[1-(3-Thienyl)-3-indolyl)-1-butyl]spiro[isobenzofuran-1 (31,4'-piperidinej, 5c, mp: 182-83 °C.
1'-[4-[1-(2-Thienyl)-3-indolyl]-1-butylJspiro[isobenzofuran-1 (3f~,4'-piperidineJ, 5d, mp: 198-202 °C.
s 1'-[4-[1-(3-Furanyl)-3-indolylj-1-butyl]spiro[isobenzofuran-1(31-x,4'-piperidine], 5e, mp: 141-42 °C.
1-(4-Fluorophenyl)-3-[4-(4-phenyl-1-piperidyl)-1-butyljindole, oxalate, 5f, mp: 171-73 °C.
1'-[4-[1-(4-Pyridyl)-3-i ndolylJ-1-butylJspiro[isobenzofuran-1 (3f~,4'-piperidineJ, ~o oxalate, 5g, mp: 127-29 °C.
1'-(4-(1-Methanesulfonyl-3-indolyl)-1-butyl)spiro[isobenzofuran-1 (3l-~,4'-piperidine], ~s oxalate, 6a.
A solution of NaOH (20 g) in water (20 ml) was cooled to 10 °C and a solution of 4-(3-indolyl)-1-butanol (4 g) in methylene chloride (60 ml) was added together with tetrabutylammonium hydrogensulfate (0.8 g). Methanesulfonyl chloride (2.5 ml) in 2o methylene chloride (25 ml) was added dropwise at 15 °C followed by stirring for 20 min. at room temperature. The phases were separated and the organic phase washed with water. Drying over magnesium sulfate and removal of solvent in vacuo gave an oil which was purified by column chromatography (silica gel, eluent:
ether/methylene chloride/heptane = 1:1:1 ) giving 1.8 g of a heavy oil, 4-(1-2s methanesulfonyl-3-indolyl)-1-butyl methanesulfonate which was converted to the title compound by the method described in EXAMPLE 2. The oxalate salt crystal-lized from acetone by addition of oxalic acid. Yield: 1.0 g, mp: 83-85 °C.
In a similar manner were also prepared:
ao 1'-(4-(1-p-Toluenesulfonyl-3-indolyl)-1-butyl)spiro[isobenzofuran-1(31-x,4'-piperidineJ, oxalate, 6b, mp: 201-4 °C.
6-Fluoro-1'-(4-(1-(2-thienyl)sulfonyl-3-indolyl)-1-butyl)spiro[isobenzofuran-1 (3f~,4'-piperidine], oxalate, 6c, mp: 184-86 °C.
1'-(4-(1-Acetyl-3-indolyl)-1-butyl)spiro[isobenzofuran-1(3H),4'-piperidineJ, oxalate, 7.
A solution of acetyl chloride (0.8 ml) in methylene chloride (10 ml) was added dropwise at 15 °C to a mixture of 2u (1.8 g), sodium hydroxide (1 g), and tetrabutyl-ammonium hydrogensulfate (0.2 g) in methylene chloride (40 ml). After stirring for 1 h at room temperature water was added, the organic phase separated and dried over magnesium sulfate. Filtration and removal of solvent in vacuo gave a viscous oil which was purified by column chromatography (silica gel, eluent:
heptane/ethyl acetate/triethyl amine = 60:40:4). The title compound crystallized as the oxalate salt from acetone by addition of oxalic acid. Yield: 0.45 g, mp: 139-40 °C.
1'-[3-[1-(4-Fluorophenyl)-3-indolyloxyJ-1-propylJspirojisobenzofuran-1 (3f~,4'-piperidineJ, oxalate, 8a.
A mixture of 3-acetyloxy-1-phenylindole (24 g), 1,3-dihydroxypropane (240 ml), and 2o conc. sulfuric acid (i0 ml) was heated to 80 °C for 2 h. Water was added followed by extraction with ether. The ether phase was dried over magnesium sulfate followed by removal of solvent in vacuo giving 3-(1-phenyl-3-indolyloxy)-1-propanol, sufficiently pure for use in the next step.
The title compound was obtained by the method described in EXAMPLE 2 using spirojisobenzofuran-1(3f-~,4'-piperidine) and.crystallized as the oxalate salt from acetone by addition of oxalic acid. Yield: 2 g, mp: 151-54 °C.
In a similar manner were also prepared:
1'-[3-[6-Chloro-1-(4-fluorophenyl)-3-indolyloxyJ-1-propylJspiro[isobenzofuran-so 1 (3!-x,4'-piperidineJ, oxalate, 8b, mp: 180-81 °C.
1'-[3-[5-Chloro-1-(4-fluorophenyl)-3-indolyloxy]-1-propylJspiro[isobenzofuran-1 (3l-i),4'-piperidineJ, oxalate, 8c, mp: 115-18 °C.
5-Chloro-1-(4-fluorophenyl)-3-[3-(4-(4-methylphenyl)-1-piperidinyl)-1-propyloxy]indol, 8d, mp: 111-12 °C.
1'-[4-[1-(4-Fluorophenyl)-3-indolyl]-1-butyl]spiro[1 H 2-benzopyran-4(3l-~,4'-piperidineJ, maleate, 9a. .
A tetrahydrofuran solution (500 ml) of methyl 4-(3-indolyl)-butyrate (103 g) was io added dropwise to a suspension of lithium aluminium hydride (25 g) in tetrahydro-furan (1000 ml) at 40 °C followed by stirring for 1 h at room temperature. Usual work-up gave 4-(3-indolyl)-1-butanol (96 g) as an oil. Arylation with 1-fluoro-iodobenzene according to the method described in EXAMPLE 5 yielded 4-[1-[4-fluorophenyl)-3-indolyl]-1-butanol which was converted to the title compound 9a by ~s the method described in EXAMPLE 2 using spiro[1 H-2-benzopyran-4(31-~,4'-piperidine]. The maleate salt crystallized from acetone by addition of malefic acid.
Yield: 1.5 g, mp: 189-90 °C.
In a similar manner were also prepared:
20 1'-[4-[5-Fluoro-1-(4-fluorophenyl)-3-indolyl]-1-butyl]spiro[isobenzofuran-1(31-~,4'-piperidine], oxalate, 9b, mp: 164-65 °C.
1'-[4-[1-(4-Fluorophenyl)-3-indolyl]-1-butyl]spiro[benzo[c]thiophene-1 (3f-~,4'-piperidine], maleate, 9c, mp: 179-80 °C.
8'-[4-[1-(4-Fluorophenyl)-3-indolyl]-1-butylspiro(isobenzofuran-1 (31,3'-8-zs azabicyclo[3,2,1 ]octane], maleate, 9d, mp: 161-62 °C.
6-Fluoro-1'-[4-[1-(4-fluorophenyl)-3-indolyl]-1-butyl]spiro[isobenzofuran-1 (31-~,4'-piperidineJ, hydrochloride, 9e, mp: 227-31 °C.
1'-[4-[1-(4-Fluorophenyl)-3-indolyl]-1-butyl]-6-isopropylspiro[isobenzofuran-1 (31~,4'-pip~eridine], oxalate, 9f, mp: 129-44 °C.
so 7-Fluoro-1'-[4-[1-(4-fluorophenyl)-3-indolyl]-1-butyl]spiro[isobenzofuran-1(31-~,4'-piperidine], oxalate, 9g, mp: 186-89 °C.
1'-[4-[1-(4-Fluorophenyl)-3-indolyl]-1-butyl]-5-methylspiro[isobenzofuran-1 (3Hj,4'-piperidine], oxalate, 9h, mp: 154-56 °C.
1'-[4-[1-(4-Methylphenyl)-3-indolyl]-1-butyljspiro[1 H-2-benzopyran-4(31~,4'-piperidine], fumarate, 9i, mp: 186-88 °C.
1'-[4-[5-Fluoro-1-(3-thienyl)-3-indolylj-1-butyl]-spiro[isobenzofuran-1 (31->7,4'-piperidine], fumarate, 9j, mp: 184-86 °C.
s 1'-(4-(1-(3-Pyridinyl)-3-indolylj-1-butyl]spiro[1 H 2-benzopyran-4(3H),4'-piperidinej, fumarate, 9k, mp: 185-87 °C.
1-(4-Fluorophenyl)-3-(4-(4-(4-fluorophenyl)-1-piperidyl)-1-butyljindole, oxalate, 91, mp: 190-91 °C.
1-(4-Fluorophenyl)-3-[4-(4-(4-methylphenyl)-1-piperidyl)-1-butyl]indole, maleate, ~0 9m, mp: 130-32 °C.
1-(4-Fluorophenyl)-3-[4-(4-(4-isopropylphenyl)-1-piperidyl)-1-butyl]indole, maleate, 9n, mp: 160-62 °C.
1-(4-Fluorophenyl)-3-[4-(4-(4-dimethylaminophenyl)-1-piperidyl)-1-butyh]indole, fumarate, 90, mp: 180-82 °C.
~s 1-Phenyl-3-[4-(4-(4-fluorophenyl)-1-piperidyl)-1-butyljindole, oxalate, 9p, mp: 174-76 °C. .
1'-[4-(1-(2-Thiazolyl)-3-indolyl)-1-butyl]spiro[isobenzofuran-1 (3H),4'-piperidine], fumarate, 9q, mp: 165-67 °C
6-Trifluoromethyl-1'-[4-[1-(4-fluorophenyl)-3-indolyl]-1-butyl]spiro[isobenzofuran-20 1 (3H),4'-piperidinej, fumarate, 9r, mp: 100-105 °C.
4-Fluoro-1'-[4-[1-(4-fluorophenyl)-3-indolylj-1-butyl]spiro[isobenzofuran-1 (3H),4'-piperidinej, oxalate, 9s, mp: 160-63 °C.
1-(4-Fluorophenyl)-3-[4-(4-(3-trifluoromethylphenyl)-1-piperidyl)-1-butyl]indole, maleate, 9t, mp: 112-13 °C.
2s 2,3-Dihydro-1'-[4-[1-(4-fluorophenyl)-3-indolyl]-1-butyl]spiro[4H 1-benzopyran-4,4'-piperidine], oxalate, 9u, mp: 187-92 °C.
6-Fluoro-1'-[4-[5-fluoro-1-(4-fluorophenyl)-3-indolyl]-1-butyl]spiro[isobenzofuran-1 (H),4'-piperidine], oxalate, 9v, mp: 144-46 °C.
3o EXAMPLE 10 1'-(4-(Benzo[b]thiophen-3-yl)-1-butyl)spiro[isobenzofuran-1 (31,4'-piperidine], maleate, 10a.
A solution of methyl benzo[b]thiophen-3-ylacetate (69 g) in dry tetrahydrofuran (100 ml) was added dropwise to a suspension of lithium aluminium hydride (10 g) in dry tetrahydrofuran (500 ml) at room temperature followed by reflux for 1 h.
Hydrolysis with water, filtration and removal of solvent gave an oil which was applied to a s silica gel column (eluent: methylene chloride) giving 34.5 g of benzo[b]thiophen-3-ylethanol as an oil.
The product was dissolved in 200 ml of methylene chloride, thionyl chloride (20 ml) was added followed by reflux for 5 h. Removal of solvent and excess thionyl chloride in vacuo gave 3-(2-chloro-1-ethyl)-benzo[b]thiophene as an oil (45 g).
to The chloride was converted to 4-benzo[b]thiophen-3-yl-1-butanol via treatment with dimethyl malonate followed by hydrolysis, decarboxylation and reduction according to the method described in EXAMPLE 11.
The title compound 10a was prepared from 4-benzo[b]thiophen-3-yl-1-butanol and spiro[isobenzofuran-1 (3f-~,4'-piperidine] by the method described in EXAMPLE
2.
is Yield: 2.2 g, mp: 144-45 °C.
In a'similar manner were also prepared:
1,4-Dihydro-1'-(4-(benzo[b]thiophen-3-yl)-1-butyl)spiro[3H-2-benzopyran-3,4'-piperidine], maleate, 10b, mp: 172-73 °C.
20 1'-(4-(5-Methylbenzo[b]thiophen-3-yl)-1-butyl)spiro[isobenzofuran-1 (31-~,4'-piperidine], maleate, 10c, mp: 164-65 °C.
,E~~AMPLE 11 2s 2,3-Dihydro-5-fluoro-3-[3-(4-(4-fluorophenyl)-1-piperidinyl)-1-propyl]benzofuran, 11 a.
To a suspension of 5-fluorobenzofuran-3-carboxylic acid (118 g) in 800 ml of dichloromethane, thionyl chloride (200 ml) and dimethyl formamide (1 ml) were so added. After reflux for 3 h the reaction mixture was concentrated in vacuo, and the remaining oil dissolved in 800 ml of dichloromethane. Methanol (1.5 I) was slowly added and the mixture stirred for 1 h. Removal of solvents in vacuo left methyl 5-fluorobenzofuran-3-carboxylate (125 g) as an oil.
,. CA 02296897 2000-O1-13 The oil was dissolved in methanol (1.8 I) and magnesium turnings {7 g) was added.
After the reaction had started additional magnesium (80 g) was added portionswise during 1.5 h keeping the reaction temperature at 30-40 °C. The reaction mixture was stirred for 1 h followed by addition of aq. ammonium chloride. Extraction with s ether, drying the ether phase over sodium sulfate followed by removal of the solvent in vacuo, left a viscous oil, methyl 2,3-dihydro-5-fluorobenzofuran-3-carboxylate (120 g).
The oil was dissolved in 500 ml of dry ether and added dropwise to a suspension of lithium aluminium hydride (32 g) in 600 ml of dry ether. The mixture was refluxed ~o for 3 h followed by hydrolysis with water. Filtration and removal of solvent in vacuo gave 2,3-dihydro-5-fluoro-3-hydroxymethyl-benzofuran (95 g) which was converted to 155 g of 2,3-dihydro-5-fluorobenzofuran-3-ylmethyl methanesulfonate by the method described in EXAMPLE 2.
Dimethyl malonate (262 g) was dissolved in NMP {2 I) and potassium tert-butoxide ~s (202 g) was added portionwise keeping the temperature at 15-20 °C.
The mixture was heated to 60 °C and a solution of 2,3-dihydro-5-fl4orobenzofuran-3-ylmethyl methanesulfonate (155 g) in NMP (150 ml) was added. dropwise. The mixture was stirred for 4 h at 70-75 °C followed by addition of cold water.
Extraction with ether, drying the ether phase over magnesium sulfate, followed by removal of solvent in 2o vacuo gave dimethyl 2-(2,3-dihydro-5-fluorobenzofuran-3-ylmethyl)malonate (160 g) as an oil, which was sufficiently pure for the further synthesis.
The oil was dissolved in 2 I of ethanol and a mixture of 120 g of solid potassium hydroxide and 200 ml of water was added followed by reflux for 2 h. The reaction mixture was concentrated in vacuo , water was added followed by extraction with zs ether. The water phase was acidified with concentrated hydrochloric acid and extracted with ethyl acetate. Drying of the organic phase over magnesium sulfate and removal of solvent in vacuo gave a viscous oil which was dissolved in NMP
(1 I) and kept at 150 °C for 2 h. Addition of water and extraction with ether gave, after drying over magnesium sulfate and removal of solvent in vacuo , 77 g of 3-(2,3-so dihydro-5-fluorobenzofuran-3-yl)-propionic acid. Reduction with lithium aluminium hydride by the method described above yielded 51 g of 3-(2,3-dihydro-5-fluoro-benzofuran-3-yl)-1-propanol which was converted to 3-(2,3-dihydro-5-fluoro-ben-zofuran-3-yl)-1-propyl methanesulfonate by the method described in EXAMPLE 2.
The title compound, 11a, was prepared from 3-(2,3-dihydro-5-fluoro-benzofuran-yl)-1-propyl methanesulfonate (4.2 g) and 4-(4-fluorophenyl)piperidine (5.5 g) by the method described in EXAMPLE 2. Yield: 1.8 g, mp: 83-85 °C.
In a similar manner was also prepared:
1'-[3-(2,3-Dihydro-5-fluoro-benzofuran-3-yl)-1-propylJspiro[isobenzofuran-1 (3l-~,4'-piperidineJ,11 b, mp: 62-63 °C.
~0 1'-[4-(2,3-Dihydro-5-fluoro-benzofuran-3-yl)-1-butyl]-spiro[isobenzofuran-1 (3f~,4'-piperidine], oxalate, '12.
3-(2,3-Dihydro-5-fluoro-benzofuran-3-yl)-1-propanol, prepared as described in EX-AMPLE 11, (51 g) was dissolved in 300 ml of dichloromethane and 0.5 ml of 15 dimethyl formamide was added. During 20 min 50 ml of thionyl chloride was added dropwise followed by stirring for 3 h. Ice cold water was added, the organic phase separated, dried over magnesium sulfate and concentrated in vacuo giving 46 g of 3-(3-chloro-1-propyl)-2,3-dihydro-5-fluoro-benzofuran as an oil.
Sodium cyanide (12 g) was suspended in dimethyl sulfoxide (180 ml) and heated to zo 80 °C. A solution of 3-(3-chloro-1-propyl)-2,3-dihydro-5-fluoro-benzofuran (42 g) in 40 ml of dimethyl sulfoxide was added dropwise followed by heating to 140 °C for 15 min. After cooling ether and water were added, the ether phase separated, washed with water and dried over magnesium sulfate. Removal of solvent in vacuo left a viscous oil which was applied to a silica gel column giving 4-(2,3-dihydro-5 2s fluoro-benzofuran-3-yl)butyronitrile as an oil (20 g).
The cyanide was dissolved in 100 ml of glacial acetic acid followed by addition of concentrated hydrochloric acid (200 ml). After reflux for 5 h, water was added followed by extraction with ethyl acetate. Drying of the organic phase over magne sium sulfate and removal of solvent in vacuo gave 4-(2,3-dihydro-5-fluoro so benzofuran-3-yl)butyric acid (20 g).
The acid (8 g) was dissolved in 50 ml of dichloromethane and 0.5 ml of dimethyl formamide was added. Thionyl chloride (20 m1) was added followed by reflux for 1.5 h. The reaction mixture was concentrated twice with heptane in vacuo giving 4-(2,3-dihydro-5-fluoro-benzofuran-3-yl)-butyric acid chloride (7 g) as an oil.
A solution of spiro[isobenzofuran-1 (3f-~,4'-piperidineJ (2 g) and triethyl amine (3 ml) in dichloromethane (50 ml) was cooled to 5 °C and a solution of 4-(2,3-dihydro-5-fluoro-benzofuran-3-yl)-butyric acid chloride (3 g) in dichloromethane (25 ml) was s added dropwise. After stirring for 1 h at room temperature the reaction mixture was washed with salt water and dried over magnesium sulfate. Removal of the solvent in vacuo gave 4.4 g of a viscous oil which was dissolved in 25 ml of dry tetrahydro-furan and added dropwise to a suspension of lithium aluminium hydride (2.6 g) in 60 ml of dry tetrahydrofuran. The reaction mixture was heated to reflux for 2'h and to hydrolyzed with water. Filtration and removal of solvent in vacuo gave a viscous oil which was applied to a silica gel column (eluent: heptane/ethyl acetate/
methyl amine = 70:25:5) giving 2.9 g of the title compound, 12, which crystallized as the oxalate salt from acetone by addition of oxalic acid. Yield: 2.2 g, mp: 102-3 °C.
~5 EXAMPLE 13 1'-[4-(2,3-Dihydro-3-indolyl)-1-butylJspiro[1;3-benzodioxole-2,4'-piperidineJ, oxalate, 13a.
2o To a solution of 25b ( 4 g) and BH3-NMe3 (10 g) in 100 ml of dioxane, conc.
hydrochloric acid (12 ml) was added. After stirring for 0.5 h the mixture was refluxed for 2 h. The mixture was cooled to room temperature and 6 N
hydrochloric acid (40 ml) was added followed by reflux for 1 h. The reaction mixture was made alkaline with aq. sodium hydroxide and extracted with dichloromethane. Drying of 2s the organic phase over magnesium sulfate and removal of the solvent in vacuo gave an orange oil which was applied to a silica gel column (eluent: ethyl acetate/-heptane/triethyl amine = 70:28:2). The title compound, 13a, crystallized as the oxalate salt from acetone by addition of oxalic acid. Yield: 2.3 g, mp: 182-84 °C.
ao In a similar manner were also prepared:
1'-[4-(2,3-Dihydro-3-indolyl)-1-butylJspiro[isobenzofuran-1 (3f-~,4'-piperidineJ, oxalate, 13b, mp: 161-64 °C.
r CA 02296897 2000-O1-13 1'-[4-(2,3-Dihydro-3-indolyl)-1-butylJspiro[1 H-2-benzopyran-4(3f-fj,4'-piperidine],oxalate, 13c, mp: 105-7 °C.
2,3-Dihydro-3-[4-(4-(2-methoxyphenyl)-1-piperidinyl)-1-butyl]indol, oxalate, 13d, mp:
160-62 °C.
1'-[2-[5-Chloro-1-(4-fluorophenyl)-3-indolyloxy]-1-ethyl]spiro[isobenzofuran-1 (3f-~,4'-piperidine], oxalate,14a.
~o To a solution of methyl 5-chloro-1-(4-fluorophenyl)-3-indolone-2-carboxylate (50 g) and potassium carbonate (40 g) in 500 ml of acetone, ethyl brornoacetate (35 g) in 100 ml of acetone was added dropwise under reflux. After reflux for 6 h the mixture was filtered and the solvent removed in vacuo. Addition of water and extraction ~s with ether gave, after drying over magnesium sulfate and removal of solvent in vacuo, a viscous oil, methyl 5-chloro-3-ethoxycarbonylmethoxy-1-(4-fluorophenyl)-indole-2-carboxylate, 62 g.
The oil was dissolved in 800 ml of ethanol and 30 g of potassium hydroxide added.
Reflux for 4 h, addition of 4 I of crushed ice followed by acidification with hydrochlo-2o ric acid gave a colorless solid which was dissolved in 250 ml of NMP.
Copper bronze (5 g) was added and the mixture kept at 200 °C for 4 h. Addition of water and extraction with ethyl acetate gave, after drying over magnesium sulfate and removal of solvent in vacuo, 27 g of 5-chloro-1-(4-fluorophenyl)-3-indolyloxy acetic acid.
2s The acid was dissolved in 500 ml of tetrahydrofuran and lithium aluminium hydride {4 g) was added. After reflux for 3 h, the reaction mixture was hydrolyzed with water, filtered, and concentrated in vacuo giving i8 g of 5-chloro-1-(4-fluorophenyl)-3-(2-hydroxyethyloxy)-indole as an oil.
The oil was dissolved in 250 ml of dichloromethane and triethyl amine (10 ml) was so added. Methanesulfonyl chloride (10 ml) was added dropwise at 0-5 °C
followed by stirring for 4 h. The reaction mixture was washed with water, dried over magnesium sulfate and concentrated in vacuo, leaving 5-chloro-1-(4-fluorophenyl)-3-indolyloxyethyl methanesulfonate (21 g) as a viscous oil.
, CA 02296897 2000-O1-13 1'-[2-[5-Chloro-1-(4-fluorophenyl)-3-indolyloxy]-1-ethylJspiro[isobenzofuran-1 (3f-~,4'-piperidine), 14a, was prepared from 5-chloro-1-(4-fluorophenyl)-3-indolyloxyethyl methanesulfonate (3 g) and spiro[isobenzofuran-1 (3H),4'-piperidinej by the method described in EXAMPLE 2 followed by purification by column chromatography (silica s gel, eluent: ethyl acetate). The title compound crystallized as the oxalate salt from acetone. Yield: 0.8 g, mp: 216-17 °C.
In a similar manner was also prepared:
5-Chloro-1-(4-fluorophenyl)-3-[2-(4-(4-fluorophenyl)-1-piperidinyl)-1-ethyloxyjindol, ~0 14b, mp: 102-5 °C.
1'-[3-(5-Fluorobenzofuran-3-yl)-1-propyl]spiro[isobenzofuran-1 (3H),4'-piperidine], ~s oxalate, 15.
The title compound was prepared from 3-(5-fluorobenzofuran.-3-y!) propionic acid (3 g) and spiro[isobenzofuran-1 (3 f-~,4'-piperidinej (2 g) by the method described in EX-AMPLE 12. 3-(5-Fluoro-benzofuran-3-yl)-propionic acid was prepared by a proce-2o dure similar to the preparation of 3-(2,3-dihydro-5-fluorobenzofuran-3-yl)-propionic acid as described in EXAMPLE 11, but omitting the reduction with magnesium turnings. The title compound, 8, crystallized as the oxalate salt from acetone by addition of oxalic acid. Yield: 2.6 g, mp: 157-59 °C.
2s F~~AMPLE 16 1'-[4-(5-Fluorobenzofuran-3-yl)-1-butylj-spiro[isobenzofuran-1 (3i-~,4'-piperidinej, oxalate, 16.
3o The title compound was prepared from 4-(5-fluorobenzofuran-3-yl) butyric acid (3.5 g) and spiro[isobenzofuran-1 (31-x,4'-piperidine] (3 g) by the method described in EXAMPLE 12. 4-(5-Fluoro-benzofuran-3-yl) butyric acid was prepared by a procedure analogous to the preparation of 4-(2,3-dihydro-5-fluoro-benzofuran-3-yl) butyric acid as described in EXAMPLE 12, applying 3-(5-fluorobenzofuran-3-yl)-propanol instead of the corresponding dihydro analogue. 3-(5-Fluoro-benzofuran-yl)-1-propanol is prepared by the procedure described in EXAMPLE 11, but omitting the reduction with magnesium turnings. The title compound, 16 , crystal-s lized as the oxalate salt from acetone by addition of oxalic acid. Yield:
4.8 g, mp:
154-56 °C.
io 1'-[4-[1-(4-Fluorophenyl)-5-trifluoromethylindazol-3-yl]-1-butyl)spiro[isobenzofuran-1 (3f-~,4'-piperidine], 17a.
To a suspension of magnesium turnings (135 g) in 300 ml of dry tetrahydrofuran, ethyl bromide (140 g) dissolved in 500 ml of dry tetrahydrofuran was slowly added ~s followed by reflux for 20 min. A solution of 4-chloro-1-butanol (274 g) in 500 ml of tetrahydrofuran was added dropwise at reflux temperature. After stirring for 20 min, the Grignard solution was filtered and added portionwise to a solution of 2-chloro-4-trifluoromethyl-benzonitril (200 g) in 600 ml of dry tetrahydrofuran. The reaction mixture, was stirred for 16 h at room temperature followed by addition of 2 N
20 hydrochloric acid and ice. Extraction with ether, drying of the ether phase over magnesium sulfate and removal of solvent in vacuo left a viscous oil which was applied to a silica gel column (eluent: dichloromethanelether = 3:1) giving 4-(2-chloro-5-trifluorornethylbenzoyl)-1-butanol (101 g) as an oil.
The oil (80 g) was dissolved in 800 ml of ethanol and hydrazine hydrate (160 ml) zs was added followed by refluxing for 20 h. The reaction mixture was cooled and concentrated in vacuo. Water was added followed by extraction with ether.
Drying of the ether phase over magnesium sulfate and removal of solvent in vacuo gave 79 g of the hydrazone of 4-(2-chloro-5-trifluoromethyl-benzoyl)-1-butanol as an oil.
The hydrazone (20 g) was dissolved in dimethyl formamide and potassium tert-so butoxide (10 g) was added. The mixture was kept at 100-120 °C for 30 min followed by addition of aq. ammonium chloride. Extraction with ethyl acetate, drying of the ethyl acetate phase over magesium sulfate, and removal of solvent in vacuo gave a viscous oil which was applied to a silica gel column (eluent: ethyl acetate) , CA 02296897 2000-O1-13 giving crystalline 4-(5-trifluoromethyl-3-indazolyl)-1-butanol (2.7 g, mp: 177-79 °C).
The indazole (2.7 g) was arylated with 1-fluoro-4-iodobenzene (5 g) by the method described in EXAMPLE 5 giving 4-[1-(4-fluorophenyl)-5-trifluoromethyl-3-indazolyl)-1-butanol (2.7 g, mp: 77-79 °C) which was converted to the corresponding metha-s nesulfonate by the method described in EXAMPLE 2. The title compound, 17a, was prepared from the methanesulfonate (2 g) and spiro[iso-benzofuran-1 (3H
),4'-piperidine) (2 g) by the method described in EXAMPLE 2. Yield: 1.7 g, mp: 74-76°C.
io In a similar manner was also prepared:
4-Fluorvphenyl-3-[4-(4-(4-fluorophenyl)-1-pipe ridinyl)-1-butyl]-5-trifluoromethyl-indazol, 17b, mp: 124-25 °C.
1'-[4-(5-Trifluoromethylindazol-3-yl)-1-butyl]-spiro[isobenzofuran-1 (3f-~,4'-piperidine],18.
4-(2-Chloro-5-trifluoromethylbenzoyl)-1-butanol, prepared as described in EXAM-2o PLE 17, was converted to the corresponding methanesulfonate by the method described in EXAMPLE 2. Treatment with spiro[isobenzofuran-1 (3H),4'-piperidine]
according to the method described in EXAMPLE 2 gave 1'-[4-(2-chloro-5-trifluoromethylbenzoyl)-1-butyl]-spiro[isobenzofuran-1(3I-~,4'-piperidineJ.
Conver-sion to the corresponding hydrazone and ring closure according to the method described in EXAMPLE 17 gave the title compound, 18, mp: 146-47 °C.
f=XAMPLE 19 1'-(4-(1,2-Benzisoxazol-3-yl)-1-butyl)spiro[isobenzofuran-1 (31-~,4'-piperidine], so oxalate, 19a, mp: 164-65 °C.
A solution of 1,2-benzisoxazole-3-acetic acid (prepared according to G. Casini et al, J. Het. Chem. 6, 1969, 279) (18 g), ether saturated with dry HCI (150 ml) and methanol (200 ml) was stirred for 2 h at room temperature. Removal of the volatiles in vacuo gave methyl 1,2-benzisoxazole-3-acetate (17 g) as an oil.
The oil was dissolved in tetrahydrofuran (100 ml) and added dropwise to a suspen sion of lithium aluminium hydride (6 g) in tetrahydrofuran (200 ml) at 0-10 °C
s followed by stirring for 30 min at 15 °C. Usual work-up gave 2-(1,2-benzisoxazol-3 yl)ethanol (13 g) as an oil.
The ethanol derivative (13 g) was converted to the corresponding methanesulfonate by the method described in EXAMPLE 2 (yield: 20 g).
A solution of the methanesulfonate (20 g) in dimethyl sulfoxide (20 ml) was added to to a suspension of sodium cyanide (15 g) in dimethyl sulfoxide {40 ml) at 70 °C
followed by stirring for 30 min at 70-80 °C. Water and ether was added, the phases separated and the ether phase dried over magnesium sulfate. Removal of solvent in vacuo gave 3-(1,2-benzisoxazol-3-yl)propionitrile a solid (13 g, mp: 67 °C).
The nitrite was dissolved in methanol (200 ml) and HCI-saturated ether (200 ml) ~s was added followed by stirring for 16 h at room temperature. The reaction mixture was concentrated in vacuo, water and ether added, arid the phases separated.
Drying of the ether phase over magnesium sulfate and removal of solvent in vacuo gave~methyl 3-(1,2-benzisoxazol-3-yl)propionate (13 g) as an oil.
By repeating the above mentioned steps the 3-(1,2-benzisoxazol-3-yl)propionate 2o was converted to methyl 4-(1,2-benzisoxazol-3-yl)butyrate which was reduced with lithium aluminium hydride according to the procedure described above to 4-(1,2 benzisoxazol-3-yl)-1-butanol. By the method described in EXAMPLE 2, 4-(1,2 benzisoxazol-3-yl)-1-butyl methanesulfonate was obtained.
The title compound 19a was obtained from 4-(1,2-benzisoxazol-3-yl)-1-butyl 2s methanesulfonate (3.4 g) and spiro[isobenzofuran-1 (3H),4'-piperidine] (2 g) by the procedure described in EXAMPLE 2. The oxalate salt crystallized from acetone by addition of oxalic acid. Yield: 2.4 g, mp: 164-65 °C.
In a similar manner were also prepared: ' 3-[4-(4-(4-Fluorophenyl)-1-piperidyl)-1-butyl]-1,2-benzisoxazole, oxalate, 19b, mp:
so 174-75 °C.
1-(4-(1,2-Benzisoxazol-3-yl)-1-butyl)spiro[3H-2-benzopyran-3,4'-piperidine], oxalate, 19c, mp: 162-63 °C.
3-[4-(4-(2,6-Dichlorophenyl)-1-piperidyl)-1-butyl] -1,2-benzisoxazol, fumarate, 19d, mp: 196-97 °C.
s 1'-(3-(1,2-Benzisoxazol-3-yl)-1-propyl)spiro[isobenzofuran-1 (3!-x,4'-piperidine], oxalate, 20, mp: 131-32 °C.
The title compound 20 was prepared from 3-(1,2-benzisoxazol-3-yl)-1-propanbl (3.2 ~o g, prepared as described in EXAMPLE 19 and spiro[isobenzofuran-1 (3 f~,4'-pipe-ridine] (2 g) by the method described in EXAMPLE 2. The product crystallized as the oxalate salt from acetone by addition of oxalic acid. Yield: 2.3 g, mp:
131-32°C.
is 3-[3-(4-(4-Fluorophenyl)-piperidin-1-yl)-1-propyloxy]-1,2-benzisothiazole, 21.
A mixture of 4-(4-fluorophenyl)-piperidine (15 g), ethyl 3-bromopropionate (20 g), and potassium carbonate (14 g) in methyl isobutyl ketone was refluxed for 16 h.
2o Filtration and removal of solvent in vacuo gave 26 g of crude ethyl 3-(4-(4-fluorophenyl)-1-piperidyl)propionate as an oil which was used directly in the next step.
The oil was dissolved in dry tetrahydrofuran (70 ml) and added dropwise to a suspension of lithium aluminium hydride (6.5 g) in dry tetrahydrofuran (250 ml) at 2s 15 °C under nitrogen gas. After stirring for 30 min at room temperature, water (6.5 ml), 10 N sodium hydroxide (7 ml), and water (30 ml) were added, subsequently.
Filtration and removal of solvent gave 20 g of crude 3-(4-(4-fluorophenyl)-1-piperidyl)-1-propanol as an oil which was sufficiently pure for use in the next step.
A solution of 3-(4-(4-fluorophenyl)-1-piperidyl)-1-propanol (10 g) in dry toluene (150 so ml) was treated portionwise with a 50% xylene suspension of sodium hydride (3 g).
A solution of 3-chloro-1,2-benzisothiazole (3.6 g) in dry toluene (30 ml) was added dropwise at room temperature followed by stirring for 1.5 h at room temperature.
Ice was added, the phases separated and the aqeous phase extracted with ether.
Drying of the combined organic phases over magnesium sulfate and removal of solvents in vacuo gave an oil which was applied to column chromatography (silica gel, eluent: ethyl acetate/heptane/triethyl amine = 50:50:4). The title compound 21 crystallized from a mixture of isopropyl ether/heptane. Yield: 1.5 g, mp: 91-92 °C.~
1'-(4-(1,2-Benzisothiazol-3-yl)-1-butyl)spiro[isobenzofuran-1 (3f-~,4'-piperidineJ, oxalate, 22.
~o 4-(1,2-Benzisothiazol-3-yl)butyric acid (C. Branca et al, Phytochemistry 14, 1975, 2545) (17 g) was dissolved in dry toluene (500 ml) and cooled to -10 °C. Di-tert -butyl aluminium hydride (120 ml of an 1 M solution in toluene) was added dropwise at -10 °C followed by stirring for 2 h at room temperature. Dilute sulfuric acid (2 M, 300 ml) was added, the phases separated, the aqeous phase extracted with ether, and the combined organic phases dried over magnesium sulfate. Removal of solvents in vacuo left a viscous oil which was purified by column chromatography (silica gel, eluent: ether). 4-(1,2-Benzisothiazol-3-yl)-1-butanol (5.2 g) was obtained as an oil.
2o The title compound 22 was obtained from 4-(1,2-benzisothiazol-3-yl)-1-butanol and spiro[isobenzofuran-1 (3!-x,4'-piperidine] by the method described in EXAMPLE
2.
The oxalate salt crystallized from acetone by addition of oxalic acid. Yield:
2 g, mp:
151-52 °C.
2s EXAMPLE 23 1-(4-Fluorophenyl)-3-[4-[3-(4-fluorophenyl)-8-azabicyclo[3,2,1 J-oct-2-en-8-ylJ-1-butyl]-indol, 23.
so A mixture of dry ether (600 ml) and 15% BuLi in hexane (500 ml) was cooled to -45 °C. A solution of 4-bromo-1-fluorobenzene (145 g) in dry ether (350 ml) was added dropwise at -45 °C followed by stirring for 1 h. A solution of 8-methyl-azabicyclo[3,2,1]octan-3-one (85 g) in dry ether (400 ml) was added dropwise at -50 °C followed by stirring for 30 min, the temperature raising to -20 °C. The reaction mixture was poured into 2 M hydrochloric acid and the phases separated.
The ether phase was extracted with 2 M hydrochloric acid and the combined aqeous phases made alkaline with aqeous NaOH. Extraction with ethyl acetate, s drying of the organic phase over magnesium sulfate and removal of solvent in vacuo, gave 3-(4-fluorophenyl)-3-hydroxy-8-methyl-8-azabicyclo[3,2,1 Joctane (96 g) as a solid, mp: 169 °C.
The product was dissolved in trifluoroacetic acid (500 ml) followed by reflux for 1 h.
The reaction mixture was concentrated in vacuo, water added and the mixture ~o made alkaline with aqeous NaOH (pH > 9). Extraction with ethyl acetate, drying of the organic phase over magnesium sulfate, and removal of solvent in vacuo gave (4-fluorophenyl)-8-methyl-8-azabicyclo[3,2,1joct-2-ene as a solid (91 g, mp:
°C).
The product was dissolved in 1,1,1-trichloroethane (550 ml) and heated to 70 °C. A
is solution of 2,2,2-trichloroethyl chloroformate (14 ml) in 1,1,1-trichloroethane (25 ml) was added dropwise at 70 °C followed by reflux for 1 h. Additional 2,2,2-trichloroethyl chloroformate (24 ml) was added followed by reflux for 5 h.
Removal of volatiles in vacuo and purification by column chromatography (silica gel, eluent:
methylene chloride) gave 3-(4-fluorophenyl)-8-(2,2,2-trichloroethyloxycarbonyl)-8-2o azabicyclo[3,2,1)oct-2-ene (59 g) as an oil.
(4-Fluorophenyl)-8-(2,2,2-trichloroethyloxycarbonyl)-8-azabicyclo[3,2,1 ]oct-2-ene (17 g) was dissolved in glacial acetic acid (170 ml) followed by addition of water (20 ml). The mixture was heated to 50 °C and zink dust (40 g) was added in portions. After stirring for 2 h at 50 °C the mixture was filtered and concentrated in 2s vacuo. Water was added and the mixture made alkaline with aqeous NaOH.
Extraction with ethyl acetate, drying of the organic phase over magnesium sulfate and removal of solvent in vacuo left 3-(4-fluorophenyl)-8-azabicyclo[3,2,i)oct-2-ene (7 g) as an oil.
The title compound 23 was prepared from 3-(4- fluorophenyl)-8-azabicyclo[3,2,1 Joct-so 2-ene according to the method described in EXAMPLE 9. Yield: 1.9 g, mp: 74-75°C.
. CA 02296897 2000-O1-13 3-[4-[3-(4-Fluorophenyl)-8-azabicyclo[3.2.1 ]octan-8-yl]-1-butyl]-1,2-benzisoxazole, oxalate, 24, mp 169-170.
A solution of 3-(4-fluorophenyl)-8-azabicyclo[3,2,1]oct-2-ene (10 g) was dissolved in glacial acetic acid (150 ml). Platinum oxide (0.5 g) was added followed by treat-ment with hydrogen gas at 3 atm of pressure in a conventional Parr apparatus.
Filtration and removal of solvent in vacuo left a viscous oil. Water was addeii and io the mixture made alkaline (pH > 9) with aqeous NaOH. Extraction with ethyl acetate, drying of the organic phase over magnesium sulfate and removal of solvent in vacuo gave 3-(4-fluorophenyl)-8-azabicyclo[3,2,1]-octane (9 g) as an oil.
The title compound 24 was obtained from 3-(4-fluorophenyl)-8-azabicyclo[3,2,1]octane and 4-(1,2-benzisoxazol-3-yl)-1-butyl methanesulfonate is (prepared as described in EXAMPLE 19) by the method described in EXAMPLE 2.
The oxalate salt crystallized from acetone by addition of oxalic acid. Yield.
1.1 g, mp: 169-70 °C.
1'-(4-Phenyl-1-butyl)-spiro(1,3-benzodioxole-2,4'-piperidine], maleate, 25a.
A mixture of 1-ethoxycarbonyl-4-piperidinone (17 g), pyrocatechol (13 g) and p-toluenesulfonic acid (2.5 g) in 250 ml of dry toluene was refluxed with continous 2s removal of water. After 3 h the reaction mixture was concentrated in vacuo , 2%
NaOH (200 rnl) was added followed by extraction with dichloromethane. After drying over magnesium sulfate and removal of solvent in vacuo , the remaining red oil was applied to a silica gel column (eluent: ethyl acetate/ heptane = 1:1 ) giving 22 g of a slightly yellow oil, 1'-ethoxycarbonyl-spiro[1,3-benzodioxole-2,4' ao piperidine].
The oil was dissolved in ethanol (250 ml), NaOH (10 g) and water (20 ml) were added and the mixture refluxed for 20 h. Removal of the solvents in vacuo , addition of salt water followed by extraction with dichloromethane gave, after drying the organic phase over magnesium sulfate and removal of the solvent in vacuo, a red oil which was applied to a silica gel column (eluent: ethyl acetate/methanol/tri-ethylamine = 4:5:1 ) yielding 10 g of colorless crystals, spiro[1,3-benzodioxole-2,4'-piperidine), mp: 108-10 °C.
s The title compound, 25a, prepared from 4-phenyl-1-butyl methanesulfonate (2.3 g) and spiro[1,3-benzodioxole-2,4'-piperidine) (1.9 g) according to the method describ-ed in EXAMPLE 2, crystallized as the maleate salt from acetone by addition of malefic acid. Yield: 1.6 g, mp: 156-57 °C.
o In a similar manner was also prepared:
1'-[4-(3-Indolyl)-1-butyl)-spiro[1,3-benzodioxole-2,4'-piperidine], 25b, mp:
144-49 °C.
~s 1'-[4-(4-Fluorophenyl)-4-hydroxy-1-butyl)-spiro[isobenzofuran-1(31-x;4'-piperidine), oxalate, 26a.
1'-(3-(4-Fluorobenzoyl)-1-propyl)-spiro[isobenzofuran-1(31,4'-piperidine), oxalate (2 g), obtained from 1-chloro-3-(4-fluorobenzoyl)-propane and spiro[isobenzofuran-20 1(3l-~,4'-piperidine) by the method described in EXAMPLE 1, was dissolved in 100 ml of EtOH. Platinum oxide (0.1 g) was added and the mixture was hydrogenated in a Parr apparatus at 3 atm of hydrogen pressure for 16 h. Filtration and concen-tration in vacuo gave, after addition of a mixture of ethyl acetate/acetone, crystal-line 26a. Yield: 1.5 g, mp: 75-80 °C.
In a similar manner were also prepared:
1'-(4-Phenyl-4-hydroxy-1-butyl)-spiro[isobenzofuran-1 (31-x,4'-piperidine), 26b, mp:
139-40 °C.
1'-(4-Cyclohexyl-4-hydroxy-1-butyl)spiro[isobenzofuran-1 (31,4'-piperidine), oxalate, 26c, mp: 87-89 °C.
1'-(4-(1 H-lnden-3-yl)-1-butyl)-spiro(isobenzofuran-1 (3i-fj,4'-piperidinej, 27.
s A suspension of activated zinc (80 g) in dry tetrahydrofuran (200 ml) was heated to reflux and a few crystals of iodine was added. A solution of 1-indanone (100 g) and methyl 4-bromo-crotonate (200 g) in 500 ml of dry tetrahydrofuran was added dropwise followed by reflux for 1 h. After cooling, ice and aq. ammonium chloride was added followed by extraction with dichloromethane. Removal of the solvent in to vacuo gave a viscous oil which was purified on a silica gel column (eluent:
dichloro-methane/ether = 1:1 ) giving methyl 4-(1-hydroxyindan-1-yl)-crotonate (78 g).
A solution of the crotonate (20 g) was dissolved in 200 ml dry ether and added dropwise to a suspension of lithium aluminium hydride (10 g) in 150 ml of-dry ether. After reflux for 1 h, the reaction mixture was hydrolyzed with water.
Filtration, 15 drying of the ether phase over magnesium sulfate, and removal of solvent in vacuo gave 4-(1-hydroxyindan-1-yl)-1-butano) (18 g) as an oil.
The alcohol (16 g) was dissolved in methanol (250 ml) and concentrated hydrochlo-ric acid (40 ml) was added. After stirring for 30 min at room temperature, the reaction mixture was concentrated in vacuo, water was added and the mixture Zo extracted with ether. Drying of the ether phase over magnesium sulfate and removal of solvent in vacuo gave a viscous oil which was applied to a silica gel column (eluent: dichloromethane/ether = 9:1 ) giving 4-((1 H)inden-3-yl)-1-butanol (1.8 g).
By the method described in EXAMPLE 2, the alcohol was converted to the 2s corresponding methanesulfonate and the title compound, 27, was obtained using spiro[isobenzofuran-1 (3H),4'-pi-peridineJ, mp: 79-80 °C.
ao 1'-[4-(Indan-1-yl)-1-butytj-spiro[isobenzofuran-1 (3H),4'-piperidinej, oxalate 28.
A suspension of activated zinc (40 g) in dry tetrahydrofuran (150 ml) was heated to reflux and a few crystals of iodine was added. A solution of 1-indanone (50 g) and . CA 02296897 2000-O1-13 methyl 4-bromo-crotonate (100 g) in 400 ml of dry tetrahydrofuran was added dropwise followed by reflux for 1 h. After cooling, ice was added and the pH
adjusted to 1 with concentrated hydrochloric acid followed by extraction with dichloromethane. Concentration of the organic phase !eft a viscous oil which was s dissolved in methanol (400 ml). Concentrated hydrochloric acid (100 ml) was added and the mixture stirred for 30 min. Removal of solvents in vacuo, addition of water, and extraction with ether gave, after drying over magnesium sulfate and removal of solvent in vacuo, an oil (34 g). The oil was dissolved in 300 ml of dry ether and added dropwise to a suspension of lithium aluminium hydride (21 g).
to After reflux for 2 h, the reaction mixture was hydrolyzed with water.
Filtration and removal of solvent in vacuo gave a mixture of isomers from which 4-(1-indanyl)-but-3-en-1-of (6 g) could be isolated by column chromatography (silica gel, eluent:
dichloromethane/ether = 9:1 ). The remaining mixture of isomers (9 g) was dis-solved in 150 ml of methanol and hydrogenated at 3 atm of hydrogen pressure in is a conventional Parr apparatus in the presence of 5% palladium on charcoal (6 g) for 12 h. Filtration and removal of solvent in vacuo gave 6 g of.4-(1-indanyl)-butanol.
The alcohol was converted to the title compound, 28, viavthe corresponding methanesulfonate following the procedures described ~in EXAMPLE 2 using 2o spiro[isobenzofuran-1 (3M,4'-piperidine), mp: 114-15 °C.
1'-[4-(1-Indanyl)-but-3-en-1-yl]-spiro[isobenzofuran-1 (3fn,4'-Zs piperidine), oxalate, 29.
4-(1-Indanyl)-but-3-en-1-ol, prepared as described in EXAMPLE 28, was converted to the corresponding methanesulfonate by the method described in EXAMPLE 2.
The title compound was prepared by the method described in EXAMPLE 2 using ao spiro[isobenzofuran-1 (3t~,4'-piperidine], mp: 108-9 °C.
1'-(4-(2,3-Dihydro-1-(4-fluorophenyl)-3-indolyl)-1-butyl)spiro[isobenzofuran-1 (3/-~,4'-s piperidine], oxalate, 30.
To a solution of 5a (2 g) in trifluoroacetic acid (30 ml), sodium cyanborohydride (0.5 g) in methanol (25 ml) was added dropwise. After stirring for 2 h at room tempera-ture the mixture was concentrated in vacuo , ethyl acetate (50 ml) was added io followed by washing with 2 N sodium hydroxide (2 x 50 ml). Drying of the organic phase over sodium sulfate and removal of solvent in vacuo gave the title base which crystallized as the oxalate salt from acetone by addition of oxalic acid. Yield:
0.7 g, mp: 172-73 °C.
is EXAMPLE 31 1'-[3-(Benzo[b]thiophen-3-ylthio)-1-propyl]spiro[isobenzofuran-1 (31,4'-piperidine], maleate,3la.
2o A solution of benzo[b]thiophen-3-one (20 g), 3-mercaptopropionic acid (25 ml), 2 N
hydrochloric acid (3 ml) in xylene (80 ml) was refluxed for 18 h. Water (100 ml) and ether (300 ml) were added and the phases separated. The ether phase was extracted with 150 ml 2 N NaOH followed by acidification of the alkaline phase with cone. hydrochloric acid. Extraction with ether, drying of the ether phase over zs magnesium sulfate and removal of solvent gave 15.6 g of a viscous oil, 3-(benzo[b]thiophen-3-ylthio)-propionic acid.
The acid was dissolved in 100 ml of tetrahydrofuran and added dropwise to a suspension of lithium aluminium hydride (4 g) in tetrahydrofuran (150 ml).
After reflux for 3 h, the reaction was quenched with water followed by usual work-up ao giving 12.7 g of 3-(benzo[b]thiophen-3-ylthio)-1-propanol as an oil.
The title compound 31 a was obtained by the method described in EXAMPLE 2 using spiro[isobenzofuran-1 (3f~,4'-piperidine] and crystallized as the maleate from acetone by addition of malefic acid. Yield: 0.9 g, mp: 154-55 °C.
In a similar manner was also prepared:
1'-(3-(Benzo[bjthiophen-3-ylthio)-1-propyl)spiro(3N-2-benzopyran-3,4'-piperidinej, maleate, 31 b, mp: 169-70 °C.
1'-[4-(2,3-Dihydro-benzo[b]thiophen-3-yliden)-1-butyljspiro[isobenzofuran-1 (3H),4'-piperidinej-S,S-dioxide, maleate, 32.
A solution of 4-(3-benzo[b)thiophen-3-yl)-1-butyl methanesulfonate (4.4 g), pre-pared as described in EXAMPLES 10 and 2, in glacial acetic acid (12 ml) was treated dropwise with aqeous 30 % hydrogen peroxide at room temperature followed by heating to 80 °C for 20 min. Upon cooling the product, 4-(3-1s benzo[b)thiophen-S,S-dioxide-3-yl)-1-butyl methanesulfonate, crystallized.
Yield:
3.7 g, mp: 100-1 °C.
The methanesulfonate (1.4 g) was treated with spi,ro[isobenzofuran-1 ( 3f~,4'-piperidine)~HCI (1.2 g) according to the method described in EXAMPLE 2 giving the title compound 32 which crystallized as the maleate from acetone by addition of ao malefic acid. Yield: 1 g, mp: 186-87 °C.
EXAMPLE ~,,'~
1'-(4-(2,3-Dihydro-benzo[bjthiophen-3-yl)-1-butyl)spiro[isobenzofuran-1 (31~,4'-25 piperidinej-S,S-dioxide, maleate, 33.
Oxidation of 4-(benzo[bjthiophen-3-yl)butyric acid (8.5 g) according to the method described in EXAMPLE 32 gave the corresponding S,S-dioxide (9.2 g).
A solution of the acid (4 g) in tetrahydrofuran (25 ml) was added dropwise to a so suspension of lithium aluminium hydride (1.3 g) in tetrahydrofuran (50 ml) at 0 °C
followed by stirring at room temperature for 2 h. Usual work-up yielded 3 q of (2,3-dihydro-benzo(bjthiophen-S,S-dioxide-3-yl)-1-butanol which was converted to the title compound by treatment with spiro[isobenzofuran-1 (3N),4'-piperidinej according to the method described in EXAMPLE 2. The product crystallized as the fumarate from an acetone/ethanol mixture upon addition of fumaric acid. Yield:
1.5 g, mp: 197-98 °C.
s _E?CAMPLE 34 1'-[3-(8enzo[b]thiophen-3-yloxy)-1-propyl]spiro[isobenzofuran-1 (31-x,4'-piperidine], maleate, 34.
~o A mixture of benzo[b]thiophen-3-one (30 g), ethyl 3-bromopropionate (73 g), potassium carbonate (55 g), potassium iodide (1.3 g) and acetone (600 ml) was refluxed for 18 h. Filtration and removal of solvent in vacuo a red oil which was dissolved in ether (200 ml) and dried over magnesium sulfate. The ether solution was added dropwise to a suspension of lithium aluminium hydride (5 g) in ether ls- (100m1) followed by reflux for 1 h. Usual work-up gave a viscous oil which was applied to a silica gel column (eluent: isopropyl ether) giving 3-(benzo[b]thiophen-3-yloxy)-1-propanol (0.54 g) as an oil.
The title compound was obtained according to the method described in EXAMPLE
2' using spiro[isobenzofuran-1 (3H),4'-piperidine] and crystallized as the maleate salt Zo from an acetone/ether mixture by addition of malefic acid. Yield: 0.34 g, mp: 116-17 °C.
~X,AMPI_E 3~
2s 1'-[2-(Benzo[b]thiophen-3-ylmethyloxy)-1-ethyl]spiro[isobenzofuran-1 (3f~,4'-piperidine], fumarate, 35a.
An ether solution (50 ml) of methyl benzo[b]thiophene-3-carboxylate (15 g) was added dropwise to a suspension of lithium aluminium hydride (3.5 g) in ether (100 so ml) followed by reflux for 2 h. Usual work-up gave benzo[b]thiophen-3-yf methanol ' (13.5 g) as an oil.
The oil was dissolved in tetrahydrofuran (50 ml) and added dropwise to a suspen-sion of NaH (5 g of an 80% paraffinsuspension) in tetrahydrofuran (100 ml) followed by reflux for 1 h. Ethyl bromoacetate (35 g) in tetrahydrofuran (50 ml) was added at 60 °C followed by reflux for 1 h. Additional ethyl bromoacetate (20 g) was added followed by reflux for 7 h. The reaction was quenched with water and the volatiles removed in vacuo. The remaining oil was applied to a silica gel column s (eluent: ethyl acetate/heptane 2:8) giving ethyl benzo[bjthiophen-3-ylmethyloxyacetate (5 g) as an oil. Reduction with lithium aluminium hydride as described above yielded 3.8 g of 2-(benzo[bjthiophen-3-ylmethyloxy)ethanol as an oil.
The title compound 35a was obtained by the method described in EXAMPLE 2 io using spiro[isobenzofuran-1(3I-n,4'-piperidine] and crystallized as the fumarate salt from an acetone/ethanol mixture by addition of fumaric acid. Yield: 0.55 g, mp: 149 50~°C.
In a similar manner was also prepared:
is 1'-[2-(5-Fluorobenzofuran-3-ylmethyloxy)-1-ethyljspiro[isobenzofuran-1 (3f-~,4'-piperidine), oxalate, 35b, mp: 148-49 °C.
1'-[2-(Benzofuran-3-ylmethyloxy)-1-ethylj-4-fluorospiro[isobenzofuran-1 (3l-~,4'-piperidinej, oxalate, 35c, mp: 120-22 °C.
2o EXAMPLE 36 1'-[4-(1-(2-Dimethylamino-1-ethyl)-3-indolyl)-1-butyljspiro[isobenzofuran-1 (31~,4'-piperidinej, dihydrochloride, 36.
2s A solution of 4-(3-indolyl)-1-butanol (5 g) in dry DMF (50 ml) was cooled to 10 °C
followed by treatment with potassium t-butoxide (3 g). After stirring for 5 min. 2-chloro-N,N-dimethylacetamide (3.5 g) dissolved in dry DMF (10 ml) was added dropwise at 10-15 °C. After stirring for 1 h at room temperature water was added followed by extraction with ethyl acetate. Drying of the organic phase over magne-so sium sulfate and removal of solvent in vacuo left a viscous oil, 4-(1-dimethylamino-carbonylmethyl-3-indolyl)-1-butanol (7 g) which was converted to 1'-[4-(1-dimethyl-aminocarbonylmethyl-3-indolyl)-1-butyljspiro[isobenzofuran-1 (3f-~,4'-piperidinej by the method described in EXAMPLE 2 using spiro[isobenzofuran-1 (3 ff),4'-piperidine). Yield: 5.7 g of a viscous oil. Conventional reduction with lithium aluminium hydride gave the title compound 36 which crystallized as the dihydro-chloride from acetone by addition of hydrochloric acid. Yield: 2.4 g, mp: 244-45 °C.
s PHARMACOLOGY
Some of the compounds of Formula I have been tested according to an established and reliable pharmacological test as follows:
to INHIBITION OF 3H-DTG BINDING TO SIGMA RECEPTORS IN RAT BRAIN IN
VITRO.
By this method the inhibition by drugs of the binding of 2 nM 3H-DTG (1,3,di-o-tolyl guanidine) to sigma receptors in homogenates or membranes from rat brain ~s without cerebellum is determined in vitro as modified from Weber et al.
Proc. Natl.
Acad Sci. 1986, 83, 8784. ' Tissue preparations:
Homogenate: Rats (150-250 g) are decapitated and the brains (without cerebellum) 2o quickly removed and placed on ice, weighed and homogenized in 100 vol ice-cold (0 °C) 50 mM Tris-buffer (pH 7.7) in an ethanol rinsed glass/teflon homogenizes at 0 °C and kept on ice until use.
P2-membranes: Brains are homogenized in 10 vol 0.32 M sucrose in an ethanol zs rinsed glass/teflon homogenizes with 10 strokes up and down. The homogenate is centrifuged for 10 min at 900 x g m at 4 °C. The supernatant is decanted -and centrifuged for 20 min at 50,000 g m at 4 °C. The resulting pellet is resuspended in vol ice-cold 50 nM Tris-buffer (pH 7.7) and incubated for 30 min. at 37 °C. The . membrane suspension is then centrifuged for further 20 min. at 50,000 g m at 4 °C.
ao The pellet is resuspended in 50 vol. of ice-cold Tris-buffer and used immediately.
Binding analysis:
0.5 ml 50 mM Tris-buffer (pH 7.7), 0.25 ml displaces (6 x 100 ~M DTG, 6 x [test compoundj, or Tris-buffer), and 0.25 ml 6 x 2 nM 3H-DTG are mixed into 5 rill s plastic test tubes and kept at 4 °C until use. The binding reaction is initiated by mixing 0.5 ml tissue suspension into this solution and incubate at 25 °C for 20 min.
Glass fiber filters (Whatman GF/B) are placed on the filter machine which is then closed tightly. Just before filtration vacuum is applied, and the filters washed with 0.1% PEI solution from a spray bottle followed by one wash with Tris-buffer.
~o The binding reaction is stopped by filtration of the assay mixture at reduced pressure (750 mbar) followed by further 3 washes with 5 ml ice-cold Tris-buffer.
The filters are then placed in counting vials and 4 ml scintillation solution added.
The vials are counted in a Beckmann scintillation counter.
~5 Buffers and solutions:
50 mM Tris-buffer pH 7.7: 7.38 g Trizma - 7.7 plus distilled H 20 ad 1 liter.
100 ml 10% polyethylenimine (PEI): 100 ml dest. H 20 is added to approx. 20 g 50% PEI which is solubilized by stirring and heating. Diluted (1+99) before use.
6 x 2 nM 3H-DTG: The exact volume depends on the actual concentration of the 2o batch, but is made as close as possible to 12 nM. The containers for the radioac-tive solution is rinsed in 96% ethanol before use.
6 x 100 ~M DTG: 14.36 mg/100 ml is kept frozen in 10 ml aliqouts.
3H-DTG was obtained from NEN Research Products, Du Pont Denmark. Specific activity 62.3 Ci/mmol.
The known sigma receptor ligands BMY 14802 and rimcazole were included in the test for comparison purposes.
Table y 3H DTG Binding Data Com oun IC50 nM Com oun IC50 nM Com oun d C 50 nM
1a 7.3 4c - 2.9 11a 0.31 _ 1b 3.7 4d 1.1 11b 0.63 2a 0.25 4e 0.20 1 2 0.30 2b 0.07 4 f 0.20 13a 3.7 2c 0.51 4 46 13b 1,0 2d 0.77 5a 0.33 13c 4,g _ ._.___ 2e 1 . 2 5 b 1 .1 13 d 2 .1 2f 0.95 5c 0.25 14a 24 2 0.36 5d 0.24 14b 3,g 2h 1.4 5e 4.7 1 5 0.42 2i 4.3 5f 0.04 16 0.15 2 ~ 0.07 5 4.0 17a 0.1 1 2k 0.19 6a 0.05 17b 0.46 21 3.8 6b 0.17 18a 0.56 2m 0.47 6c <0.1 19a 0.08 2n 6.0 7 0.21 19b 0.49 20 0.26 8a 0.21 19c 0.84 2 0.32 8b 1.7 19d 4.4 2 430 8c 0.66 20 0.63 2 r ' 3.0 8d 1 1 2 1 0.2 2s 3.1 9a 0.34 2 2 0.05 2f 5.4 9b 0.06 23 2.5 2u 0.41 9c 0.14 24 1,g 2v 1 .8 9d 2 6 25a 1 1 2x 1 .6 9e 0.31 25b 3 6 2 0.84 9 f 2 7 26a 0.89 2z 1 5 9 4.2 26b i ,g 2aa 0 . 3 9 h__ 2 . 3 2 6 c 0 . i 4 2bb 0.30 9 i 0.62 2 7 0.1 1 2cc 1 .1 9 ' 0.1 1 2 8 0.15 2dd 1.7 9k 0.92 29 0.12 Zee 1 . 0 9 I 0 .14 3 0 0 . 0 7 2ff 0.43 9m 1.6 31a 0.23 2 3.3 9n 6.3 31b 2.6 2hh 0.02 90 _ 6.7 3 2 0.89 2ii 5.8 9 0.28 33 0.95 2~~ 1.4 9 0.12 34 0.27 3a 2.2 9 r 0.42 35a 0.73 3b 4.8 9s 5 6 35b f 2.8 3c 1 .0 91 3.2 3 6 4.5 3d 7 . 3 10 a 0 . 0 9 4a - 23 ______ 1.3 BMY 14802 230 4b 0.53 1Ob 0.35 rimcazole 180 10c ( I t is seen from Table I that the compounds used in the present invention are very potent sigma receptor ligands as compai~ed to the reference compounds which are known in the art to be sigma receptor ligands, the potencies for the compounds tested being better than about 40 nM, and for most of the compounds tested better s than about 1 nm.
Furthermore, the ability of the present compounds in inhibiting the binding of Prazosin to a1 adrenoceptors in membranes from rat brain were determined in vitro according to Hyttel, J et al, J. Neurochem, 1985, 44, 1615; Skarsfeldt, T. et al, Eur.
1o J. Pharmacol. 1986, 125, 323.
Additionally the compounds of the invention were tested with respect to dopamine D2 receptor binding activity according to van der Welde et a!, Eur. J.
Pharmacol.
1987, 134, 211.
For most compounds, the affinities for a1 adrenoceptors and D2 receptors were weak as compared to the potent binding to sigma receptors. Thus many of the com-pounds are very selective sigma receptor ligands, having ratios of binding affinities (ICso alpha/ICso sigma and ICso dopamine/ICSO sigma, respectively) of 30-10000.
LIGHT/DARK DISCRIMINATION TEST IN RATS.
The test was carried out in accodance with F.C.Colpaert et al., Psychopharmacolo-gy (1985) 86: 45-54. The test used Wistar WU rats.
2s The test was conducted using a two compartment activity box in which the actions of anxiolytic compounds to reduce aversion against a brightly-lit environment may be readily detected. The box is designed as an open-top experimental box one third of which was partitioned from the rest, painted black and illuminated with red light. The remainder of the box was painted white and brightly illuminated.
The so floor of each area was lined into squares. Behavioural changes were recorded.
Data obtained from dose groups were analysed using single factor analysis of variance, and Dunnett's t-test. Test compounds were given intraperitoneally 45 min before testing.
Several compounds have been tested in this test model and showed significant anxiolytic activities with EDSO values in the ng-pg/kg dose range.
FORMULATION EXAMPLES
The pharmaceutical formulations of the invention may be prepared by conventional methods in the art.
For example: Tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conven-~o tional tabletting machine. Examples of adjuvants or diluents comprise: corn starch, potato starch, talcum, magnesium stearate, gelatine, lactose, gums, and the like.
Any other adjuvants or additives usually used for such purposes such as colourings, flavourings, preservatives etc. may be used provided that they are compatible with the active ingredients.
is Solutions for injections may be prepared by dissolving the active ingredient and possible additives in a part of the solvent for injection, preferably sterile water, adjusting the solution to desired volume, sterilization of the solution and filling in suitable ampules or vials. Any suitable additive conventionally used in the art may be added, such as tonicity agents, preservatives, antioxidants, etc.
Typical examples of recipes for the formulation of the invention are as follows:
1 ) Tablets containing 0.5 milligrams of Compound 3c calculated as the frbese:
2s Comp. 3c ~ 0.5 mg Lactose 18 mg Potato starch 27 mg Sucrose 58 mg Sorbitol 3 mg so Talcum 5 mg Gelatine 2 rng Povidone 1 mg Magnesium stearate 0.5 mg 2) Tablets containing 5 milligrams of Compound 2m calculated as the free base:
Comp. 2m 5 mg Lactose 16 mg Potato starch 45 mg s Sucrose 106 mg Sorbitol 6 mg Talcum 9 mg Gelatine 4 mg Povidone 3 mg ' io Magnesium stearate0.6 mg 3) Syrup containing per milliliter:
Comp. 6b 2.5 mg Sorbitol 500 mg ~s Tragacanth . 7 mg Glycerol 50 mg Methyl-paraben 1 mg Propyl-paraben _0.1 mg Ethanol 0.005 ml 2o Water ad 1 ml 4) Solution for injection containing per milliliter:
Comp. 17 a 1 mg Acetic acid 17.9 mg 2s Sterile water ad 1 ml 5) Solution for injection containing per milliliter:
Comp. 17b 0.1 mg Sorbitol 42.9 mg so Acetic acid 0.63 mg Sodium hydroxide 22 mg Sterile water ad 1 ml
1'-(4-(1-Acetyl-3-indolyl)-1-butyl)spiro[isobenzofuran-1(3H),4'-piperidineJ, oxalate, 7.
A solution of acetyl chloride (0.8 ml) in methylene chloride (10 ml) was added dropwise at 15 °C to a mixture of 2u (1.8 g), sodium hydroxide (1 g), and tetrabutyl-ammonium hydrogensulfate (0.2 g) in methylene chloride (40 ml). After stirring for 1 h at room temperature water was added, the organic phase separated and dried over magnesium sulfate. Filtration and removal of solvent in vacuo gave a viscous oil which was purified by column chromatography (silica gel, eluent:
heptane/ethyl acetate/triethyl amine = 60:40:4). The title compound crystallized as the oxalate salt from acetone by addition of oxalic acid. Yield: 0.45 g, mp: 139-40 °C.
1'-[3-[1-(4-Fluorophenyl)-3-indolyloxyJ-1-propylJspirojisobenzofuran-1 (3f~,4'-piperidineJ, oxalate, 8a.
A mixture of 3-acetyloxy-1-phenylindole (24 g), 1,3-dihydroxypropane (240 ml), and 2o conc. sulfuric acid (i0 ml) was heated to 80 °C for 2 h. Water was added followed by extraction with ether. The ether phase was dried over magnesium sulfate followed by removal of solvent in vacuo giving 3-(1-phenyl-3-indolyloxy)-1-propanol, sufficiently pure for use in the next step.
The title compound was obtained by the method described in EXAMPLE 2 using spirojisobenzofuran-1(3f-~,4'-piperidine) and.crystallized as the oxalate salt from acetone by addition of oxalic acid. Yield: 2 g, mp: 151-54 °C.
In a similar manner were also prepared:
1'-[3-[6-Chloro-1-(4-fluorophenyl)-3-indolyloxyJ-1-propylJspiro[isobenzofuran-so 1 (3!-x,4'-piperidineJ, oxalate, 8b, mp: 180-81 °C.
1'-[3-[5-Chloro-1-(4-fluorophenyl)-3-indolyloxy]-1-propylJspiro[isobenzofuran-1 (3l-i),4'-piperidineJ, oxalate, 8c, mp: 115-18 °C.
5-Chloro-1-(4-fluorophenyl)-3-[3-(4-(4-methylphenyl)-1-piperidinyl)-1-propyloxy]indol, 8d, mp: 111-12 °C.
1'-[4-[1-(4-Fluorophenyl)-3-indolyl]-1-butyl]spiro[1 H 2-benzopyran-4(3l-~,4'-piperidineJ, maleate, 9a. .
A tetrahydrofuran solution (500 ml) of methyl 4-(3-indolyl)-butyrate (103 g) was io added dropwise to a suspension of lithium aluminium hydride (25 g) in tetrahydro-furan (1000 ml) at 40 °C followed by stirring for 1 h at room temperature. Usual work-up gave 4-(3-indolyl)-1-butanol (96 g) as an oil. Arylation with 1-fluoro-iodobenzene according to the method described in EXAMPLE 5 yielded 4-[1-[4-fluorophenyl)-3-indolyl]-1-butanol which was converted to the title compound 9a by ~s the method described in EXAMPLE 2 using spiro[1 H-2-benzopyran-4(31-~,4'-piperidine]. The maleate salt crystallized from acetone by addition of malefic acid.
Yield: 1.5 g, mp: 189-90 °C.
In a similar manner were also prepared:
20 1'-[4-[5-Fluoro-1-(4-fluorophenyl)-3-indolyl]-1-butyl]spiro[isobenzofuran-1(31-~,4'-piperidine], oxalate, 9b, mp: 164-65 °C.
1'-[4-[1-(4-Fluorophenyl)-3-indolyl]-1-butyl]spiro[benzo[c]thiophene-1 (3f-~,4'-piperidine], maleate, 9c, mp: 179-80 °C.
8'-[4-[1-(4-Fluorophenyl)-3-indolyl]-1-butylspiro(isobenzofuran-1 (31,3'-8-zs azabicyclo[3,2,1 ]octane], maleate, 9d, mp: 161-62 °C.
6-Fluoro-1'-[4-[1-(4-fluorophenyl)-3-indolyl]-1-butyl]spiro[isobenzofuran-1 (31-~,4'-piperidineJ, hydrochloride, 9e, mp: 227-31 °C.
1'-[4-[1-(4-Fluorophenyl)-3-indolyl]-1-butyl]-6-isopropylspiro[isobenzofuran-1 (31~,4'-pip~eridine], oxalate, 9f, mp: 129-44 °C.
so 7-Fluoro-1'-[4-[1-(4-fluorophenyl)-3-indolyl]-1-butyl]spiro[isobenzofuran-1(31-~,4'-piperidine], oxalate, 9g, mp: 186-89 °C.
1'-[4-[1-(4-Fluorophenyl)-3-indolyl]-1-butyl]-5-methylspiro[isobenzofuran-1 (3Hj,4'-piperidine], oxalate, 9h, mp: 154-56 °C.
1'-[4-[1-(4-Methylphenyl)-3-indolyl]-1-butyljspiro[1 H-2-benzopyran-4(31~,4'-piperidine], fumarate, 9i, mp: 186-88 °C.
1'-[4-[5-Fluoro-1-(3-thienyl)-3-indolylj-1-butyl]-spiro[isobenzofuran-1 (31->7,4'-piperidine], fumarate, 9j, mp: 184-86 °C.
s 1'-(4-(1-(3-Pyridinyl)-3-indolylj-1-butyl]spiro[1 H 2-benzopyran-4(3H),4'-piperidinej, fumarate, 9k, mp: 185-87 °C.
1-(4-Fluorophenyl)-3-(4-(4-(4-fluorophenyl)-1-piperidyl)-1-butyljindole, oxalate, 91, mp: 190-91 °C.
1-(4-Fluorophenyl)-3-[4-(4-(4-methylphenyl)-1-piperidyl)-1-butyl]indole, maleate, ~0 9m, mp: 130-32 °C.
1-(4-Fluorophenyl)-3-[4-(4-(4-isopropylphenyl)-1-piperidyl)-1-butyl]indole, maleate, 9n, mp: 160-62 °C.
1-(4-Fluorophenyl)-3-[4-(4-(4-dimethylaminophenyl)-1-piperidyl)-1-butyh]indole, fumarate, 90, mp: 180-82 °C.
~s 1-Phenyl-3-[4-(4-(4-fluorophenyl)-1-piperidyl)-1-butyljindole, oxalate, 9p, mp: 174-76 °C. .
1'-[4-(1-(2-Thiazolyl)-3-indolyl)-1-butyl]spiro[isobenzofuran-1 (3H),4'-piperidine], fumarate, 9q, mp: 165-67 °C
6-Trifluoromethyl-1'-[4-[1-(4-fluorophenyl)-3-indolyl]-1-butyl]spiro[isobenzofuran-20 1 (3H),4'-piperidinej, fumarate, 9r, mp: 100-105 °C.
4-Fluoro-1'-[4-[1-(4-fluorophenyl)-3-indolylj-1-butyl]spiro[isobenzofuran-1 (3H),4'-piperidinej, oxalate, 9s, mp: 160-63 °C.
1-(4-Fluorophenyl)-3-[4-(4-(3-trifluoromethylphenyl)-1-piperidyl)-1-butyl]indole, maleate, 9t, mp: 112-13 °C.
2s 2,3-Dihydro-1'-[4-[1-(4-fluorophenyl)-3-indolyl]-1-butyl]spiro[4H 1-benzopyran-4,4'-piperidine], oxalate, 9u, mp: 187-92 °C.
6-Fluoro-1'-[4-[5-fluoro-1-(4-fluorophenyl)-3-indolyl]-1-butyl]spiro[isobenzofuran-1 (H),4'-piperidine], oxalate, 9v, mp: 144-46 °C.
3o EXAMPLE 10 1'-(4-(Benzo[b]thiophen-3-yl)-1-butyl)spiro[isobenzofuran-1 (31,4'-piperidine], maleate, 10a.
A solution of methyl benzo[b]thiophen-3-ylacetate (69 g) in dry tetrahydrofuran (100 ml) was added dropwise to a suspension of lithium aluminium hydride (10 g) in dry tetrahydrofuran (500 ml) at room temperature followed by reflux for 1 h.
Hydrolysis with water, filtration and removal of solvent gave an oil which was applied to a s silica gel column (eluent: methylene chloride) giving 34.5 g of benzo[b]thiophen-3-ylethanol as an oil.
The product was dissolved in 200 ml of methylene chloride, thionyl chloride (20 ml) was added followed by reflux for 5 h. Removal of solvent and excess thionyl chloride in vacuo gave 3-(2-chloro-1-ethyl)-benzo[b]thiophene as an oil (45 g).
to The chloride was converted to 4-benzo[b]thiophen-3-yl-1-butanol via treatment with dimethyl malonate followed by hydrolysis, decarboxylation and reduction according to the method described in EXAMPLE 11.
The title compound 10a was prepared from 4-benzo[b]thiophen-3-yl-1-butanol and spiro[isobenzofuran-1 (3f-~,4'-piperidine] by the method described in EXAMPLE
2.
is Yield: 2.2 g, mp: 144-45 °C.
In a'similar manner were also prepared:
1,4-Dihydro-1'-(4-(benzo[b]thiophen-3-yl)-1-butyl)spiro[3H-2-benzopyran-3,4'-piperidine], maleate, 10b, mp: 172-73 °C.
20 1'-(4-(5-Methylbenzo[b]thiophen-3-yl)-1-butyl)spiro[isobenzofuran-1 (31-~,4'-piperidine], maleate, 10c, mp: 164-65 °C.
,E~~AMPLE 11 2s 2,3-Dihydro-5-fluoro-3-[3-(4-(4-fluorophenyl)-1-piperidinyl)-1-propyl]benzofuran, 11 a.
To a suspension of 5-fluorobenzofuran-3-carboxylic acid (118 g) in 800 ml of dichloromethane, thionyl chloride (200 ml) and dimethyl formamide (1 ml) were so added. After reflux for 3 h the reaction mixture was concentrated in vacuo, and the remaining oil dissolved in 800 ml of dichloromethane. Methanol (1.5 I) was slowly added and the mixture stirred for 1 h. Removal of solvents in vacuo left methyl 5-fluorobenzofuran-3-carboxylate (125 g) as an oil.
,. CA 02296897 2000-O1-13 The oil was dissolved in methanol (1.8 I) and magnesium turnings {7 g) was added.
After the reaction had started additional magnesium (80 g) was added portionswise during 1.5 h keeping the reaction temperature at 30-40 °C. The reaction mixture was stirred for 1 h followed by addition of aq. ammonium chloride. Extraction with s ether, drying the ether phase over sodium sulfate followed by removal of the solvent in vacuo, left a viscous oil, methyl 2,3-dihydro-5-fluorobenzofuran-3-carboxylate (120 g).
The oil was dissolved in 500 ml of dry ether and added dropwise to a suspension of lithium aluminium hydride (32 g) in 600 ml of dry ether. The mixture was refluxed ~o for 3 h followed by hydrolysis with water. Filtration and removal of solvent in vacuo gave 2,3-dihydro-5-fluoro-3-hydroxymethyl-benzofuran (95 g) which was converted to 155 g of 2,3-dihydro-5-fluorobenzofuran-3-ylmethyl methanesulfonate by the method described in EXAMPLE 2.
Dimethyl malonate (262 g) was dissolved in NMP {2 I) and potassium tert-butoxide ~s (202 g) was added portionwise keeping the temperature at 15-20 °C.
The mixture was heated to 60 °C and a solution of 2,3-dihydro-5-fl4orobenzofuran-3-ylmethyl methanesulfonate (155 g) in NMP (150 ml) was added. dropwise. The mixture was stirred for 4 h at 70-75 °C followed by addition of cold water.
Extraction with ether, drying the ether phase over magnesium sulfate, followed by removal of solvent in 2o vacuo gave dimethyl 2-(2,3-dihydro-5-fluorobenzofuran-3-ylmethyl)malonate (160 g) as an oil, which was sufficiently pure for the further synthesis.
The oil was dissolved in 2 I of ethanol and a mixture of 120 g of solid potassium hydroxide and 200 ml of water was added followed by reflux for 2 h. The reaction mixture was concentrated in vacuo , water was added followed by extraction with zs ether. The water phase was acidified with concentrated hydrochloric acid and extracted with ethyl acetate. Drying of the organic phase over magnesium sulfate and removal of solvent in vacuo gave a viscous oil which was dissolved in NMP
(1 I) and kept at 150 °C for 2 h. Addition of water and extraction with ether gave, after drying over magnesium sulfate and removal of solvent in vacuo , 77 g of 3-(2,3-so dihydro-5-fluorobenzofuran-3-yl)-propionic acid. Reduction with lithium aluminium hydride by the method described above yielded 51 g of 3-(2,3-dihydro-5-fluoro-benzofuran-3-yl)-1-propanol which was converted to 3-(2,3-dihydro-5-fluoro-ben-zofuran-3-yl)-1-propyl methanesulfonate by the method described in EXAMPLE 2.
The title compound, 11a, was prepared from 3-(2,3-dihydro-5-fluoro-benzofuran-yl)-1-propyl methanesulfonate (4.2 g) and 4-(4-fluorophenyl)piperidine (5.5 g) by the method described in EXAMPLE 2. Yield: 1.8 g, mp: 83-85 °C.
In a similar manner was also prepared:
1'-[3-(2,3-Dihydro-5-fluoro-benzofuran-3-yl)-1-propylJspiro[isobenzofuran-1 (3l-~,4'-piperidineJ,11 b, mp: 62-63 °C.
~0 1'-[4-(2,3-Dihydro-5-fluoro-benzofuran-3-yl)-1-butyl]-spiro[isobenzofuran-1 (3f~,4'-piperidine], oxalate, '12.
3-(2,3-Dihydro-5-fluoro-benzofuran-3-yl)-1-propanol, prepared as described in EX-AMPLE 11, (51 g) was dissolved in 300 ml of dichloromethane and 0.5 ml of 15 dimethyl formamide was added. During 20 min 50 ml of thionyl chloride was added dropwise followed by stirring for 3 h. Ice cold water was added, the organic phase separated, dried over magnesium sulfate and concentrated in vacuo giving 46 g of 3-(3-chloro-1-propyl)-2,3-dihydro-5-fluoro-benzofuran as an oil.
Sodium cyanide (12 g) was suspended in dimethyl sulfoxide (180 ml) and heated to zo 80 °C. A solution of 3-(3-chloro-1-propyl)-2,3-dihydro-5-fluoro-benzofuran (42 g) in 40 ml of dimethyl sulfoxide was added dropwise followed by heating to 140 °C for 15 min. After cooling ether and water were added, the ether phase separated, washed with water and dried over magnesium sulfate. Removal of solvent in vacuo left a viscous oil which was applied to a silica gel column giving 4-(2,3-dihydro-5 2s fluoro-benzofuran-3-yl)butyronitrile as an oil (20 g).
The cyanide was dissolved in 100 ml of glacial acetic acid followed by addition of concentrated hydrochloric acid (200 ml). After reflux for 5 h, water was added followed by extraction with ethyl acetate. Drying of the organic phase over magne sium sulfate and removal of solvent in vacuo gave 4-(2,3-dihydro-5-fluoro so benzofuran-3-yl)butyric acid (20 g).
The acid (8 g) was dissolved in 50 ml of dichloromethane and 0.5 ml of dimethyl formamide was added. Thionyl chloride (20 m1) was added followed by reflux for 1.5 h. The reaction mixture was concentrated twice with heptane in vacuo giving 4-(2,3-dihydro-5-fluoro-benzofuran-3-yl)-butyric acid chloride (7 g) as an oil.
A solution of spiro[isobenzofuran-1 (3f-~,4'-piperidineJ (2 g) and triethyl amine (3 ml) in dichloromethane (50 ml) was cooled to 5 °C and a solution of 4-(2,3-dihydro-5-fluoro-benzofuran-3-yl)-butyric acid chloride (3 g) in dichloromethane (25 ml) was s added dropwise. After stirring for 1 h at room temperature the reaction mixture was washed with salt water and dried over magnesium sulfate. Removal of the solvent in vacuo gave 4.4 g of a viscous oil which was dissolved in 25 ml of dry tetrahydro-furan and added dropwise to a suspension of lithium aluminium hydride (2.6 g) in 60 ml of dry tetrahydrofuran. The reaction mixture was heated to reflux for 2'h and to hydrolyzed with water. Filtration and removal of solvent in vacuo gave a viscous oil which was applied to a silica gel column (eluent: heptane/ethyl acetate/
methyl amine = 70:25:5) giving 2.9 g of the title compound, 12, which crystallized as the oxalate salt from acetone by addition of oxalic acid. Yield: 2.2 g, mp: 102-3 °C.
~5 EXAMPLE 13 1'-[4-(2,3-Dihydro-3-indolyl)-1-butylJspiro[1;3-benzodioxole-2,4'-piperidineJ, oxalate, 13a.
2o To a solution of 25b ( 4 g) and BH3-NMe3 (10 g) in 100 ml of dioxane, conc.
hydrochloric acid (12 ml) was added. After stirring for 0.5 h the mixture was refluxed for 2 h. The mixture was cooled to room temperature and 6 N
hydrochloric acid (40 ml) was added followed by reflux for 1 h. The reaction mixture was made alkaline with aq. sodium hydroxide and extracted with dichloromethane. Drying of 2s the organic phase over magnesium sulfate and removal of the solvent in vacuo gave an orange oil which was applied to a silica gel column (eluent: ethyl acetate/-heptane/triethyl amine = 70:28:2). The title compound, 13a, crystallized as the oxalate salt from acetone by addition of oxalic acid. Yield: 2.3 g, mp: 182-84 °C.
ao In a similar manner were also prepared:
1'-[4-(2,3-Dihydro-3-indolyl)-1-butylJspiro[isobenzofuran-1 (3f-~,4'-piperidineJ, oxalate, 13b, mp: 161-64 °C.
r CA 02296897 2000-O1-13 1'-[4-(2,3-Dihydro-3-indolyl)-1-butylJspiro[1 H-2-benzopyran-4(3f-fj,4'-piperidine],oxalate, 13c, mp: 105-7 °C.
2,3-Dihydro-3-[4-(4-(2-methoxyphenyl)-1-piperidinyl)-1-butyl]indol, oxalate, 13d, mp:
160-62 °C.
1'-[2-[5-Chloro-1-(4-fluorophenyl)-3-indolyloxy]-1-ethyl]spiro[isobenzofuran-1 (3f-~,4'-piperidine], oxalate,14a.
~o To a solution of methyl 5-chloro-1-(4-fluorophenyl)-3-indolone-2-carboxylate (50 g) and potassium carbonate (40 g) in 500 ml of acetone, ethyl brornoacetate (35 g) in 100 ml of acetone was added dropwise under reflux. After reflux for 6 h the mixture was filtered and the solvent removed in vacuo. Addition of water and extraction ~s with ether gave, after drying over magnesium sulfate and removal of solvent in vacuo, a viscous oil, methyl 5-chloro-3-ethoxycarbonylmethoxy-1-(4-fluorophenyl)-indole-2-carboxylate, 62 g.
The oil was dissolved in 800 ml of ethanol and 30 g of potassium hydroxide added.
Reflux for 4 h, addition of 4 I of crushed ice followed by acidification with hydrochlo-2o ric acid gave a colorless solid which was dissolved in 250 ml of NMP.
Copper bronze (5 g) was added and the mixture kept at 200 °C for 4 h. Addition of water and extraction with ethyl acetate gave, after drying over magnesium sulfate and removal of solvent in vacuo, 27 g of 5-chloro-1-(4-fluorophenyl)-3-indolyloxy acetic acid.
2s The acid was dissolved in 500 ml of tetrahydrofuran and lithium aluminium hydride {4 g) was added. After reflux for 3 h, the reaction mixture was hydrolyzed with water, filtered, and concentrated in vacuo giving i8 g of 5-chloro-1-(4-fluorophenyl)-3-(2-hydroxyethyloxy)-indole as an oil.
The oil was dissolved in 250 ml of dichloromethane and triethyl amine (10 ml) was so added. Methanesulfonyl chloride (10 ml) was added dropwise at 0-5 °C
followed by stirring for 4 h. The reaction mixture was washed with water, dried over magnesium sulfate and concentrated in vacuo, leaving 5-chloro-1-(4-fluorophenyl)-3-indolyloxyethyl methanesulfonate (21 g) as a viscous oil.
, CA 02296897 2000-O1-13 1'-[2-[5-Chloro-1-(4-fluorophenyl)-3-indolyloxy]-1-ethylJspiro[isobenzofuran-1 (3f-~,4'-piperidine), 14a, was prepared from 5-chloro-1-(4-fluorophenyl)-3-indolyloxyethyl methanesulfonate (3 g) and spiro[isobenzofuran-1 (3H),4'-piperidinej by the method described in EXAMPLE 2 followed by purification by column chromatography (silica s gel, eluent: ethyl acetate). The title compound crystallized as the oxalate salt from acetone. Yield: 0.8 g, mp: 216-17 °C.
In a similar manner was also prepared:
5-Chloro-1-(4-fluorophenyl)-3-[2-(4-(4-fluorophenyl)-1-piperidinyl)-1-ethyloxyjindol, ~0 14b, mp: 102-5 °C.
1'-[3-(5-Fluorobenzofuran-3-yl)-1-propyl]spiro[isobenzofuran-1 (3H),4'-piperidine], ~s oxalate, 15.
The title compound was prepared from 3-(5-fluorobenzofuran.-3-y!) propionic acid (3 g) and spiro[isobenzofuran-1 (3 f-~,4'-piperidinej (2 g) by the method described in EX-AMPLE 12. 3-(5-Fluoro-benzofuran-3-yl)-propionic acid was prepared by a proce-2o dure similar to the preparation of 3-(2,3-dihydro-5-fluorobenzofuran-3-yl)-propionic acid as described in EXAMPLE 11, but omitting the reduction with magnesium turnings. The title compound, 8, crystallized as the oxalate salt from acetone by addition of oxalic acid. Yield: 2.6 g, mp: 157-59 °C.
2s F~~AMPLE 16 1'-[4-(5-Fluorobenzofuran-3-yl)-1-butylj-spiro[isobenzofuran-1 (3i-~,4'-piperidinej, oxalate, 16.
3o The title compound was prepared from 4-(5-fluorobenzofuran-3-yl) butyric acid (3.5 g) and spiro[isobenzofuran-1 (31-x,4'-piperidine] (3 g) by the method described in EXAMPLE 12. 4-(5-Fluoro-benzofuran-3-yl) butyric acid was prepared by a procedure analogous to the preparation of 4-(2,3-dihydro-5-fluoro-benzofuran-3-yl) butyric acid as described in EXAMPLE 12, applying 3-(5-fluorobenzofuran-3-yl)-propanol instead of the corresponding dihydro analogue. 3-(5-Fluoro-benzofuran-yl)-1-propanol is prepared by the procedure described in EXAMPLE 11, but omitting the reduction with magnesium turnings. The title compound, 16 , crystal-s lized as the oxalate salt from acetone by addition of oxalic acid. Yield:
4.8 g, mp:
154-56 °C.
io 1'-[4-[1-(4-Fluorophenyl)-5-trifluoromethylindazol-3-yl]-1-butyl)spiro[isobenzofuran-1 (3f-~,4'-piperidine], 17a.
To a suspension of magnesium turnings (135 g) in 300 ml of dry tetrahydrofuran, ethyl bromide (140 g) dissolved in 500 ml of dry tetrahydrofuran was slowly added ~s followed by reflux for 20 min. A solution of 4-chloro-1-butanol (274 g) in 500 ml of tetrahydrofuran was added dropwise at reflux temperature. After stirring for 20 min, the Grignard solution was filtered and added portionwise to a solution of 2-chloro-4-trifluoromethyl-benzonitril (200 g) in 600 ml of dry tetrahydrofuran. The reaction mixture, was stirred for 16 h at room temperature followed by addition of 2 N
20 hydrochloric acid and ice. Extraction with ether, drying of the ether phase over magnesium sulfate and removal of solvent in vacuo left a viscous oil which was applied to a silica gel column (eluent: dichloromethanelether = 3:1) giving 4-(2-chloro-5-trifluorornethylbenzoyl)-1-butanol (101 g) as an oil.
The oil (80 g) was dissolved in 800 ml of ethanol and hydrazine hydrate (160 ml) zs was added followed by refluxing for 20 h. The reaction mixture was cooled and concentrated in vacuo. Water was added followed by extraction with ether.
Drying of the ether phase over magnesium sulfate and removal of solvent in vacuo gave 79 g of the hydrazone of 4-(2-chloro-5-trifluoromethyl-benzoyl)-1-butanol as an oil.
The hydrazone (20 g) was dissolved in dimethyl formamide and potassium tert-so butoxide (10 g) was added. The mixture was kept at 100-120 °C for 30 min followed by addition of aq. ammonium chloride. Extraction with ethyl acetate, drying of the ethyl acetate phase over magesium sulfate, and removal of solvent in vacuo gave a viscous oil which was applied to a silica gel column (eluent: ethyl acetate) , CA 02296897 2000-O1-13 giving crystalline 4-(5-trifluoromethyl-3-indazolyl)-1-butanol (2.7 g, mp: 177-79 °C).
The indazole (2.7 g) was arylated with 1-fluoro-4-iodobenzene (5 g) by the method described in EXAMPLE 5 giving 4-[1-(4-fluorophenyl)-5-trifluoromethyl-3-indazolyl)-1-butanol (2.7 g, mp: 77-79 °C) which was converted to the corresponding metha-s nesulfonate by the method described in EXAMPLE 2. The title compound, 17a, was prepared from the methanesulfonate (2 g) and spiro[iso-benzofuran-1 (3H
),4'-piperidine) (2 g) by the method described in EXAMPLE 2. Yield: 1.7 g, mp: 74-76°C.
io In a similar manner was also prepared:
4-Fluorvphenyl-3-[4-(4-(4-fluorophenyl)-1-pipe ridinyl)-1-butyl]-5-trifluoromethyl-indazol, 17b, mp: 124-25 °C.
1'-[4-(5-Trifluoromethylindazol-3-yl)-1-butyl]-spiro[isobenzofuran-1 (3f-~,4'-piperidine],18.
4-(2-Chloro-5-trifluoromethylbenzoyl)-1-butanol, prepared as described in EXAM-2o PLE 17, was converted to the corresponding methanesulfonate by the method described in EXAMPLE 2. Treatment with spiro[isobenzofuran-1 (3H),4'-piperidine]
according to the method described in EXAMPLE 2 gave 1'-[4-(2-chloro-5-trifluoromethylbenzoyl)-1-butyl]-spiro[isobenzofuran-1(3I-~,4'-piperidineJ.
Conver-sion to the corresponding hydrazone and ring closure according to the method described in EXAMPLE 17 gave the title compound, 18, mp: 146-47 °C.
f=XAMPLE 19 1'-(4-(1,2-Benzisoxazol-3-yl)-1-butyl)spiro[isobenzofuran-1 (31-~,4'-piperidine], so oxalate, 19a, mp: 164-65 °C.
A solution of 1,2-benzisoxazole-3-acetic acid (prepared according to G. Casini et al, J. Het. Chem. 6, 1969, 279) (18 g), ether saturated with dry HCI (150 ml) and methanol (200 ml) was stirred for 2 h at room temperature. Removal of the volatiles in vacuo gave methyl 1,2-benzisoxazole-3-acetate (17 g) as an oil.
The oil was dissolved in tetrahydrofuran (100 ml) and added dropwise to a suspen sion of lithium aluminium hydride (6 g) in tetrahydrofuran (200 ml) at 0-10 °C
s followed by stirring for 30 min at 15 °C. Usual work-up gave 2-(1,2-benzisoxazol-3 yl)ethanol (13 g) as an oil.
The ethanol derivative (13 g) was converted to the corresponding methanesulfonate by the method described in EXAMPLE 2 (yield: 20 g).
A solution of the methanesulfonate (20 g) in dimethyl sulfoxide (20 ml) was added to to a suspension of sodium cyanide (15 g) in dimethyl sulfoxide {40 ml) at 70 °C
followed by stirring for 30 min at 70-80 °C. Water and ether was added, the phases separated and the ether phase dried over magnesium sulfate. Removal of solvent in vacuo gave 3-(1,2-benzisoxazol-3-yl)propionitrile a solid (13 g, mp: 67 °C).
The nitrite was dissolved in methanol (200 ml) and HCI-saturated ether (200 ml) ~s was added followed by stirring for 16 h at room temperature. The reaction mixture was concentrated in vacuo, water and ether added, arid the phases separated.
Drying of the ether phase over magnesium sulfate and removal of solvent in vacuo gave~methyl 3-(1,2-benzisoxazol-3-yl)propionate (13 g) as an oil.
By repeating the above mentioned steps the 3-(1,2-benzisoxazol-3-yl)propionate 2o was converted to methyl 4-(1,2-benzisoxazol-3-yl)butyrate which was reduced with lithium aluminium hydride according to the procedure described above to 4-(1,2 benzisoxazol-3-yl)-1-butanol. By the method described in EXAMPLE 2, 4-(1,2 benzisoxazol-3-yl)-1-butyl methanesulfonate was obtained.
The title compound 19a was obtained from 4-(1,2-benzisoxazol-3-yl)-1-butyl 2s methanesulfonate (3.4 g) and spiro[isobenzofuran-1 (3H),4'-piperidine] (2 g) by the procedure described in EXAMPLE 2. The oxalate salt crystallized from acetone by addition of oxalic acid. Yield: 2.4 g, mp: 164-65 °C.
In a similar manner were also prepared: ' 3-[4-(4-(4-Fluorophenyl)-1-piperidyl)-1-butyl]-1,2-benzisoxazole, oxalate, 19b, mp:
so 174-75 °C.
1-(4-(1,2-Benzisoxazol-3-yl)-1-butyl)spiro[3H-2-benzopyran-3,4'-piperidine], oxalate, 19c, mp: 162-63 °C.
3-[4-(4-(2,6-Dichlorophenyl)-1-piperidyl)-1-butyl] -1,2-benzisoxazol, fumarate, 19d, mp: 196-97 °C.
s 1'-(3-(1,2-Benzisoxazol-3-yl)-1-propyl)spiro[isobenzofuran-1 (3!-x,4'-piperidine], oxalate, 20, mp: 131-32 °C.
The title compound 20 was prepared from 3-(1,2-benzisoxazol-3-yl)-1-propanbl (3.2 ~o g, prepared as described in EXAMPLE 19 and spiro[isobenzofuran-1 (3 f~,4'-pipe-ridine] (2 g) by the method described in EXAMPLE 2. The product crystallized as the oxalate salt from acetone by addition of oxalic acid. Yield: 2.3 g, mp:
131-32°C.
is 3-[3-(4-(4-Fluorophenyl)-piperidin-1-yl)-1-propyloxy]-1,2-benzisothiazole, 21.
A mixture of 4-(4-fluorophenyl)-piperidine (15 g), ethyl 3-bromopropionate (20 g), and potassium carbonate (14 g) in methyl isobutyl ketone was refluxed for 16 h.
2o Filtration and removal of solvent in vacuo gave 26 g of crude ethyl 3-(4-(4-fluorophenyl)-1-piperidyl)propionate as an oil which was used directly in the next step.
The oil was dissolved in dry tetrahydrofuran (70 ml) and added dropwise to a suspension of lithium aluminium hydride (6.5 g) in dry tetrahydrofuran (250 ml) at 2s 15 °C under nitrogen gas. After stirring for 30 min at room temperature, water (6.5 ml), 10 N sodium hydroxide (7 ml), and water (30 ml) were added, subsequently.
Filtration and removal of solvent gave 20 g of crude 3-(4-(4-fluorophenyl)-1-piperidyl)-1-propanol as an oil which was sufficiently pure for use in the next step.
A solution of 3-(4-(4-fluorophenyl)-1-piperidyl)-1-propanol (10 g) in dry toluene (150 so ml) was treated portionwise with a 50% xylene suspension of sodium hydride (3 g).
A solution of 3-chloro-1,2-benzisothiazole (3.6 g) in dry toluene (30 ml) was added dropwise at room temperature followed by stirring for 1.5 h at room temperature.
Ice was added, the phases separated and the aqeous phase extracted with ether.
Drying of the combined organic phases over magnesium sulfate and removal of solvents in vacuo gave an oil which was applied to column chromatography (silica gel, eluent: ethyl acetate/heptane/triethyl amine = 50:50:4). The title compound 21 crystallized from a mixture of isopropyl ether/heptane. Yield: 1.5 g, mp: 91-92 °C.~
1'-(4-(1,2-Benzisothiazol-3-yl)-1-butyl)spiro[isobenzofuran-1 (3f-~,4'-piperidineJ, oxalate, 22.
~o 4-(1,2-Benzisothiazol-3-yl)butyric acid (C. Branca et al, Phytochemistry 14, 1975, 2545) (17 g) was dissolved in dry toluene (500 ml) and cooled to -10 °C. Di-tert -butyl aluminium hydride (120 ml of an 1 M solution in toluene) was added dropwise at -10 °C followed by stirring for 2 h at room temperature. Dilute sulfuric acid (2 M, 300 ml) was added, the phases separated, the aqeous phase extracted with ether, and the combined organic phases dried over magnesium sulfate. Removal of solvents in vacuo left a viscous oil which was purified by column chromatography (silica gel, eluent: ether). 4-(1,2-Benzisothiazol-3-yl)-1-butanol (5.2 g) was obtained as an oil.
2o The title compound 22 was obtained from 4-(1,2-benzisothiazol-3-yl)-1-butanol and spiro[isobenzofuran-1 (3!-x,4'-piperidine] by the method described in EXAMPLE
2.
The oxalate salt crystallized from acetone by addition of oxalic acid. Yield:
2 g, mp:
151-52 °C.
2s EXAMPLE 23 1-(4-Fluorophenyl)-3-[4-[3-(4-fluorophenyl)-8-azabicyclo[3,2,1 J-oct-2-en-8-ylJ-1-butyl]-indol, 23.
so A mixture of dry ether (600 ml) and 15% BuLi in hexane (500 ml) was cooled to -45 °C. A solution of 4-bromo-1-fluorobenzene (145 g) in dry ether (350 ml) was added dropwise at -45 °C followed by stirring for 1 h. A solution of 8-methyl-azabicyclo[3,2,1]octan-3-one (85 g) in dry ether (400 ml) was added dropwise at -50 °C followed by stirring for 30 min, the temperature raising to -20 °C. The reaction mixture was poured into 2 M hydrochloric acid and the phases separated.
The ether phase was extracted with 2 M hydrochloric acid and the combined aqeous phases made alkaline with aqeous NaOH. Extraction with ethyl acetate, s drying of the organic phase over magnesium sulfate and removal of solvent in vacuo, gave 3-(4-fluorophenyl)-3-hydroxy-8-methyl-8-azabicyclo[3,2,1 Joctane (96 g) as a solid, mp: 169 °C.
The product was dissolved in trifluoroacetic acid (500 ml) followed by reflux for 1 h.
The reaction mixture was concentrated in vacuo, water added and the mixture ~o made alkaline with aqeous NaOH (pH > 9). Extraction with ethyl acetate, drying of the organic phase over magnesium sulfate, and removal of solvent in vacuo gave (4-fluorophenyl)-8-methyl-8-azabicyclo[3,2,1joct-2-ene as a solid (91 g, mp:
°C).
The product was dissolved in 1,1,1-trichloroethane (550 ml) and heated to 70 °C. A
is solution of 2,2,2-trichloroethyl chloroformate (14 ml) in 1,1,1-trichloroethane (25 ml) was added dropwise at 70 °C followed by reflux for 1 h. Additional 2,2,2-trichloroethyl chloroformate (24 ml) was added followed by reflux for 5 h.
Removal of volatiles in vacuo and purification by column chromatography (silica gel, eluent:
methylene chloride) gave 3-(4-fluorophenyl)-8-(2,2,2-trichloroethyloxycarbonyl)-8-2o azabicyclo[3,2,1)oct-2-ene (59 g) as an oil.
(4-Fluorophenyl)-8-(2,2,2-trichloroethyloxycarbonyl)-8-azabicyclo[3,2,1 ]oct-2-ene (17 g) was dissolved in glacial acetic acid (170 ml) followed by addition of water (20 ml). The mixture was heated to 50 °C and zink dust (40 g) was added in portions. After stirring for 2 h at 50 °C the mixture was filtered and concentrated in 2s vacuo. Water was added and the mixture made alkaline with aqeous NaOH.
Extraction with ethyl acetate, drying of the organic phase over magnesium sulfate and removal of solvent in vacuo left 3-(4-fluorophenyl)-8-azabicyclo[3,2,i)oct-2-ene (7 g) as an oil.
The title compound 23 was prepared from 3-(4- fluorophenyl)-8-azabicyclo[3,2,1 Joct-so 2-ene according to the method described in EXAMPLE 9. Yield: 1.9 g, mp: 74-75°C.
. CA 02296897 2000-O1-13 3-[4-[3-(4-Fluorophenyl)-8-azabicyclo[3.2.1 ]octan-8-yl]-1-butyl]-1,2-benzisoxazole, oxalate, 24, mp 169-170.
A solution of 3-(4-fluorophenyl)-8-azabicyclo[3,2,1]oct-2-ene (10 g) was dissolved in glacial acetic acid (150 ml). Platinum oxide (0.5 g) was added followed by treat-ment with hydrogen gas at 3 atm of pressure in a conventional Parr apparatus.
Filtration and removal of solvent in vacuo left a viscous oil. Water was addeii and io the mixture made alkaline (pH > 9) with aqeous NaOH. Extraction with ethyl acetate, drying of the organic phase over magnesium sulfate and removal of solvent in vacuo gave 3-(4-fluorophenyl)-8-azabicyclo[3,2,1]-octane (9 g) as an oil.
The title compound 24 was obtained from 3-(4-fluorophenyl)-8-azabicyclo[3,2,1]octane and 4-(1,2-benzisoxazol-3-yl)-1-butyl methanesulfonate is (prepared as described in EXAMPLE 19) by the method described in EXAMPLE 2.
The oxalate salt crystallized from acetone by addition of oxalic acid. Yield.
1.1 g, mp: 169-70 °C.
1'-(4-Phenyl-1-butyl)-spiro(1,3-benzodioxole-2,4'-piperidine], maleate, 25a.
A mixture of 1-ethoxycarbonyl-4-piperidinone (17 g), pyrocatechol (13 g) and p-toluenesulfonic acid (2.5 g) in 250 ml of dry toluene was refluxed with continous 2s removal of water. After 3 h the reaction mixture was concentrated in vacuo , 2%
NaOH (200 rnl) was added followed by extraction with dichloromethane. After drying over magnesium sulfate and removal of solvent in vacuo , the remaining red oil was applied to a silica gel column (eluent: ethyl acetate/ heptane = 1:1 ) giving 22 g of a slightly yellow oil, 1'-ethoxycarbonyl-spiro[1,3-benzodioxole-2,4' ao piperidine].
The oil was dissolved in ethanol (250 ml), NaOH (10 g) and water (20 ml) were added and the mixture refluxed for 20 h. Removal of the solvents in vacuo , addition of salt water followed by extraction with dichloromethane gave, after drying the organic phase over magnesium sulfate and removal of the solvent in vacuo, a red oil which was applied to a silica gel column (eluent: ethyl acetate/methanol/tri-ethylamine = 4:5:1 ) yielding 10 g of colorless crystals, spiro[1,3-benzodioxole-2,4'-piperidine), mp: 108-10 °C.
s The title compound, 25a, prepared from 4-phenyl-1-butyl methanesulfonate (2.3 g) and spiro[1,3-benzodioxole-2,4'-piperidine) (1.9 g) according to the method describ-ed in EXAMPLE 2, crystallized as the maleate salt from acetone by addition of malefic acid. Yield: 1.6 g, mp: 156-57 °C.
o In a similar manner was also prepared:
1'-[4-(3-Indolyl)-1-butyl)-spiro[1,3-benzodioxole-2,4'-piperidine], 25b, mp:
144-49 °C.
~s 1'-[4-(4-Fluorophenyl)-4-hydroxy-1-butyl)-spiro[isobenzofuran-1(31-x;4'-piperidine), oxalate, 26a.
1'-(3-(4-Fluorobenzoyl)-1-propyl)-spiro[isobenzofuran-1(31,4'-piperidine), oxalate (2 g), obtained from 1-chloro-3-(4-fluorobenzoyl)-propane and spiro[isobenzofuran-20 1(3l-~,4'-piperidine) by the method described in EXAMPLE 1, was dissolved in 100 ml of EtOH. Platinum oxide (0.1 g) was added and the mixture was hydrogenated in a Parr apparatus at 3 atm of hydrogen pressure for 16 h. Filtration and concen-tration in vacuo gave, after addition of a mixture of ethyl acetate/acetone, crystal-line 26a. Yield: 1.5 g, mp: 75-80 °C.
In a similar manner were also prepared:
1'-(4-Phenyl-4-hydroxy-1-butyl)-spiro[isobenzofuran-1 (31-x,4'-piperidine), 26b, mp:
139-40 °C.
1'-(4-Cyclohexyl-4-hydroxy-1-butyl)spiro[isobenzofuran-1 (31,4'-piperidine), oxalate, 26c, mp: 87-89 °C.
1'-(4-(1 H-lnden-3-yl)-1-butyl)-spiro(isobenzofuran-1 (3i-fj,4'-piperidinej, 27.
s A suspension of activated zinc (80 g) in dry tetrahydrofuran (200 ml) was heated to reflux and a few crystals of iodine was added. A solution of 1-indanone (100 g) and methyl 4-bromo-crotonate (200 g) in 500 ml of dry tetrahydrofuran was added dropwise followed by reflux for 1 h. After cooling, ice and aq. ammonium chloride was added followed by extraction with dichloromethane. Removal of the solvent in to vacuo gave a viscous oil which was purified on a silica gel column (eluent:
dichloro-methane/ether = 1:1 ) giving methyl 4-(1-hydroxyindan-1-yl)-crotonate (78 g).
A solution of the crotonate (20 g) was dissolved in 200 ml dry ether and added dropwise to a suspension of lithium aluminium hydride (10 g) in 150 ml of-dry ether. After reflux for 1 h, the reaction mixture was hydrolyzed with water.
Filtration, 15 drying of the ether phase over magnesium sulfate, and removal of solvent in vacuo gave 4-(1-hydroxyindan-1-yl)-1-butano) (18 g) as an oil.
The alcohol (16 g) was dissolved in methanol (250 ml) and concentrated hydrochlo-ric acid (40 ml) was added. After stirring for 30 min at room temperature, the reaction mixture was concentrated in vacuo, water was added and the mixture Zo extracted with ether. Drying of the ether phase over magnesium sulfate and removal of solvent in vacuo gave a viscous oil which was applied to a silica gel column (eluent: dichloromethane/ether = 9:1 ) giving 4-((1 H)inden-3-yl)-1-butanol (1.8 g).
By the method described in EXAMPLE 2, the alcohol was converted to the 2s corresponding methanesulfonate and the title compound, 27, was obtained using spiro[isobenzofuran-1 (3H),4'-pi-peridineJ, mp: 79-80 °C.
ao 1'-[4-(Indan-1-yl)-1-butytj-spiro[isobenzofuran-1 (3H),4'-piperidinej, oxalate 28.
A suspension of activated zinc (40 g) in dry tetrahydrofuran (150 ml) was heated to reflux and a few crystals of iodine was added. A solution of 1-indanone (50 g) and . CA 02296897 2000-O1-13 methyl 4-bromo-crotonate (100 g) in 400 ml of dry tetrahydrofuran was added dropwise followed by reflux for 1 h. After cooling, ice was added and the pH
adjusted to 1 with concentrated hydrochloric acid followed by extraction with dichloromethane. Concentration of the organic phase !eft a viscous oil which was s dissolved in methanol (400 ml). Concentrated hydrochloric acid (100 ml) was added and the mixture stirred for 30 min. Removal of solvents in vacuo, addition of water, and extraction with ether gave, after drying over magnesium sulfate and removal of solvent in vacuo, an oil (34 g). The oil was dissolved in 300 ml of dry ether and added dropwise to a suspension of lithium aluminium hydride (21 g).
to After reflux for 2 h, the reaction mixture was hydrolyzed with water.
Filtration and removal of solvent in vacuo gave a mixture of isomers from which 4-(1-indanyl)-but-3-en-1-of (6 g) could be isolated by column chromatography (silica gel, eluent:
dichloromethane/ether = 9:1 ). The remaining mixture of isomers (9 g) was dis-solved in 150 ml of methanol and hydrogenated at 3 atm of hydrogen pressure in is a conventional Parr apparatus in the presence of 5% palladium on charcoal (6 g) for 12 h. Filtration and removal of solvent in vacuo gave 6 g of.4-(1-indanyl)-butanol.
The alcohol was converted to the title compound, 28, viavthe corresponding methanesulfonate following the procedures described ~in EXAMPLE 2 using 2o spiro[isobenzofuran-1 (3M,4'-piperidine), mp: 114-15 °C.
1'-[4-(1-Indanyl)-but-3-en-1-yl]-spiro[isobenzofuran-1 (3fn,4'-Zs piperidine), oxalate, 29.
4-(1-Indanyl)-but-3-en-1-ol, prepared as described in EXAMPLE 28, was converted to the corresponding methanesulfonate by the method described in EXAMPLE 2.
The title compound was prepared by the method described in EXAMPLE 2 using ao spiro[isobenzofuran-1 (3t~,4'-piperidine], mp: 108-9 °C.
1'-(4-(2,3-Dihydro-1-(4-fluorophenyl)-3-indolyl)-1-butyl)spiro[isobenzofuran-1 (3/-~,4'-s piperidine], oxalate, 30.
To a solution of 5a (2 g) in trifluoroacetic acid (30 ml), sodium cyanborohydride (0.5 g) in methanol (25 ml) was added dropwise. After stirring for 2 h at room tempera-ture the mixture was concentrated in vacuo , ethyl acetate (50 ml) was added io followed by washing with 2 N sodium hydroxide (2 x 50 ml). Drying of the organic phase over sodium sulfate and removal of solvent in vacuo gave the title base which crystallized as the oxalate salt from acetone by addition of oxalic acid. Yield:
0.7 g, mp: 172-73 °C.
is EXAMPLE 31 1'-[3-(Benzo[b]thiophen-3-ylthio)-1-propyl]spiro[isobenzofuran-1 (31,4'-piperidine], maleate,3la.
2o A solution of benzo[b]thiophen-3-one (20 g), 3-mercaptopropionic acid (25 ml), 2 N
hydrochloric acid (3 ml) in xylene (80 ml) was refluxed for 18 h. Water (100 ml) and ether (300 ml) were added and the phases separated. The ether phase was extracted with 150 ml 2 N NaOH followed by acidification of the alkaline phase with cone. hydrochloric acid. Extraction with ether, drying of the ether phase over zs magnesium sulfate and removal of solvent gave 15.6 g of a viscous oil, 3-(benzo[b]thiophen-3-ylthio)-propionic acid.
The acid was dissolved in 100 ml of tetrahydrofuran and added dropwise to a suspension of lithium aluminium hydride (4 g) in tetrahydrofuran (150 ml).
After reflux for 3 h, the reaction was quenched with water followed by usual work-up ao giving 12.7 g of 3-(benzo[b]thiophen-3-ylthio)-1-propanol as an oil.
The title compound 31 a was obtained by the method described in EXAMPLE 2 using spiro[isobenzofuran-1 (3f~,4'-piperidine] and crystallized as the maleate from acetone by addition of malefic acid. Yield: 0.9 g, mp: 154-55 °C.
In a similar manner was also prepared:
1'-(3-(Benzo[bjthiophen-3-ylthio)-1-propyl)spiro(3N-2-benzopyran-3,4'-piperidinej, maleate, 31 b, mp: 169-70 °C.
1'-[4-(2,3-Dihydro-benzo[b]thiophen-3-yliden)-1-butyljspiro[isobenzofuran-1 (3H),4'-piperidinej-S,S-dioxide, maleate, 32.
A solution of 4-(3-benzo[b)thiophen-3-yl)-1-butyl methanesulfonate (4.4 g), pre-pared as described in EXAMPLES 10 and 2, in glacial acetic acid (12 ml) was treated dropwise with aqeous 30 % hydrogen peroxide at room temperature followed by heating to 80 °C for 20 min. Upon cooling the product, 4-(3-1s benzo[b)thiophen-S,S-dioxide-3-yl)-1-butyl methanesulfonate, crystallized.
Yield:
3.7 g, mp: 100-1 °C.
The methanesulfonate (1.4 g) was treated with spi,ro[isobenzofuran-1 ( 3f~,4'-piperidine)~HCI (1.2 g) according to the method described in EXAMPLE 2 giving the title compound 32 which crystallized as the maleate from acetone by addition of ao malefic acid. Yield: 1 g, mp: 186-87 °C.
EXAMPLE ~,,'~
1'-(4-(2,3-Dihydro-benzo[bjthiophen-3-yl)-1-butyl)spiro[isobenzofuran-1 (31~,4'-25 piperidinej-S,S-dioxide, maleate, 33.
Oxidation of 4-(benzo[bjthiophen-3-yl)butyric acid (8.5 g) according to the method described in EXAMPLE 32 gave the corresponding S,S-dioxide (9.2 g).
A solution of the acid (4 g) in tetrahydrofuran (25 ml) was added dropwise to a so suspension of lithium aluminium hydride (1.3 g) in tetrahydrofuran (50 ml) at 0 °C
followed by stirring at room temperature for 2 h. Usual work-up yielded 3 q of (2,3-dihydro-benzo(bjthiophen-S,S-dioxide-3-yl)-1-butanol which was converted to the title compound by treatment with spiro[isobenzofuran-1 (3N),4'-piperidinej according to the method described in EXAMPLE 2. The product crystallized as the fumarate from an acetone/ethanol mixture upon addition of fumaric acid. Yield:
1.5 g, mp: 197-98 °C.
s _E?CAMPLE 34 1'-[3-(8enzo[b]thiophen-3-yloxy)-1-propyl]spiro[isobenzofuran-1 (31-x,4'-piperidine], maleate, 34.
~o A mixture of benzo[b]thiophen-3-one (30 g), ethyl 3-bromopropionate (73 g), potassium carbonate (55 g), potassium iodide (1.3 g) and acetone (600 ml) was refluxed for 18 h. Filtration and removal of solvent in vacuo a red oil which was dissolved in ether (200 ml) and dried over magnesium sulfate. The ether solution was added dropwise to a suspension of lithium aluminium hydride (5 g) in ether ls- (100m1) followed by reflux for 1 h. Usual work-up gave a viscous oil which was applied to a silica gel column (eluent: isopropyl ether) giving 3-(benzo[b]thiophen-3-yloxy)-1-propanol (0.54 g) as an oil.
The title compound was obtained according to the method described in EXAMPLE
2' using spiro[isobenzofuran-1 (3H),4'-piperidine] and crystallized as the maleate salt Zo from an acetone/ether mixture by addition of malefic acid. Yield: 0.34 g, mp: 116-17 °C.
~X,AMPI_E 3~
2s 1'-[2-(Benzo[b]thiophen-3-ylmethyloxy)-1-ethyl]spiro[isobenzofuran-1 (3f~,4'-piperidine], fumarate, 35a.
An ether solution (50 ml) of methyl benzo[b]thiophene-3-carboxylate (15 g) was added dropwise to a suspension of lithium aluminium hydride (3.5 g) in ether (100 so ml) followed by reflux for 2 h. Usual work-up gave benzo[b]thiophen-3-yf methanol ' (13.5 g) as an oil.
The oil was dissolved in tetrahydrofuran (50 ml) and added dropwise to a suspen-sion of NaH (5 g of an 80% paraffinsuspension) in tetrahydrofuran (100 ml) followed by reflux for 1 h. Ethyl bromoacetate (35 g) in tetrahydrofuran (50 ml) was added at 60 °C followed by reflux for 1 h. Additional ethyl bromoacetate (20 g) was added followed by reflux for 7 h. The reaction was quenched with water and the volatiles removed in vacuo. The remaining oil was applied to a silica gel column s (eluent: ethyl acetate/heptane 2:8) giving ethyl benzo[bjthiophen-3-ylmethyloxyacetate (5 g) as an oil. Reduction with lithium aluminium hydride as described above yielded 3.8 g of 2-(benzo[bjthiophen-3-ylmethyloxy)ethanol as an oil.
The title compound 35a was obtained by the method described in EXAMPLE 2 io using spiro[isobenzofuran-1(3I-n,4'-piperidine] and crystallized as the fumarate salt from an acetone/ethanol mixture by addition of fumaric acid. Yield: 0.55 g, mp: 149 50~°C.
In a similar manner was also prepared:
is 1'-[2-(5-Fluorobenzofuran-3-ylmethyloxy)-1-ethyljspiro[isobenzofuran-1 (3f-~,4'-piperidine), oxalate, 35b, mp: 148-49 °C.
1'-[2-(Benzofuran-3-ylmethyloxy)-1-ethylj-4-fluorospiro[isobenzofuran-1 (3l-~,4'-piperidinej, oxalate, 35c, mp: 120-22 °C.
2o EXAMPLE 36 1'-[4-(1-(2-Dimethylamino-1-ethyl)-3-indolyl)-1-butyljspiro[isobenzofuran-1 (31~,4'-piperidinej, dihydrochloride, 36.
2s A solution of 4-(3-indolyl)-1-butanol (5 g) in dry DMF (50 ml) was cooled to 10 °C
followed by treatment with potassium t-butoxide (3 g). After stirring for 5 min. 2-chloro-N,N-dimethylacetamide (3.5 g) dissolved in dry DMF (10 ml) was added dropwise at 10-15 °C. After stirring for 1 h at room temperature water was added followed by extraction with ethyl acetate. Drying of the organic phase over magne-so sium sulfate and removal of solvent in vacuo left a viscous oil, 4-(1-dimethylamino-carbonylmethyl-3-indolyl)-1-butanol (7 g) which was converted to 1'-[4-(1-dimethyl-aminocarbonylmethyl-3-indolyl)-1-butyljspiro[isobenzofuran-1 (3f-~,4'-piperidinej by the method described in EXAMPLE 2 using spiro[isobenzofuran-1 (3 ff),4'-piperidine). Yield: 5.7 g of a viscous oil. Conventional reduction with lithium aluminium hydride gave the title compound 36 which crystallized as the dihydro-chloride from acetone by addition of hydrochloric acid. Yield: 2.4 g, mp: 244-45 °C.
s PHARMACOLOGY
Some of the compounds of Formula I have been tested according to an established and reliable pharmacological test as follows:
to INHIBITION OF 3H-DTG BINDING TO SIGMA RECEPTORS IN RAT BRAIN IN
VITRO.
By this method the inhibition by drugs of the binding of 2 nM 3H-DTG (1,3,di-o-tolyl guanidine) to sigma receptors in homogenates or membranes from rat brain ~s without cerebellum is determined in vitro as modified from Weber et al.
Proc. Natl.
Acad Sci. 1986, 83, 8784. ' Tissue preparations:
Homogenate: Rats (150-250 g) are decapitated and the brains (without cerebellum) 2o quickly removed and placed on ice, weighed and homogenized in 100 vol ice-cold (0 °C) 50 mM Tris-buffer (pH 7.7) in an ethanol rinsed glass/teflon homogenizes at 0 °C and kept on ice until use.
P2-membranes: Brains are homogenized in 10 vol 0.32 M sucrose in an ethanol zs rinsed glass/teflon homogenizes with 10 strokes up and down. The homogenate is centrifuged for 10 min at 900 x g m at 4 °C. The supernatant is decanted -and centrifuged for 20 min at 50,000 g m at 4 °C. The resulting pellet is resuspended in vol ice-cold 50 nM Tris-buffer (pH 7.7) and incubated for 30 min. at 37 °C. The . membrane suspension is then centrifuged for further 20 min. at 50,000 g m at 4 °C.
ao The pellet is resuspended in 50 vol. of ice-cold Tris-buffer and used immediately.
Binding analysis:
0.5 ml 50 mM Tris-buffer (pH 7.7), 0.25 ml displaces (6 x 100 ~M DTG, 6 x [test compoundj, or Tris-buffer), and 0.25 ml 6 x 2 nM 3H-DTG are mixed into 5 rill s plastic test tubes and kept at 4 °C until use. The binding reaction is initiated by mixing 0.5 ml tissue suspension into this solution and incubate at 25 °C for 20 min.
Glass fiber filters (Whatman GF/B) are placed on the filter machine which is then closed tightly. Just before filtration vacuum is applied, and the filters washed with 0.1% PEI solution from a spray bottle followed by one wash with Tris-buffer.
~o The binding reaction is stopped by filtration of the assay mixture at reduced pressure (750 mbar) followed by further 3 washes with 5 ml ice-cold Tris-buffer.
The filters are then placed in counting vials and 4 ml scintillation solution added.
The vials are counted in a Beckmann scintillation counter.
~5 Buffers and solutions:
50 mM Tris-buffer pH 7.7: 7.38 g Trizma - 7.7 plus distilled H 20 ad 1 liter.
100 ml 10% polyethylenimine (PEI): 100 ml dest. H 20 is added to approx. 20 g 50% PEI which is solubilized by stirring and heating. Diluted (1+99) before use.
6 x 2 nM 3H-DTG: The exact volume depends on the actual concentration of the 2o batch, but is made as close as possible to 12 nM. The containers for the radioac-tive solution is rinsed in 96% ethanol before use.
6 x 100 ~M DTG: 14.36 mg/100 ml is kept frozen in 10 ml aliqouts.
3H-DTG was obtained from NEN Research Products, Du Pont Denmark. Specific activity 62.3 Ci/mmol.
The known sigma receptor ligands BMY 14802 and rimcazole were included in the test for comparison purposes.
Table y 3H DTG Binding Data Com oun IC50 nM Com oun IC50 nM Com oun d C 50 nM
1a 7.3 4c - 2.9 11a 0.31 _ 1b 3.7 4d 1.1 11b 0.63 2a 0.25 4e 0.20 1 2 0.30 2b 0.07 4 f 0.20 13a 3.7 2c 0.51 4 46 13b 1,0 2d 0.77 5a 0.33 13c 4,g _ ._.___ 2e 1 . 2 5 b 1 .1 13 d 2 .1 2f 0.95 5c 0.25 14a 24 2 0.36 5d 0.24 14b 3,g 2h 1.4 5e 4.7 1 5 0.42 2i 4.3 5f 0.04 16 0.15 2 ~ 0.07 5 4.0 17a 0.1 1 2k 0.19 6a 0.05 17b 0.46 21 3.8 6b 0.17 18a 0.56 2m 0.47 6c <0.1 19a 0.08 2n 6.0 7 0.21 19b 0.49 20 0.26 8a 0.21 19c 0.84 2 0.32 8b 1.7 19d 4.4 2 430 8c 0.66 20 0.63 2 r ' 3.0 8d 1 1 2 1 0.2 2s 3.1 9a 0.34 2 2 0.05 2f 5.4 9b 0.06 23 2.5 2u 0.41 9c 0.14 24 1,g 2v 1 .8 9d 2 6 25a 1 1 2x 1 .6 9e 0.31 25b 3 6 2 0.84 9 f 2 7 26a 0.89 2z 1 5 9 4.2 26b i ,g 2aa 0 . 3 9 h__ 2 . 3 2 6 c 0 . i 4 2bb 0.30 9 i 0.62 2 7 0.1 1 2cc 1 .1 9 ' 0.1 1 2 8 0.15 2dd 1.7 9k 0.92 29 0.12 Zee 1 . 0 9 I 0 .14 3 0 0 . 0 7 2ff 0.43 9m 1.6 31a 0.23 2 3.3 9n 6.3 31b 2.6 2hh 0.02 90 _ 6.7 3 2 0.89 2ii 5.8 9 0.28 33 0.95 2~~ 1.4 9 0.12 34 0.27 3a 2.2 9 r 0.42 35a 0.73 3b 4.8 9s 5 6 35b f 2.8 3c 1 .0 91 3.2 3 6 4.5 3d 7 . 3 10 a 0 . 0 9 4a - 23 ______ 1.3 BMY 14802 230 4b 0.53 1Ob 0.35 rimcazole 180 10c ( I t is seen from Table I that the compounds used in the present invention are very potent sigma receptor ligands as compai~ed to the reference compounds which are known in the art to be sigma receptor ligands, the potencies for the compounds tested being better than about 40 nM, and for most of the compounds tested better s than about 1 nm.
Furthermore, the ability of the present compounds in inhibiting the binding of Prazosin to a1 adrenoceptors in membranes from rat brain were determined in vitro according to Hyttel, J et al, J. Neurochem, 1985, 44, 1615; Skarsfeldt, T. et al, Eur.
1o J. Pharmacol. 1986, 125, 323.
Additionally the compounds of the invention were tested with respect to dopamine D2 receptor binding activity according to van der Welde et a!, Eur. J.
Pharmacol.
1987, 134, 211.
For most compounds, the affinities for a1 adrenoceptors and D2 receptors were weak as compared to the potent binding to sigma receptors. Thus many of the com-pounds are very selective sigma receptor ligands, having ratios of binding affinities (ICso alpha/ICso sigma and ICso dopamine/ICSO sigma, respectively) of 30-10000.
LIGHT/DARK DISCRIMINATION TEST IN RATS.
The test was carried out in accodance with F.C.Colpaert et al., Psychopharmacolo-gy (1985) 86: 45-54. The test used Wistar WU rats.
2s The test was conducted using a two compartment activity box in which the actions of anxiolytic compounds to reduce aversion against a brightly-lit environment may be readily detected. The box is designed as an open-top experimental box one third of which was partitioned from the rest, painted black and illuminated with red light. The remainder of the box was painted white and brightly illuminated.
The so floor of each area was lined into squares. Behavioural changes were recorded.
Data obtained from dose groups were analysed using single factor analysis of variance, and Dunnett's t-test. Test compounds were given intraperitoneally 45 min before testing.
Several compounds have been tested in this test model and showed significant anxiolytic activities with EDSO values in the ng-pg/kg dose range.
FORMULATION EXAMPLES
The pharmaceutical formulations of the invention may be prepared by conventional methods in the art.
For example: Tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conven-~o tional tabletting machine. Examples of adjuvants or diluents comprise: corn starch, potato starch, talcum, magnesium stearate, gelatine, lactose, gums, and the like.
Any other adjuvants or additives usually used for such purposes such as colourings, flavourings, preservatives etc. may be used provided that they are compatible with the active ingredients.
is Solutions for injections may be prepared by dissolving the active ingredient and possible additives in a part of the solvent for injection, preferably sterile water, adjusting the solution to desired volume, sterilization of the solution and filling in suitable ampules or vials. Any suitable additive conventionally used in the art may be added, such as tonicity agents, preservatives, antioxidants, etc.
Typical examples of recipes for the formulation of the invention are as follows:
1 ) Tablets containing 0.5 milligrams of Compound 3c calculated as the frbese:
2s Comp. 3c ~ 0.5 mg Lactose 18 mg Potato starch 27 mg Sucrose 58 mg Sorbitol 3 mg so Talcum 5 mg Gelatine 2 rng Povidone 1 mg Magnesium stearate 0.5 mg 2) Tablets containing 5 milligrams of Compound 2m calculated as the free base:
Comp. 2m 5 mg Lactose 16 mg Potato starch 45 mg s Sucrose 106 mg Sorbitol 6 mg Talcum 9 mg Gelatine 4 mg Povidone 3 mg ' io Magnesium stearate0.6 mg 3) Syrup containing per milliliter:
Comp. 6b 2.5 mg Sorbitol 500 mg ~s Tragacanth . 7 mg Glycerol 50 mg Methyl-paraben 1 mg Propyl-paraben _0.1 mg Ethanol 0.005 ml 2o Water ad 1 ml 4) Solution for injection containing per milliliter:
Comp. 17 a 1 mg Acetic acid 17.9 mg 2s Sterile water ad 1 ml 5) Solution for injection containing per milliliter:
Comp. 17b 0.1 mg Sorbitol 42.9 mg so Acetic acid 0.63 mg Sodium hydroxide 22 mg Sterile water ad 1 ml
Claims (9)
1. A piperidine compound having Formula I:
Wherein R1 is -D-B-A-R
wherein B is an up to 19 membered spacer group selected from alkylene which may be branched or straight chain and optionally substituted with hydroxy, which again may be esterified with an aliphatic carboxylic acid having from two to twenty-four carbon atoms, inclusive, A is a bond or a divalent group selected from O, S, SO, SO2, and W being O or S and the dashed line designating an optional bond;
R is alkyl, alkenyl, cycloalkyl, cycloalkenyl, phenyl, cycloalkylalkyl, cycloalkenylalkyl, phenylalkyl, any alkyl group optionally being substituted with one or two hydroxy groups, which again may be optionally esterified with an aliphatic carboxylic acid having from two to twenty-four carbon atoms inclusive, and any phenyl group being optionally substituted with one or more substituents on the phenyl ring; and D is CR8R9 where R8 and R9 are independently selected from the substituents defined below for R4-R7; or a cycloalkylene group;
R2 and R3 are independently hydrogen, lower alkyl or they may be linked together to form an ethylene or propylene bridge;
R4 to R7 are independently selected from hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy, lower alkylthio, lower alkylamino and lower dialkylamino;
and Z1 and Z2 are linked together; wherein Z1 is CH2, O or S; Z2 and Z3 are independently (CH2)n, n being 1, O or S; with the proviso that Z1 may not be S
or O when Z2 is S or O; or Z1 and Z2 may together represent a group -CH=CH-;
wherein at least one of Z1, Z2 and Z3 is Q or S; or when Z3 is (CH2)n wherein n is O, Z1 and Z2 may together represent a 3-membered divalent group containing one O- or S- heteroatom;
with the proviso that Z1, Z2 and Z3 cannot represent a dihydrobenzofuranyl ring system and D-B-A-R may not be cycloalkyl-C1-3 alkyl, lower alkyl or lower alkenyl, optionally substituted phenyl-C1-4 alkyl, and if Z1 is O, and Z2 and Z3 are both CH2 then -D-B-A-R may not be optionally hydroxy-substituted hexyl or heptyl;
or an acid addition salt or a prodrug thereof.
Wherein R1 is -D-B-A-R
wherein B is an up to 19 membered spacer group selected from alkylene which may be branched or straight chain and optionally substituted with hydroxy, which again may be esterified with an aliphatic carboxylic acid having from two to twenty-four carbon atoms, inclusive, A is a bond or a divalent group selected from O, S, SO, SO2, and W being O or S and the dashed line designating an optional bond;
R is alkyl, alkenyl, cycloalkyl, cycloalkenyl, phenyl, cycloalkylalkyl, cycloalkenylalkyl, phenylalkyl, any alkyl group optionally being substituted with one or two hydroxy groups, which again may be optionally esterified with an aliphatic carboxylic acid having from two to twenty-four carbon atoms inclusive, and any phenyl group being optionally substituted with one or more substituents on the phenyl ring; and D is CR8R9 where R8 and R9 are independently selected from the substituents defined below for R4-R7; or a cycloalkylene group;
R2 and R3 are independently hydrogen, lower alkyl or they may be linked together to form an ethylene or propylene bridge;
R4 to R7 are independently selected from hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy, lower alkylthio, lower alkylamino and lower dialkylamino;
and Z1 and Z2 are linked together; wherein Z1 is CH2, O or S; Z2 and Z3 are independently (CH2)n, n being 1, O or S; with the proviso that Z1 may not be S
or O when Z2 is S or O; or Z1 and Z2 may together represent a group -CH=CH-;
wherein at least one of Z1, Z2 and Z3 is Q or S; or when Z3 is (CH2)n wherein n is O, Z1 and Z2 may together represent a 3-membered divalent group containing one O- or S- heteroatom;
with the proviso that Z1, Z2 and Z3 cannot represent a dihydrobenzofuranyl ring system and D-B-A-R may not be cycloalkyl-C1-3 alkyl, lower alkyl or lower alkenyl, optionally substituted phenyl-C1-4 alkyl, and if Z1 is O, and Z2 and Z3 are both CH2 then -D-B-A-R may not be optionally hydroxy-substituted hexyl or heptyl;
or an acid addition salt or a prodrug thereof.
2. A compound according to claim 1, wherein Z3 is (CH2)n wherein n is 0, and Z2 is O or S and Z1 is CH2, or Z1 and Z2 together represent CH2-O-CH2.
3. A compound according to claim 1, wherein Z1 is CH2, Z2 is O and Z3 is CH2.
4. A compound according to claim 1, wherein Z3 is O and Z1-Z2 is CH=CH.
5. A compound according to claim 1, wherein said compound is selected from the group consisting of:
1'-(3-Adamantyloxy-1-propyl)spiro[3H-2benzopyran-3,4'-piperidine];
and 1'-(3-(3-Phenylimidazolidin-2-on-1-yl)-1-propyl)spiro[iso-benzofuran-1(3H), 4'-piperidine].
1'-(3-Adamantyloxy-1-propyl)spiro[3H-2benzopyran-3,4'-piperidine];
and 1'-(3-(3-Phenylimidazolidin-2-on-1-yl)-1-propyl)spiro[iso-benzofuran-1(3H), 4'-piperidine].
6. A pharmaceutical composition, wherein said composition comprises from 0.01 to about 50 mg of at least one piperidine compound according to any one of claims 1 to 5, or a pharmaceutically acceptable acid addition salt thereof in combination with one or more pharmaceutically acceptable carriers or diluents.
7. A pharmaceutical composition, according to claim 6, for treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebro-vascular diseases, senile dementia of the Alzheimer's type or Parkinson's disease.
8. Use of a therapeutically effective amount of a compound according to any one of claims 1 to 5, or a pharmaceutically acceptable acid addition salt thereof, for treating anxiety, psychosis, epilepsy, convulsions, movement disorders, motor disturbances, amnesia, 65~
cerebrovascular disease, senile dementia of the Alzheimer's type or Parkinson's disease.
cerebrovascular disease, senile dementia of the Alzheimer's type or Parkinson's disease.
9. A pharmaceutical composition for treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases, senile dementia of the Alzheimer's type or Parkinson's disease, comprising therapeutically effective amount of a compound of any one of claims 1 to 5.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK113191A DK113191D0 (en) | 1991-06-13 | 1991-06-13 | SPIROCYCLIC COMPOUNDS |
DK112991A DK112991D0 (en) | 1991-06-13 | 1991-06-13 | CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS |
DK1131/91 | 1991-06-13 | ||
DK1129/91 | 1991-06-13 | ||
DK15792A DK15792D0 (en) | 1992-02-10 | 1992-02-10 | SPIROCYCLIC COMPOUNDS |
DK157/92 | 1992-02-10 | ||
CA002111204A CA2111204C (en) | 1991-06-13 | 1992-06-12 | Piperidine derivatives having anxiolytic effect |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002111204A Division CA2111204C (en) | 1991-06-13 | 1992-06-12 | Piperidine derivatives having anxiolytic effect |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2296897A1 true CA2296897A1 (en) | 1992-12-23 |
Family
ID=31892116
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002296897A Abandoned CA2296897A1 (en) | 1991-06-13 | 1992-06-12 | Piperidine derivates having anxiolytic effect |
CA002296901A Expired - Fee Related CA2296901C (en) | 1991-06-13 | 1992-06-12 | Piperidine derivates having anxiolytic effect |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002296901A Expired - Fee Related CA2296901C (en) | 1991-06-13 | 1992-06-12 | Piperidine derivates having anxiolytic effect |
Country Status (1)
Country | Link |
---|---|
CA (2) | CA2296897A1 (en) |
-
1992
- 1992-06-12 CA CA002296897A patent/CA2296897A1/en not_active Abandoned
- 1992-06-12 CA CA002296901A patent/CA2296901C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2296901A1 (en) | 1992-12-23 |
CA2296901C (en) | 2004-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2111204C (en) | Piperidine derivatives having anxiolytic effect | |
US5576321A (en) | Compounds having effects on serotonin-related systems | |
US5741789A (en) | Compounds having effects on serotonin-related systems | |
US5614523A (en) | Compounds having effects on serotonin-related systems | |
US5627196A (en) | Compounds having effects on serotonin-related systems | |
US5789402A (en) | Compounds having effects on serotonin-related systems | |
DE60022504T2 (en) | PHENOXYPROPYLAMIN DERIVATIVES | |
AU643241B2 (en) | Serotonin antagonists, their preparation and compositions containing them | |
JP2007517014A (en) | N-substituted piperidine and piperazine derivatives | |
RU2156249C2 (en) | Phenylendole compounds | |
CA2296901C (en) | Piperidine derivates having anxiolytic effect | |
JPH09202784A (en) | Pharmaceutical compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |